13th AEP CONGRESS
Association of European Psychiatrists

2 – 6 April 2005
Munich, Germany

European Psychiatry: The interface between biological and social factors

ORGANIZER
Association of European Psychiatrists (AEP)

www.aep-munich.de

CME accredited  •  CME accredited  •  CME accredited
OVERVIEW OF CONGRESS LOCATION

Gasteig, Holiday Inn, Hilton

Station: Rosenheimer Platz (S1 - S8)
Access by public transportation with all rapid transport trains including airport line.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Welcome Address</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Committees</td>
<td></td>
</tr>
<tr>
<td>Acknowledgements</td>
<td></td>
</tr>
<tr>
<td>Social Events</td>
<td></td>
</tr>
<tr>
<td>General Information</td>
<td></td>
</tr>
<tr>
<td>CME Credits</td>
<td></td>
</tr>
<tr>
<td>Congress Counter</td>
<td></td>
</tr>
<tr>
<td>Registration Fees</td>
<td></td>
</tr>
<tr>
<td>CME Courses</td>
<td></td>
</tr>
<tr>
<td>Name Badges</td>
<td></td>
</tr>
<tr>
<td>Media Check</td>
<td></td>
</tr>
<tr>
<td>CO Congress Online</td>
<td></td>
</tr>
<tr>
<td>Technical Exhibition</td>
<td></td>
</tr>
<tr>
<td>Poster Exhibition</td>
<td></td>
</tr>
<tr>
<td>Young Psychiatrists Lounge</td>
<td></td>
</tr>
<tr>
<td>AEP Administrative Meetings</td>
<td></td>
</tr>
<tr>
<td>Format Descriptions</td>
<td></td>
</tr>
<tr>
<td>Scientific Program Schedule</td>
<td></td>
</tr>
<tr>
<td>Scientific Program</td>
<td></td>
</tr>
<tr>
<td>Saturday, 2 April 2005</td>
<td></td>
</tr>
<tr>
<td>Sunday, 3 April 2005</td>
<td></td>
</tr>
<tr>
<td>Monday, 4 April 2005</td>
<td></td>
</tr>
<tr>
<td>Tuesday, 5 April 2005</td>
<td></td>
</tr>
<tr>
<td>Wednesday, 6 April 2005</td>
<td></td>
</tr>
<tr>
<td>Poster Presentation</td>
<td></td>
</tr>
<tr>
<td>Young Psychiatrists Program</td>
<td></td>
</tr>
<tr>
<td>List of Exhibitors</td>
<td></td>
</tr>
<tr>
<td>Exhibition Plan</td>
<td></td>
</tr>
<tr>
<td>List of Chairpersons and Presenters</td>
<td></td>
</tr>
</tbody>
</table>

## CONGRESS ORGANIZER AND EXHIBITION OFFICE

**CPO HANSER SERVICE**  
Hanser & Co GmbH  
P.O. Box 1221  
D-22882 Barsbüttel  
Tel.: +49-40-670 88 20  
Fax: +49-40-670 32 83  
E-mail: aep@cpo-hanser.de

## CONGRESS VENUE

**Kulturzentrum Gasteig**  
Rosenheimer Strasse 5  
D-81667 München  
and opposite Hotel Holiday Inn and Hotel Hilton

## AEP SECRETARIAT

Association of European Psychiatrists  
Hôpitaux Universitaires – Clinique Psychiatrique 1, place de l’Hôpital  
F-67091 Strasbourg Cedex  
Tel.: +33-3-8811 5406/24  
Fax: +33-3-8811 6189  
E-mail: aep.strasbourg@wanadoo.fr

## ORGANIZING CHAIRMAN

Prof. Dr. Manfred Ackenheil  
Klinik und Poliklinik für Psychiatrie und Psychotherapie  
Nußbaumstrasse 7  
D-80336 Munich  
Tel.: +49-89-5160 2730  
Fax: +49-89-5160 4741  
E-mail: manfred.ackenheil@med.uni-muenchen.de

## CONGRESS PRESIDENT

Prof. Dr. Henning Saß  
Universitätsklinikum Aachen  
Pauwelstrasse 30  
D-52074 Aachen  
Tel.: +49-241-808 81 25  
Fax: +49-241-808 24 64  
E-mail: hsass@ukaachen.de

## SCIENTIFIC CHAIRMAN

Prof. Dr. Hans-Jürgen Möller  
Klinik und Poliklinik für Psychiatrie und Psychotherapie  
Nußbaumstrasse 7  
D-80336 Munich  
Tel.: +49-89-5160 5501  
Fax: +49-89-5160 5522  
E-mail: hans-juergen.moeller@med.uni-muenchen.de

## SCIENTIFIC CONTACT

Dr. Dan Rujescu  
Klinik und Poliklinik für Psychiatrie und Psychotherapie  
Nußbaumstrasse 7  
D-80336 Munich  
Tel.: +49-89-5160 5756  
Fax: +49-89-5160 5779  
E-mail: Dan.Rujescu@med.uni-muenchen.de
Dear Colleagues,

It is our great pleasure to welcome you very cordially to the 13th Congress of the Association of European Psychiatrists (AEP) which will take place in Munich, Germany.

The AEP, founded in 1983, is the largest international association of psychiatrists in Europe with members in 58 countries. In order to support the exchange of scientific and clinical knowledge, the AEP organizes its congresses now annually started with Geneva in 2004.

Due to its excellent facilities Munich has been chosen to host the AEP meeting for the first time in Germany. The theme of the Congress is:

"European Psychiatry: The interface between biological and social factors".

In the tradition of AEP and with the intention to cover all aspects of modern psychiatry, issues related to patients' care and life will be the focus of the scientific and educational program. You are all aware of the tremendous progress of neurobiological knowledge on brain functioning with main contributions coming from such different fields like genetics or neuroimaging. On the other hand, psychiatry has always been a discipline with a close contact to social sciences as there are sociology, psychology, philosophy or anthropology. The main challenge for psychiatry in our days is to organize a fruitful dialogue between the disciplines and to build an interface for the exchange of ideas and the latest discoveries.

Munich, where pioneer work in psychiatry has been done even before the times of Emil Kraepelin, is up to day still in the front line of psychiatry. Having always been a city of art and culture with a special flair, Munich traditionally had a strong attraction for psychiatry and is still one of the basis of psychiatric thinking.

The congress venue is the Gasteig culture centre, the residence of the famous Munich Philharmonic Orchestra. Located in the centre of Munich, it offers best facilities for such a congress as well as a closeness to all the attractive places of Munich like e.g. many famous museums, opera or theatres.

Please join us for this important and exciting scientific and social event, which will bring together colleagues from all over the world.

Henning E. Saß  
President of AEP  
Congress President

Manfred Ackenheil  
Chairman of the  
Organizing Committee

Hans-Jürgen Möller  
Chairman of the  
Scientific Program Committee
## President of the AEP/Congress President

H. Saß, Germany

## Executive Committee

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Past President</td>
<td>M. Maj</td>
<td>Italy</td>
</tr>
<tr>
<td>President Elect</td>
<td>C. Höschl</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>Sections Secretary</td>
<td>M. Katrup</td>
<td>Denmark</td>
</tr>
<tr>
<td>Treasurer</td>
<td>K. Mann</td>
<td>Germany</td>
</tr>
<tr>
<td>Secretary General</td>
<td>M. Musalek</td>
<td>Austria</td>
</tr>
<tr>
<td>Counsellor</td>
<td>P. Boyer</td>
<td>Canada</td>
</tr>
<tr>
<td>Counsellor</td>
<td>S. Tyano</td>
<td>Israel</td>
</tr>
</tbody>
</table>

## Scientific Program Committee

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman</td>
<td>H.-J. Möller</td>
<td>Germany</td>
</tr>
<tr>
<td>Vice-Chairman</td>
<td>M. Maj</td>
<td>Italy</td>
</tr>
<tr>
<td>Members</td>
<td>M. Ackenheim</td>
<td>Germany</td>
</tr>
<tr>
<td></td>
<td>J. Bobes</td>
<td>Spain</td>
</tr>
<tr>
<td></td>
<td>P. Boyer</td>
<td>Canada</td>
</tr>
<tr>
<td></td>
<td>G. Christodoulou</td>
<td>Greece</td>
</tr>
<tr>
<td></td>
<td>W. Gaebel</td>
<td>Germany</td>
</tr>
<tr>
<td></td>
<td>C. Gillberg</td>
<td>Sweden</td>
</tr>
<tr>
<td></td>
<td>F. Hohagen</td>
<td>Russia</td>
</tr>
<tr>
<td></td>
<td>M. Kastrup</td>
<td>Denmark</td>
</tr>
<tr>
<td></td>
<td>V. Krasnov</td>
<td>Russia</td>
</tr>
<tr>
<td></td>
<td>J. Lopez-Ibor</td>
<td>Spain</td>
</tr>
<tr>
<td></td>
<td>W. Maier</td>
<td>Germany</td>
</tr>
<tr>
<td></td>
<td>K. Mann</td>
<td>Germany</td>
</tr>
<tr>
<td></td>
<td>D. Marazziti</td>
<td>Italy</td>
</tr>
<tr>
<td></td>
<td>M. Müller-Spahn</td>
<td>Switzerland</td>
</tr>
<tr>
<td></td>
<td>P. Munk-Jørgensen</td>
<td>Denmark</td>
</tr>
<tr>
<td></td>
<td>R. Murray</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td>M. Musalek</td>
<td>Austria</td>
</tr>
<tr>
<td></td>
<td>J. Raboch</td>
<td>Czech Republic</td>
</tr>
<tr>
<td></td>
<td>A. Riecher-Rössler</td>
<td>Switzerland</td>
</tr>
<tr>
<td></td>
<td>W. Rössler</td>
<td>Switzerland</td>
</tr>
<tr>
<td></td>
<td>D. Rujescu</td>
<td>Germany</td>
</tr>
<tr>
<td></td>
<td>J. Rybakowski</td>
<td>Poland</td>
</tr>
<tr>
<td></td>
<td>N. Sartorius</td>
<td>Switzerland</td>
</tr>
<tr>
<td></td>
<td>H. Saß</td>
<td>Germany</td>
</tr>
<tr>
<td></td>
<td>G. Sedvall</td>
<td>Sweden</td>
</tr>
<tr>
<td></td>
<td>C. Soldatos</td>
<td>Greece</td>
</tr>
<tr>
<td></td>
<td>L. Träskman-Bendz</td>
<td>Sweden</td>
</tr>
</tbody>
</table>

## Local Organizing Committee

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>City</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman</td>
<td>M. Ackenheil</td>
<td>Munich</td>
</tr>
<tr>
<td>Members</td>
<td>B. Bondy</td>
<td>Munich</td>
</tr>
<tr>
<td></td>
<td>M. Fichter</td>
<td>Munich</td>
</tr>
<tr>
<td></td>
<td>H. Förstl</td>
<td>Munich</td>
</tr>
<tr>
<td></td>
<td>H. Hegerl</td>
<td>Munich</td>
</tr>
<tr>
<td></td>
<td>N. Müller</td>
<td>Munich</td>
</tr>
<tr>
<td></td>
<td>D. Rujescu</td>
<td>Munich</td>
</tr>
<tr>
<td></td>
<td>M. Schwarz</td>
<td>Munich</td>
</tr>
</tbody>
</table>

## National Advisory Committee

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>City</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman</td>
<td>M. Berger</td>
<td>Freiburg</td>
</tr>
<tr>
<td>Vice-Chairman</td>
<td>F. Hohagen</td>
<td>Lübeck</td>
</tr>
<tr>
<td>Members</td>
<td>H. Beckmann</td>
<td>Würzburg</td>
</tr>
<tr>
<td></td>
<td>W. Bender</td>
<td>Munich</td>
</tr>
<tr>
<td></td>
<td>B. Bogerts</td>
<td>Magdeburg</td>
</tr>
<tr>
<td></td>
<td>G. Buchkremer</td>
<td>Tübingen</td>
</tr>
<tr>
<td></td>
<td>M. von Cranach</td>
<td>Kaufbeuren</td>
</tr>
<tr>
<td></td>
<td>H.J. Freyberger</td>
<td>Stralsund</td>
</tr>
<tr>
<td></td>
<td>W. Gaebel</td>
<td>Düsseldorf</td>
</tr>
<tr>
<td></td>
<td>M. Gastpar</td>
<td>Essen</td>
</tr>
<tr>
<td></td>
<td>A. Heinz</td>
<td>Berlin</td>
</tr>
<tr>
<td></td>
<td>F. Henn</td>
<td>Mannheim</td>
</tr>
<tr>
<td></td>
<td>I. Heuser</td>
<td>Berlin</td>
</tr>
<tr>
<td></td>
<td>H. Hippius</td>
<td>Munich</td>
</tr>
<tr>
<td></td>
<td>F. Holsboer</td>
<td>Munich</td>
</tr>
<tr>
<td></td>
<td>H. Klein</td>
<td>Munich</td>
</tr>
<tr>
<td></td>
<td>J. Klosterkötter</td>
<td>Regensburg</td>
</tr>
<tr>
<td></td>
<td>J. Kornhuber</td>
<td>Erlangen</td>
</tr>
<tr>
<td></td>
<td>C. Krieg</td>
<td>Marburg</td>
</tr>
<tr>
<td></td>
<td>K. Mann</td>
<td>Mannheim</td>
</tr>
<tr>
<td></td>
<td>A. Marneros</td>
<td>Hallé</td>
</tr>
<tr>
<td></td>
<td>K. Maurer</td>
<td>Frankfurt</td>
</tr>
<tr>
<td></td>
<td>Ch. Mundt</td>
<td>Heidelberg</td>
</tr>
<tr>
<td></td>
<td>D. Naber</td>
<td>Hamburg</td>
</tr>
<tr>
<td></td>
<td>E. Rüther</td>
<td>Göttingen</td>
</tr>
<tr>
<td></td>
<td>H. Sauer</td>
<td>Jena</td>
</tr>
<tr>
<td></td>
<td>M. Schmauß</td>
<td>Augsburg</td>
</tr>
</tbody>
</table>
The organizers of the 13th Congress of the Association of European Psychiatrists gratefully acknowledge the support of the following companies:

<table>
<thead>
<tr>
<th>PRINCIPLE SPONSORS</th>
<th>SPONSORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Inc.</td>
<td>AstraZeneca GmbH</td>
</tr>
<tr>
<td>Servier</td>
<td>Avon &amp; Wilthshire NHS Mental Health Trust</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MAJOR SPONSORS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Eli Lilly &amp; Company</td>
<td>GlaxoSmithKline GmbH &amp; Co. KG</td>
</tr>
</tbody>
</table>

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lundbeck A/S</td>
<td>Hormosan Pharma GmbH</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SOCIAL EVENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>The following social events are free of charge for registered congress participants:</td>
</tr>
<tr>
<td>Saturday, 2 April 2005 16.30 h</td>
</tr>
<tr>
<td>Saturday, 2 April 2005 18.00 h</td>
</tr>
<tr>
<td>Monday, 4 April 2005 20.00 h</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
**CONGRESS VENUE**

Kulturzentrum Gasteig  
Rosenheimer Strasse 5  
81667 München

Some sessions will also take place at the Hilton Hotel City Munich and the Holiday Inn Hotel which are opposite of the Kulturzentrum Gasteig.

**CONGRESS COUNTER**

All Congress materials will be available at the Congress counter located on the mezzanine in the main entrance area at the Kulturzentrum Gasteig.

Opening hours:

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>2 April 2005</td>
<td>11.00 - 19.00 h</td>
</tr>
<tr>
<td>Sunday</td>
<td>3 April 2005</td>
<td>07.30 - 18.00 h</td>
</tr>
<tr>
<td>Monday</td>
<td>4 April 2005</td>
<td>08.00 - 18.00 h</td>
</tr>
<tr>
<td>Tuesday</td>
<td>5 April 2005</td>
<td>08.00 - 18.00 h</td>
</tr>
<tr>
<td>Wednesday</td>
<td>6 April 2005</td>
<td>08.00 - 13.00 h</td>
</tr>
</tbody>
</table>

During these opening hours the Congress counter can be reached at:

Telephone: +49-89-48098-97010  
Telefax: +49-89-48098-97712  
Email: aep@cpo-hanser.de

The Congress counter has the following sections:

- **On-Site Registration**  
  On-site registration for the Congress

- **Pre-Registration**  
  Participants who have already registered for the Congress will receive their documents here.

- **Help Desk**  
  The CPO staff will assist the congress participants here.

- **CME Certificates**  
  The CME Certificates will be issued here.

- **Hotel Reservation/Social Events**  
  Assistance for the reservation of hotel rooms in Munich and tickets for the Social Events will be provided here.

**REGISTRATION CONGRESS FEES**

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee (EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members AEP</td>
<td>600</td>
</tr>
<tr>
<td>from countries on list A</td>
<td></td>
</tr>
<tr>
<td>Non-Members AEP</td>
<td>700</td>
</tr>
<tr>
<td>from countries on list A</td>
<td></td>
</tr>
<tr>
<td>Members AEP</td>
<td>480</td>
</tr>
<tr>
<td>from countries on list B</td>
<td></td>
</tr>
<tr>
<td>Non-Members AEP</td>
<td>570</td>
</tr>
<tr>
<td>from countries on list B</td>
<td></td>
</tr>
<tr>
<td>Residents (in training)*</td>
<td>310</td>
</tr>
<tr>
<td>psychiatric nurses, psychologists, psychiatric social workers</td>
<td></td>
</tr>
</tbody>
</table>

* A letter of the Chairman of the Department is necessary

Registrations fee for the participant includes:

- Admission to the scientific sessions
- Congress materials (delegate bag, name badge, final program, abstract book, etc.)
- Admission to poster and technical exhibition
- Opening Ceremony and Welcome Reception on 2 April 2005
- Concert at the Gasteig on 2 April 2005
- Concert at the Residenz on 4 April 2005

**REGISTRATION FEES CME-COURSES**

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee (EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants from countries on list A</td>
<td>70</td>
</tr>
<tr>
<td>Participants from countries on list B</td>
<td>35</td>
</tr>
</tbody>
</table>

**CME CREDITS**

The 13th AEP Congress has been accredited by the European Union on Medical Specialists (U.E.M.S.) as well as by the Federal Accreditation Council of the Medical Association in Germany, represented by the Bavarian Council: Bayerische Ärztekammer.

European physicians will be accorded 0-000 credits per day from the U.E.M.S for the attendance to the scientific sessions from Sunday, 3 April to Wednesday, 6 April. A maximum of 000 credit points is awarded.
**GENERAL INFORMATION**

**CME CREDITS**

Physicians from Germany can obtain 30 credit points for the participation of the entire Congress from Sunday, 02 April to Wednesday, 06 April 2005. Participating in a course (half day) will be accorded 6 credit points. Of course, each physician should claim only those sessions for credit that he or she actually has attended in the educational activity.

In order to maintain CME accreditation, the AEP requires feedback on its educational activities. Therefore, we kindly ask you to complete your evaluation form at the end of each educational activity and to return it to the Congress counter signed “CME” — at the mezzanine in the Gasteig Munich.

The CME Certificate of U.E.M.S. or the Bayerische Ärztekammer will be issued to you at the Congress counter. Upon request the Certificate can also be mailed to you after the Congress.

**CONGRESS LANGUAGE**

The Congress language is English. There is no simultaneous translation provided.

**NAME BADGES**

All participants are strongly requested to wear their name badges at all times during the Congress. The colours of the name badge have the following significance:

- **Blue:** Delegates
- **Yellow:** Accompanying person
- **Green:** Exhibitors
- **Red:** Staff

**MEDIA CHECK**

The media check is situated on the first floor in the Gasteig. All participants including those who present at the Holiday Inn Hotel or in the Hilton Hotel City Munich are requested to hand in their CD ROM or USB stick containing their PowerPoint presentation at least 3 hours prior to their presentation.

**Please note:** A presentation from an own notebook is not possible.

**CO CONGRESS ONLINE ®**

For the 13th AEP Congress the web based Congress Information System AEP CO CONGRESS ONLINE® has been set up: [www.aep-munich.de](http://www.aep-munich.de). Benefit from the web based information system CO CONGRESS ONLINE®, on-site: Here you can set up and print out your personal congress program schedule. CO CONGRESS ONLINE® provides you with information on:

- Updated scientific program of the 13th AEP Congress
- Program by days
- Program by tracks
- Program by formats
- Accepted abstracts
- Keyword search
- List of participants (Who is Who)

**TECHNICAL EXHIBITION**

A major technical exhibition will take place in the foyers on the first floor of the Gasteig.

**Opening hours:**

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>3 April 2005</td>
<td>9.00 – 17.00 h</td>
</tr>
<tr>
<td>Monday</td>
<td>4 April 2005</td>
<td>9.00 – 17.00 h</td>
</tr>
<tr>
<td>Tuesday</td>
<td>5 April 2005</td>
<td>9.00 – 17.00 h</td>
</tr>
<tr>
<td>Wednesday</td>
<td>6 April 2005</td>
<td>9.00 – 13.00 h</td>
</tr>
</tbody>
</table>

**POSTER EXHIBITION**

The poster exhibition will be located in the foyers on the first and second floor of the Gasteig. The posters will be arranged according to topics.

**Poster set-up:**

Saturday, 2 April 2005 11.00 – 18.00 h

**Opening hours:**

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>3 April 2005</td>
<td>8.00 – 18.00 h</td>
</tr>
<tr>
<td>Monday</td>
<td>4 April 2005</td>
<td>8.00 – 18.00 h</td>
</tr>
<tr>
<td>Tuesday</td>
<td>5 April 2005</td>
<td>8.00 – 18.00 h</td>
</tr>
<tr>
<td>Wednesday</td>
<td>6 April 2005</td>
<td>8.00 – 13.00 h</td>
</tr>
</tbody>
</table>

**Poster removal:**

Wednesday, 6 April 2005 13.00 – 16.00 h
GENERAL INFORMATION

POSTER EXHIBITION

Moderated Poster sessions will take place from Sunday till Wednesday and are held on:

- **Sunday, 3 April 2005** 11.15 - 12.15 h
- **Tuesday, 5 April 2005** 11.15 - 12.15 h and 18.00 - 19.30 h
- **Wednesday, 6 April 2005** 11.15 - 12.15 h

YOUNG PSYCHIATRISTS LOUNGE

You will find the Young Psychiatrists Lounge in the foyer of Carl Orff hall above the first floor in the Gasteig. This meeting point of young psychiatrists of the Congress is open during the whole Congress.

MESSAGES

You can leave or receive personal messages at the Congress counter in the main entrance area.

TELEPHONE

There are public telephones on the ground floor, which can be used either with coins or telephone cards. Telephone cards are available at the information desk on the ground floor.

FOOD AND BEVERAGES

At the Gasteig, a self-service restaurant on the ground floor offers food and beverage from 8.30 h till 20.00 h. In the exhibition area you will find several little snack bars where you can purchase beverages, sandwiches, cakes and snacks.

At the Hilton City Munich, the coffee bar Café Cino is opened all day, where you can also purchase beverages and snacks. You will find there as well a typical Bavarian restaurant called “Zum Gasteig”, which offers a variety of dishes.

At the Holiday Inn Munich, the Lobby Bar offers small dishes and beverages the whole day. They have also a restaurant called Spices where a choice of different types of dishes will be offered. Additionally you will find restaurants of different categories in the surrounding of the Gasteig.

CLOAKROOM

A cloakroom is available in the main entrance area. You can also store your luggage here.

FIRST AID

Please contact our staff at the Congress counter when you need medical help.

CAR PARK

You can use the parking garage of the Gasteig. Parking fees are EUR 12,- per day. The entrance is in the “Rosenheimer Straße”.

STATIONS NEAR THE GASTEIG

The station at the Gasteig is called “Rosenheimer Platz” and you can use S-Bahn (express city train) line S1, S2, S4, S5, S6, S7 and S8. The U-Bahn (subway) line U8 will also stop at the Gasteig.

AIRPORT

All international and domestic flights arrive at airport Franz Josef Strauss which is located approximately 25 kilometres from the Gasteig and city centre. Taxi fares from the Gasteig to the airport are about EUR 50,-. There is also a S-Bahn (city express train), Line S1 or S8 which connects the city centre with the airport.

TAXIS

Taxis are located outside the main entrance of the Gasteig. You can order a taxi at any time at the following telephone numbers: +49-89 - 19410 or +49-89 - 21610.
**LEADERS OF EUROPEAN PSYCHIATRY**

6th Meeting of Leaders of European Psychiatry  
(A joint AEP-UEMS-WHO-WPA Initiative)

Saturday, 2 April 2005  
09.00 - 17.00 h  
Holiday Inn, Room 3

---

**AEP CME EVALUATION MEETING**

Saturday, 2 April 2005  
16.00 - 17.00 h  
Holiday Inn, Room 7

---

**SECTIONS COORDINATION MEETING**

Monday 4. April 2005  
12.00 - 13.00 h  
Gasteig, Stimmzimmer 1.212

---

**CORE ORGANIZING/SCIENTIFIC COMMITTEE MEETING**

Wednesday, 6 April 2005  
08.00 - 10.00 h  
Gasteig, Stimmzimmer 1.213

---

**AEP BOARD MEETING**

Wednesday, 6 April 2005  
14.00 - 16.00 h  
Holiday Inn, Room 4

---

**AEP EXECUTIVE MEETING**

Wednesday, 6 April 2005  
16.00 - 18.00 h  
Holiday Inn, Room 4,

---

**POSTER OF THE DAY**

Three experts will evaluate all posters of the daily poster presentations from Sunday to Wednesday and vote for the most interesting posters. Three posters will be awarded at the beginning of the next days’ plenary lecture and on Wednesday during the Closing Ceremony as the posters of the day.

**Posters of 3 April 2005**
Announced at the Plenary Lecture  
Understanding the similarities and differences between schizophrenia and bipolar disorder  
4 April 2005, 10.30 – 11.15 h  
Gasteig, Philharmonie

**Posters of 4 April 2005**
Announced at the Plenary Lecture  
Dementia: Aetiopathogenesis and future perspectives in the treatment  
5 April 2005, 10.30 – 11.15 h  
Gasteig, Philharmonie

**Posters of 5 April 2005**
Announced at the Plenary Lecture  
Modern classification of affective disorders  
6 April 2005, 10.30 – 11.15 h  
Gasteig, Philharmonie

**Posters of 6 April 2005**
Announced at the Closing Ceremony  
6 April 2005, 12.00 – 13.00 h  
Gasteig, Philharmonie
PLENARY LECTURES

Each plenary lecture of 45 minutes will be given by leading psychiatrists and other mental health professionals and will cover major topics of the program.

SYMPOSIA

The symposia are organized and chaired by the proposer and have been accepted by an International Scientific Committee. These 90 minutes sessions focus on a specific topic in psychiatry, representing several point of views.

SECTION SYMPOSIA

These sessions have the same format as the symposia but are proposed by the AEP Sections.

WORKSHOPS

Workshops are 90 minutes sessions which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This session type provides substantial audience participation and should be highly interactive.

COURSES

These 180 minutes sessions present advanced material on a chosen topic. Courses are designed to emphasize learning experiences that actively involve participants and include an opportunity for informal exchange with the faculty. They are devoted to topics of practical relevance and given by distinguished experts. Courses are part of the educational program and will give an excellent opportunity for learning new facts and treatment procedures. Fees are charged separately for the courses.

DEBATES/PRO - AND CON - DEBATES

During the 90 minutes debates and pro- and con-debates actual controversial issues will be introduced and discussed. One moderator and two speakers will raise various opinions on different subjects. The debates present two opinions from a different point of view; pro- and con-debates are designed to discussion with a pro- and con speaker.

MEET-THE-EXPERT SESSIONS

These very interactive sessions will start on 11.15 h for 60 minutes each day. Cases will be discussed with the participants. Delegates should actively participate in these Meet-the-Expert sessions.

BREAKFAST MEETINGS

From the 3 April to the 5 April 2005 breakfast meetings of 45 minutes are organized by the Young Psychiatrists on state-of-the-art topics of clinical and academic psychiatry relevant to young psychiatrists and trainees.

ORAL PRESENTATIONS

Authors were invited to submit papers on their latest research findings. Oral presentations were selected based on the review of all abstract submissions. The 90 minutes sessions are grouped by tracks and are conducted by a selected chairperson and co-chairperson.

POSTERS/POSTER PRESENTATIONS

The poster exhibition will be located on the first and second floor of the Gasteig. The posters are arranged according to the poster sessions and are numbered within these sessions. The posters will be presented for the whole congress time. The poster exhibition times are:

3 – 5 April 2005 08.00 – 18.00 h
6 April 2005 08.00 – 13.00 h

To give the posters special attention, the Organizing Committee has arranged poster presentations. Up to 15 -25 posters have been grouped by tracks for the poster presentations. These poster presentations will be guided by chairpersons and are held on:

Sunday, 3 April 2005 till 11.15 - 12.15 h
Tuesday, 5 April 2005 11.15 - 12.15 h
18.00 - 19.30 h
and
Wednesday, 6 April 2005 11.15 - 12.15 h

LUNCHEON SYMPOSIA

Luncheon symposia are organized by the Industry in consultation with the Scientific Committee and presented at the lunch time from 12.30 h until 14.00 h from Sunday, 3 April 2005 till Tuesday, 5 April 2005.
HOW TO READ THE PROGRAM

The scientific program is structured by day and time. From the colour and the abbreviations you can easily identify the format of the session. Each session was assigned to one track by the scientific committee. After the program by day, the posters are listed separately. They are structured by group and will be presented at the indicated times. The Young Psychiatrist Program is outlined after the posters.
ORGAN CONCERT
exclusive for the 13th AEP Congress

Philharmonie at the Gasteig
Saturday, 2 April 2005, 16.30 – 17.30 h

Famous Pieces of Organ Music
played on The Grand Organ
of the Munich Philharmonic Concert Hall

Johann Sebastian Bach (1685–1750)
Concerto II in A minor, adaptation of
Vivaldi’s concerto for violin No. 13
(AMML)

Passacaglia in C minor, BWV 582
(AMML)

Partita on the chorale „Sei gegrüßet, Jesu gütig”, BWV 768
(H-JM)

Max Reger (1873 – 1916)
Fantasia on the chorale
„Ein feste Burg ist unser Gott”, op. 27
(AMML)

Organ:
Anna Maria Möller-Leimkühler
Hans-Jürgen Möller
OPENING CEREMONY

Carl-Orff Hall at the Gasteig

Saturday, 2 April 2005, 18.00 – 19.30 h

Moderation: Franziska Bronnen

Camille Saint-Saëns (1835-1921)
Septet for trumpet, 2 violins, viola, violoncello, double bass and piano in Es Major, op. 65
Préambule-Più allegro - Menuet

Welcome Addresses
Henning Saß, President of AEP, Congress President
Hans-Jürgen Möller, Chairman of the Scientific Program Committee
Manfred Ackenheil, Chairman of the Organizing Committee

Ceremonial Lecture: About Psychopathology and Fiction
Gerhard Köpf, Professor emeritus of Literature, Munich

Camille Saint-Saëns (1835-1921)
Septet for trumpet, 2 violins, viola, violoncello, double bass and piano in Es Major, op. 65
Andante - Gavotte et Final

Musicians:
Members of the Bavarian Orchestra of Physicians:
Hans-Hubert Gerards, trumpet
David Rehm, violin
Klaus Storck, violin
Martin Brennenstuhl, viola
Cornelius Schüle, violoncello
Thomas Sikezsdy, double bass
Rainer Rupprecht, piano

At the end of the Opening Ceremony the participants are invited to join the Welcome Reception in the foyers of the Gasteig. Typical Bavarian food and beverages are provided.
### Registration
- **From 7.30 - 18.00 h**

### Technical Exhibition
- **From 9.00 - 17.00 h**

### Day 1: Sunday, 3 April 2005

#### Gasteig Foyer
- **T-2**
  - **SS.01**
- **T-4**
  - **S.01**
- **T-3**
  - **S.02**
- **T-6**
  - **S.03**
- **T-7**
  - **S.04**
- **T-6 YP-BF.01**
  - **S.02**

#### Gasteig Philharmonie
- **T-2**
  - **L.01**
- **T-7**
  - **L.02**

#### Gasteig Carl-Otto
- **T-1**
  - **P.01**
- **T-2**
  - **P.02**
- **T-3**
  - **P.03**

#### Gasteig Black Box
- **T-4**
  - **S.08**
- **T-6**
  - **S.09**
- **T-2**
  - **S.10**

#### Gasteig Bibliothek
- **T-6**
  - **M.01**

#### Gasteig 0.131
- **T-4**
  - **L.01**
- **T-6**
  - **L.02**

#### Gasteig 0.131
- **P.01**
- **P.02**
- **P.03**

#### Gasteig Black Box
- **T-2**
  - **SS.03**
- **T-6**
  - **D**
- **T-2**
  - **S.08**
- **T-3**
  - **S.09**
- **T-4**
  - **S.10**
- **T-2**
  - **S.11**

#### Gasteig Bibliothek
- **T-6**
  - **S.05**
- **T-4**
  - **D**
- **T-2**
  - **S.14**
- **T-3**
  - **S.15**
- **T-0**
  - **S.16**
- **T-7**
  - **S.17**

#### Gasteig Bibliothek
- **T-2**
  - **P.04**
- **T-4**
  - **P.05**
- **T-6**
  - **P.06**

### Abbreviations for Tracks:
- **T-0** = Dementia
- **T-1** = Substance related disorders
- **T-2** = Psychotic disorders
- **T-3** = Affective disorders
- **T-4** = Anxiety-related and eating disorders
- **T-5** = Personality and behavioural disorders
- **T-6** = Interdisciplinary
- **T-7** = Social psychiatry

### Scientific Program
- **S-01** Treatment of anxiety disorders and obsessions compulsive disorder
- **S-02** Community based programs against depression and suicidality
- **S-03** New aspects in therapeutic drug monitoring
- **S-04** Results from most recent European studies on relatives burden
- **S-08** The impact of genetics on schizophrenia: First schizophrenia genes
- **S-09** What can we learn from naturalistic observational studies and medication
- **S-10** OCD dimension: From clinical psychopharmacology to psychopathology
- **S-11** Neurobiological and neurocognitive findings in persons at risk for psychosis
- **S-14** Polypharmacy in psychiatry
- **S-15** Progress in pharmacogenomics: Focus on treatment and adverse effects
- **S-16** Recent advances in the development of biomarkers in Alzheimer’s disease
- **S-17** Recent directions in cognitive and experimental research on delusions
- **SS-01** Treatment of anxiety disorders and obsessions compulsive disorder
- **SS-02** Community based programs against depression and suicidality
- **SS-03** New aspects in therapeutic drug monitoring
- **SS-04** Results from most recent European studies on relatives burden
- **SS-08** The impact of genetics on schizophrenia: First schizophrenia genes
- **SS-09** What can we learn from naturalistic observational studies and medication
- **SS-10** OCD dimension: From clinical psychopharmacology to psychopathology
- **SS-11** Neurobiological and neurocognitive findings in persons at risk for psychosis
- **SS-14** Polypharmacy in psychiatry
- **SS-15** Progress in pharmacogenomics: Focus on treatment and adverse effects
- **SS-16** Recent advances in the development of biomarkers in Alzheimer’s disease
- **SS-17** Recent directions in cognitive and experimental research on delusions
- **SS-01** Treatment of anxiety disorders and obsessions compulsive disorder
- **SS-02** Community based programs against depression and suicidality
- **SS-03** New aspects in therapeutic drug monitoring
- **SS-04** Results from most recent European studies on relatives burden
- **SS-05** Genes for schizophrenia: Susceptibility to what? Part II: insights from neuroimaging
- **SS-06** Genes for schizophrenia: Susceptibility to what? Part II: insights from neuroimaging
- **SS-07** Genes for schizophrenia: Susceptibility to what? Part II: insights from neuroimaging
- **SS-08** Genes for schizophrenia: Susceptibility to what? Part II: insights from neuroimaging
- **SS-09** Genes for schizophrenia: Susceptibility to what? Part II: insights from neuroimaging
- **SS-10** Genes for schizophrenia: Susceptibility to what? Part II: insights from neuroimaging
- **SS-11** Genes for schizophrenia: Susceptibility to what? Part II: insights from neuroimaging
- **SS-12** Genes for schizophrenia: Susceptibility to what? Part II: insights from neuroimaging
- **SS-13** Genes for schizophrenia: Susceptibility to what? Part II: insights from neuroimaging
- **SS-14** Genes for schizophrenia: Susceptibility to what? Part II: insights from neuroimaging
- **SS-15** Genes for schizophrenia: Susceptibility to what? Part II: insights from neuroimaging
- **SS-16** Genes for schizophrenia: Susceptibility to what? Part II: insights from neuroimaging
- **SS-17** Genes for schizophrenia: Susceptibility to what? Part II: insights from neuroimaging

### Abbreviations for Room Numbers:
- **Gasteig Gasteig**
- **Gasteig Gasteig**
- **Foyer Gasteig**
- **Carl-Orff Gasteig**
- **Philharmonie Gasteig**
- **Black Box Gasteig**
- **Bibliothek Gasteig**
- **YP Lounge Gasteig**
- **Holiday Inn Room 1**
- **YP Lounge Holiday Inn**
- **Room 1**

### Room Schedule
- **Room Time**
  - **08.00**
  - **08.30**
  - **09.00**
  - **09.30**
  - **10.00**
  - **10.30**
  - **11.00**
  - **11.30**
  - **12.00**
  - **12.30**
  - **13.00**
  - **13.30**
  - **14.00**
  - **14.30**
  - **15.00**
  - **15.30**
  - **16.00**
  - **16.30**
  - **17.00**
  - **17.30**
  - **18.00**
  - **18.30**
  - **19.00**
  - **19.30**

### SF-02
- **SF-03**
- **SF-04**
- **SF-08**
- **SF-09**
- **SF-10**
- **SF-11**
- **SF-14**
- **SF-15**
- **SF-16**
- **SF-17**
- **SF-01**
- **SF-02**
- **SF-03**
- **SF-04**
- **SF-05**
- **SF-06**
- **SF-07**
- **SF-08**
- **SF-09**
- **SF-10**
- **SF-11**
- **SF-12**
- **SF-13**
- **SF-14**
- **SF-15**
- **SF-16**
- **SF-17**

### Abbreviations for Tracks:
- **T-0** = Dementia
- **T-1** = Substance related disorders
- **T-2** = Psychotic disorders
- **T-3** = Affective disorders
- **T-4** = Anxiety-related and eating disorders
- **T-5** = Personality and behavioural disorders
- **T-6** = Interdisciplinary
- **T-7** = Social psychiatry
### SCIENTIFIC PROGRAM

**SUNDAY, 3 APRIL 2005**

<table>
<thead>
<tr>
<th>Time</th>
<th>Holiday Inn Room 2</th>
<th>Holiday Inn Room 3</th>
<th>Holiday Inn Room 4</th>
<th>Holiday Inn Room 5</th>
<th>Holiday Inn Room 6</th>
<th>Holiday Inn Room 7</th>
<th>Holiday Inn Room 8</th>
<th>Hilton Room Bialas</th>
<th>Hilton Room Grff</th>
<th>Hilton Room Studer</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>T-3 S-05</td>
<td>T-5 S-06</td>
<td>T-6 W-01</td>
<td>T-6 W-02</td>
<td>T-7 W-16</td>
<td>T-3 O-01</td>
<td>T-6 S-07</td>
<td>T-1 C-01</td>
<td>T-3 C-02</td>
<td>T-2 C-03</td>
<td>08.00</td>
</tr>
<tr>
<td>08.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>08.30</td>
</tr>
<tr>
<td>09.00</td>
<td>T-3 T-3</td>
<td>T-5 T-6</td>
<td>T-6 T-6</td>
<td>T-7 T-7</td>
<td>T-3 T-3</td>
<td>T-6 T-6</td>
<td>T-1 T-1</td>
<td>T-3 T-3</td>
<td>T-2 T-2</td>
<td></td>
<td>09.00</td>
</tr>
<tr>
<td>09.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>09.30</td>
</tr>
<tr>
<td>10.00</td>
<td>T-3 T-3</td>
<td>T-5 T-6</td>
<td>T-6 T-6</td>
<td>T-7 T-7</td>
<td>T-3 T-3</td>
<td>T-6 T-6</td>
<td>T-1 T-1</td>
<td>T-3 T-3</td>
<td>T-2 T-2</td>
<td></td>
<td>10.00</td>
</tr>
<tr>
<td>10.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10.30</td>
</tr>
<tr>
<td>11.00</td>
<td>T-3 T-3</td>
<td>T-5 T-6</td>
<td>T-6 T-6</td>
<td>T-7 T-7</td>
<td>T-3 T-3</td>
<td>T-6 T-6</td>
<td>T-1 T-1</td>
<td>T-3 T-3</td>
<td>T-2 T-2</td>
<td></td>
<td>11.00</td>
</tr>
<tr>
<td>11.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11.30</td>
</tr>
<tr>
<td>12.00</td>
<td>T-3 T-3</td>
<td>T-5 T-6</td>
<td>T-6 T-6</td>
<td>T-7 T-7</td>
<td>T-3 T-3</td>
<td>T-6 T-6</td>
<td>T-1 T-1</td>
<td>T-3 T-3</td>
<td>T-2 T-2</td>
<td></td>
<td>12.00</td>
</tr>
<tr>
<td>12.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12.30</td>
</tr>
<tr>
<td>13.00</td>
<td>T-3 T-3</td>
<td>T-5 T-6</td>
<td>T-6 T-6</td>
<td>T-7 T-7</td>
<td>T-3 T-3</td>
<td>T-6 T-6</td>
<td>T-1 T-1</td>
<td>T-3 T-3</td>
<td>T-2 T-2</td>
<td></td>
<td>13.00</td>
</tr>
<tr>
<td>13.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>13.30</td>
</tr>
<tr>
<td>14.00</td>
<td>T-3 T-3</td>
<td>T-5 T-6</td>
<td>T-6 T-6</td>
<td>T-7 T-7</td>
<td>T-3 T-3</td>
<td>T-6 T-6</td>
<td>T-1 T-1</td>
<td>T-3 T-3</td>
<td>T-2 T-2</td>
<td></td>
<td>14.00</td>
</tr>
<tr>
<td>14.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>14.30</td>
</tr>
<tr>
<td>15.00</td>
<td>T-3 T-3</td>
<td>T-5 T-6</td>
<td>T-6 T-6</td>
<td>T-7 T-7</td>
<td>T-3 T-3</td>
<td>T-6 T-6</td>
<td>T-1 T-1</td>
<td>T-3 T-3</td>
<td>T-2 T-2</td>
<td></td>
<td>15.00</td>
</tr>
<tr>
<td>15.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>15.30</td>
</tr>
<tr>
<td>16.00</td>
<td>T-3 T-3</td>
<td>T-5 T-6</td>
<td>T-6 T-6</td>
<td>T-7 T-7</td>
<td>T-3 T-3</td>
<td>T-6 T-6</td>
<td>T-1 T-1</td>
<td>T-3 T-3</td>
<td>T-2 T-2</td>
<td></td>
<td>16.00</td>
</tr>
<tr>
<td>16.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16.30</td>
</tr>
<tr>
<td>17.00</td>
<td>T-3 T-3</td>
<td>T-5 T-6</td>
<td>T-6 T-6</td>
<td>T-7 T-7</td>
<td>T-3 T-3</td>
<td>T-6 T-6</td>
<td>T-1 T-1</td>
<td>T-3 T-3</td>
<td>T-2 T-2</td>
<td></td>
<td>17.00</td>
</tr>
<tr>
<td>17.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17.30</td>
</tr>
<tr>
<td>18.00</td>
<td>T-3 T-3</td>
<td>T-5 T-6</td>
<td>T-6 T-6</td>
<td>T-7 T-7</td>
<td>T-3 T-3</td>
<td>T-6 T-6</td>
<td>T-1 T-1</td>
<td>T-3 T-3</td>
<td>T-2 T-2</td>
<td></td>
<td>18.00</td>
</tr>
<tr>
<td>18.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>18.30</td>
</tr>
<tr>
<td>19.00</td>
<td>T-3 T-3</td>
<td>T-5 T-6</td>
<td>T-6 T-6</td>
<td>T-7 T-7</td>
<td>T-3 T-3</td>
<td>T-6 T-6</td>
<td>T-1 T-1</td>
<td>T-3 T-3</td>
<td>T-2 T-2</td>
<td></td>
<td>19.00</td>
</tr>
<tr>
<td>19.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>19.30</td>
</tr>
</tbody>
</table>

**Abbreviations for Tracks:**

- **T-0** = Dementia
- **T-1** = Substance related disorders
- **T-2** = Psychotic disorders
- **T-3** = Affective disorders
- **T-4** = Anxiety-related and eating disorders
- **T-5** = Personality and behavioural disorders
- **T-6** = Interdisciplinary
- **T-7** = Social psychiatry
- **S-05** = Affective disorders: Traditional understanding and new approaches in psychiatry of Eastern Europe
- **S-06** = Cost-effective treatment of patients with borderline personality disorders
- **S-07** = Neuroplasticity in psychiatric diseases
- **S-12** = Stress, glucocorticoids and affective disorders: From bench to bedside
- **S-13** = Research on mental health sequelae of war and migration in the Balkans
- **S-18** = Trauma and posttraumatic disorders in psychiatric patients
- **S-19** = Update on treatment and prevention of eating disorders
- **S-20** = Evolutionary psychiatry
- **W-01** = Driving ability and psychiatric illness
- **W-02** = Outpatient commitment - Will it change (forensic) psychiatric treatment?
- **W-04** = Bridging the gap between evidence-based treatment and complementary and alternative medicine
- **W-05** = Prediction of treatment response in psychiatry: Integration of concepts
- **W-06** = Neuropsychological and neuroanatomical correlates of affective-cognitive interaction in major depression
- **W-07** = Cycloid psychoses
- **O-01** = Affective disorders I
- **O-02** = Personality and behavioural disorders
- **O-03** = Interdisciplinary
- **SS-04** = Recent development in psychotherapy - from schools to evidence based approaches
- **SS-06** = The interface between biological and social factors in borderline personality disorder
- **C-01** = Early recognition and early diagnosis of addiction
- **C-02** = Teaching general practitioners about depression
- **C-03** = How to develop a programme against stigma and discrimination because of schizophrenia
- **C-04** = Introduction to cognitive psychotherapy
- **C-05** = Liaison psychiatry: Identifying and treating psychiatric problems in a medical population
- **C-06** = Care and custody of children by mothers with psychiatric illness
### SCIENTIFIC PROGRAM

**MONDAY, 4 APRIL 2005**

#### Abbreviations for Tracks:
- **T-0** = Dementia
- **T-1** = Substance related disorders
- **T-2** = Psychotic disorders
- **T-3** = Affective disorders
- **T-4** = Anxiety-related and eating disorders
- **T-5** = Personality and behavioural disorders
- **T-6** = Interdisciplinary
- **T-7** = Social psychiatry

<table>
<thead>
<tr>
<th>Room</th>
<th>Time</th>
<th>Session</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gasteig Foyer</td>
<td>08.00 - 18.00 h</td>
<td>Registration from 08.00 - 18.00 h</td>
<td></td>
</tr>
<tr>
<td>Gasteig Philharmonie</td>
<td>08.30</td>
<td>T-3</td>
<td>S-21</td>
</tr>
<tr>
<td>Gasteig Carl-Crée</td>
<td>09.00</td>
<td>T-2</td>
<td>S-22</td>
</tr>
<tr>
<td>Gasteig Black Box</td>
<td>09.30</td>
<td>T-1</td>
<td>S-23</td>
</tr>
<tr>
<td>Gasteig Bibliothek</td>
<td>10.00</td>
<td>T-7</td>
<td>S-24</td>
</tr>
<tr>
<td>Gasteig 0.131</td>
<td>10.30</td>
<td>T-0</td>
<td>SS-07</td>
</tr>
<tr>
<td>Gasteig YP Lounge</td>
<td>11.00</td>
<td>T-6</td>
<td>YP-BF-02</td>
</tr>
<tr>
<td>Holiday Inn Room 1</td>
<td>11.30</td>
<td>T-2</td>
<td>SS-08</td>
</tr>
</tbody>
</table>

#### Registration from 08.00 - 18.00 h

- **Technical Exhibition from 09.00 - 17.00 h**

#### T-3 Sessions:
- **S-21** Anxiety and depression, first results of the DSM-5 steering group
- **S-22** Brain morphology in schizophrenia: New findings and perspectives
- **S-23** Psychopharmacology of opiate addiction
- **S-24** Adjusting to cultural differences for interventions in mental health care
- **S-29** AEP Presidential Symposium on ethical issues: Ethics in psychiatry
- **S-30** New challenges to the dichotomy schizophrenia versus affective disorder
- **S-31** Future of education in ethics in psychiatry: Evidence-based medicine (EBM)
- **S-32** Biological background and psychopathological targets of therapeutic approaches to eating disorders
- **S-33** Molecular foundations of schizophrenic psychoses
- **S-34** German depression research network: Results from randomised and intervention studies
- **S-35** Pharmacogenetics of antipsychotic treatment: Predicting clinical efficacy and side effects
- **S-36** Psychotherapy and pharmacotherapy of obsessive-compulsive disorder: New findings
- **S-37** Early recognition of psychoses
- **SS-07** The European Network on Old Age Psychiatry (EANOP)- Results and perspectives for nations and WHO
- **SS-08** Schizophrenia - Nature and narratives

#### T-2 Sessions:
- **T-2** S-21
- **T-2** S-22
- **T-2** S-23
- **T-2** S-24
- **T-2** SS-07
- **T-2** YP-BF-02
- **T-2** SS-08

#### T-1 Sessions:
- **T-1** S-29

#### T-6 Sessions:
- **T-6** M-02

#### T-0 Sessions:
- **T-0** LS-02
- **T-0** LS-03

#### T-3 Sessions:
- **T-3** LS-02
- **T-3** LS-03

#### T-4 Sessions:
- **T-4** SS-09

#### T-5 Sessions:
- **T-5** D-

#### T-7 Sessions:
- **T-7** S-36
- **T-7** D-

#### Additional Sessions:
- **M-01** Meet the experts: Forensic
- **P-07** The concept of schizophrenia is not useful anymore
- **P-08** Antidepressant myths and facts: Do the data reflect clinical reality?
- **P-09** Implication of serotonergic and melatonergic systems: New perspectives for the treatment of depression
- **P-10** Overcoming common barriers to treatment adherence in bipolar disorder
- **P-11** Anticonvulsants are fully sufficient for treatment of acute bipolar disorders
- **YP** Antipsychotics: Effectiveness beyond mere symptom control in schizophrenia patients
- **SS-09** Mood disorders and somatic syndromes
- **SS-10** Antidepressant myths and facts: Do the data reflect clinical reality?
### SCIENTIFIC PROGRAM
**MONDAY, 4 APRIL 2005**

<table>
<thead>
<tr>
<th>Room</th>
<th>Holiday Inn Room 2</th>
<th>Holiday Inn Room 3</th>
<th>Holiday Inn Room 4</th>
<th>Holiday Inn Room 5</th>
<th>Holiday Inn Room 6</th>
<th>Holiday Inn Room 7</th>
<th>Holiday Inn Room 8</th>
<th>Hilton Room Biales</th>
<th>Hilton Room Orff</th>
<th>Hilton Room Studer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.00</td>
<td>T-4 S-25</td>
<td>T-5 S-26</td>
<td>T-6 YP-S-01</td>
<td>T-7 W-08</td>
<td>T-2 S-27</td>
<td>T-3 O-04</td>
<td>T-4 S-28</td>
<td>T-6 C-07</td>
<td>T-6 C-08</td>
<td></td>
</tr>
<tr>
<td>08.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.30</td>
<td>T-4 S-25</td>
<td>T-5 S-26</td>
<td>T-6 YP-S-01</td>
<td>T-7 W-08</td>
<td>T-2 S-27</td>
<td>T-3 O-04</td>
<td>T-4 S-28</td>
<td>T-6 C-07</td>
<td>T-6 C-08</td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations for Tracks:**
- **T-0** = Dementia
- **T-1** = Substance related disorders
- **T-2** = Psychotic disorders
- **T-3** = Affective disorders
- **T-4** = Anxiety-related and eating disorders
- **T-5** = Personality and behavioural disorders
- **T-6** = Interdisciplinary
- **T-7** = Social psychiatry

**S-25** Future perspectives in the treatment of anxiety: Targeting the GABA system
- **S-26** Neurobiological, genetic and developmental aspects of personality
- **S-27** Catatonia - a neuropsychiatric syndrome across psychiatric diagnosis
- **S-28** Psychopathological consequences of the 11M terrorists attacks
- **S-34** Neuropsychological aspects of suicidal behaviour
- **S-35** Psychosocial aspects of depressive disorders in ethnic minority groups
- **S-40** Pathological cruelty against animals and people: Contributions from Russia and the USA
- **S-41** The Addictions: Young Researchers Symposium
- **S-42** Affectivity - interactions with psychiatric and psychosomatic disorders

**W-08** Semiotic between neuro-myths and social romanticism - Part I Semiotics and neuro-sciences
- **W-09** Schizophrenia, schizoaffective disorder and the cortex: Molecular and functional neuroimaging studies
- **W-10** Ligand-gated ion channels as targets for psychotropic drugs
- **W-11** New forms of cooperation between mental health care professionals and users of services
- **W-12** Mental health in Eastern Europe and the Balkans

**O-04** Affective disorders II
- **O-05** Dementia/Gerontopsychotry
- **O-06** PTSD and somatoform disorders
- **S-11** Psychodynamic in postpartum
- **C-07** Therapeutic drug monitoring of psychotropic drugs and pharmacogenetic tests in psychiatry
- **C-08** Prevention of suicide
- **C-09** Cognitive behaviour therapy in anxiety disorders
- **C-10** ADHD through the life span
- **C-11** Psychoeducation and risk management strategies with borderline personality disorder patients

**YP**
- **S-01** New challenges for young psychiatrists in Europe
- **W-01** European and International networks of young psychiatrists and trainees
### SCIENTIFIC PROGRAM

**TUESDAY, 5 APRIL 2005**

#### ROOMS

<table>
<thead>
<tr>
<th>Room</th>
<th>Time</th>
<th>Gasteig Foyer</th>
<th>Gasteig Philharmonie</th>
<th>Gasteig Carl Orff</th>
<th>Gasteig Black Box</th>
<th>Gasteig Bibliothek</th>
<th>Gasteig 0.131</th>
<th>Gasteig YP Lounge</th>
<th>Holiday Inn Room 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Abbreviations for Tracks:

- **T-0** = Dementia
- **T-1** = Substance related disorders
- **T-2** = Psychotic disorders
- **T-3** = Affective disorders
- **T-4** = Anxiety-related and eating disorders
- **T-5** = Personality and behavioural disorders
- **T-6** = Interdisciplinary
- **T-7** = Social psychiatry

---

| S-43 | German schizophrenia research network: Results from clinical follow-up and intervention studies |
| S-44 | Sleep, depression and antidepressants |
| S-45 | Genetic analysis of treatment-relevant phenotypes in alcohol dependence |
| S-46 | Neurophysiological indicators of vulnerability to schizophrenia - endophenotypes of the disease |
| S-51 | Treatment of first episode schizophrenia |
| S-52 | Can we improve treatment for depression in the medically ill? |
| S-53 | Sleep depression: Neuropsychological basis and therapeutic aspects |
| S-54 | Dissociation across the trauma spectrum - neuropsychology and treatment issues |
| S-55 | Endophenotypes for molecular genetic studies in schizophrenia |
| S-56 | Placebo-controlled studies for the research of new antidepressant drugs: Necessary, ethical and feasible? |
| S-57 | Difficult to treat addicted patients |
| S-58 | The European Prediction of Psychosis Study (EPOS) - First follow-up results |
| S-59 | Physical illness in mentally disordered |
| S-60 | Cognitive endophenotypes and pharmacological treatment of schizophrenia |
| S-61 | Biological rhythm in psychiatry |
| L-03 | Dementia: Aetopathogenesis and future perspectives in the treatment of Alzheimer’s disease |
| S-04 | Meet the experts: Alzheimer’s disease |
| LS-05 | The promise of atypical antipsychotics: Fewer side effects mean enhanced compliance and improved functioning |
| D-03 | The results of meta-analysis give the highest level of evidence |
| D-04 | Behaviour is mostly genetically determined |
| BF-03 | Breakfast Meeting: Session on clinically relevant psychiatric syndromes |
| M-02 | Meet the experts: Meet-the-Expert Session |
| P-12 | Affective disorders II |
| P-13 | PSYD and eating disorders |
| P-14 | Psychotic disorders IV |
| P-15 | Affective disorders IV |
| P-16 | Personality and behavioural disorders |
**SCIENTIFIC PROGRAM**

**TUESDAY, 5 APRIL 2005**

<table>
<thead>
<tr>
<th>Room</th>
<th>Time</th>
<th>Holiday Inn Room 2</th>
<th>Holiday Inn Room 3</th>
<th>Holiday Inn Room 4</th>
<th>Holiday Inn Room 5</th>
<th>Holiday Inn Room 6</th>
<th>Holiday Inn Room 7</th>
<th>Holiday Inn Room 8</th>
<th>Hilton Room Rades</th>
<th>Hilton Room Orff</th>
<th>Hilton Room Studier</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>08.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>08.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>09.00</td>
<td>T-3 S-47</td>
<td>T-5 S-48</td>
<td>W-13 T-6 W-14</td>
<td>T-5 S-49</td>
<td>T-2 O-07</td>
<td>T-4 S-50</td>
<td>T-2 C-12</td>
<td>T-7 C-13</td>
<td>T-6 C-14</td>
<td></td>
</tr>
<tr>
<td></td>
<td>09.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>11.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>11.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>17.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>17.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>19.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>19.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations for Tracks:**

- **T-0** = Dementia
- **T-1** = Substance related disorders
- **T-2** = Psychotic disorders
- **T-3** = Affective disorders
- **T-4** = Anxiety-related and eating disorders
- **T-5** = Personality and behavioural disorders
- **T-6** = Interdisciplinary
- **T-7** = Social psychiatry
- **S-47** = Relationship between dose and response in trials of antidepressants
- **S-48** = Social brain and psychopathology
- **S-49** = ADHD, autism and personality disorders: Cookbook diagnosis?
- **S-50** = Resolving the heterogeneity of obsessive-compulsive disorder
- **S-56** = Added value? European multi-centre service studies
- **S-57** = The many facets of stalking
- **S-61** = Overlapping of schizophrenic and affective spectra
- **S-62** = Trauma- and stress-related disorders: New research findings
- **S-63** = Future directions of mental health care
- **S-64** = It’s the people, stupid: Taking care of the mental health workforce
- **W-13** = AEP Human Rights Workshop (Under the Auspices of The Secretary General of the Council of Europe)
- **W-14** = COX-2 inhibitors in the therapy of psychiatric disorders
- **W-15** = Comorbidity in bipolar disorders
- **W-17** = Addictive behaviours across the lifespan of a doctor
- **W-18** = Rate of psychotropic drugs at the blood-brain-barrier and in the brain: Pharmacokinetic, pharmacodynamic and clinical consequences
- **W-03** = Care competences for the psychiatrist of the future - a comparison bet.....
- **O-07** = Psychotic disorders I
- **D-08** = Psychotic disorders II
- **D-09** = Substance-related disorders
- **SS-14** = Emotional neuroscience in psychiatry (under auspices of AEP neuroimaging section)
- **C-12** = Cognitive dysfunction in schizophrenia - brief clinical assessments and treatment strategies
- **C-13** = Principles of psychiatric interview how to examine and assess personal experiences
- **C-14** = Interpersonal treatment in psychiatry
- **C-15** = Alcohal dependence
- **C-16** = Masterclass on “patient-level needs assessment”
- **C-17** = Interpersonal psychotherapy of depression
## SCIENTIFIC PROGRAM

**WEDNESDAY, 6 APRIL 2005**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Gasteig Foyer</th>
<th>Gasteig Philharmonie</th>
<th>Gasteig Carl-Ottf</th>
<th>Gasteig Black Box</th>
<th>Gasteig Bibliothek</th>
<th>Gasteig 0.131</th>
<th>Gasteig YP Lounge</th>
<th>Holiday Inn Room 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00</td>
<td></td>
<td>T-2</td>
<td>S-65</td>
<td>S-66</td>
<td>T-0</td>
<td>SS-17</td>
<td>T-2</td>
<td>S-69</td>
<td></td>
</tr>
<tr>
<td>09.30</td>
<td></td>
<td>T-3</td>
<td>S-67</td>
<td>S-68</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td></td>
<td>T-5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30</td>
<td></td>
<td>T-0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td></td>
<td>T-3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td></td>
<td>T-0</td>
<td>T-2</td>
<td>L-05</td>
<td></td>
<td></td>
<td>T-6</td>
<td>M-04</td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td></td>
<td>P-17</td>
<td>P-18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00</td>
<td></td>
<td>Closing Ceremony</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Abbreviations for Tracks:
- **T-0** = Dementia
- **T-1** = Substance related disorders
- **T-2** = Psychotic disorders
- **T-3** = Affective disorders
- **T-4** = Anxiety-related and eating disorders
- **T-5** = Personality and behavioural disorders
- **T-6** = Interdisciplinary
- **T-7** = Social psychiatry

### Schedule:
- **S-65** New challenges to the dichotomy schizophrenia versus affective disorder
- **S-66** Bipolar disorder – Differential diagnosis as basis for differential treatment
- **S-67** Influence of neurobiological factors on the course of depressive disorders
- **S-68** IMRI of emotion and cognition
- **S-69** Imaging genomics in psychiatric research
- **SS-17** Specialised geriatric inpatient wards: Benefits and disadvantage
- **L-05** Modern classification of affective disorders
- **M-04** Meet the experts: Sleep and its disorders
- **P-17** Dementia and Child psychiatry
- **P-18** Psychotic disorders IV
### Scientific Program

**Wednesday, 6 April 2005**

<table>
<thead>
<tr>
<th>Room</th>
<th>Holiday Inn Room 2</th>
<th>Holiday Inn Room 3</th>
<th>Holiday Inn Room 4</th>
<th>Holiday Inn Room 5</th>
<th>Holiday Inn Room 6</th>
<th>Holiday Inn Room 7</th>
<th>Holiday Inn Room 8</th>
<th>Hilton Room Bialas</th>
<th>Hilton Room Orff</th>
<th>Hilton Room Studer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time</td>
<td>08.00</td>
<td>08.30</td>
<td>09.00</td>
<td>09.30</td>
<td>10.00</td>
<td>10.30</td>
<td>11.00</td>
<td>11.30</td>
<td>12.00</td>
<td>12.30</td>
</tr>
<tr>
<td><strong>T-4</strong></td>
<td>S-70</td>
<td>T-7</td>
<td>T-7</td>
<td>T-6</td>
<td>T-7</td>
<td>T-4</td>
<td>O-10</td>
<td>T-6</td>
<td>T-2</td>
<td>T-5</td>
</tr>
<tr>
<td><strong>T-7</strong></td>
<td>S-71</td>
<td>W-20</td>
<td>W-21</td>
<td>W-22</td>
<td>O-10</td>
<td>C-18</td>
<td>C-19</td>
<td>C-20</td>
<td>C-17</td>
<td></td>
</tr>
<tr>
<td><strong>T-6</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>O-10</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations for Tracks:**

- **T-0** = Dementia
- **T-1** = Substance related disorders
- **T-2** = Psychotic disorders
- **T-3** = Affective disorders
- **T-4** = Anxiety-related and eating disorders
- **T-5** = Personality and behavioural disorders
- **T-6** = Interdisciplinary
- **T-7** = Social psychiatry

**Tracks:***

- **S-70** = Posttraumatic stress disorders and quality of life after intensive care
- **S-71** = The QUATRO study - an European randomised controlled trial of compliance therapy
- **W-20** = Future directions of soteria-concepts in the treatment of acute psychosis
- **W-21** = Psychotropic drugs in pregnancy and lactation
- **W-22** = Semiotic between neuro-myths and social romanticism - Part II Semiotics and social psychiatry
- **O-10** = Anxiety-related and eating disorders
- **C-18** = How to write and publish a scientific paper (editor in chief Acta Psychiatrica Scandinavica)
- **C-13** = Principles of psychiatric interview how to examine and assess personal experiences
- **C-14** = Internet-based treatment in psychiatry
- **C-15** = Alcohol dependence
- **C-16** = Masterclass on “patient-level needs assessment”
- **C-17** = Interpersonal psychotherapy of depression
SCIENTIFIC PROGRAM
SUNDAY, 3 APRIL 2005

SYMPOSIUM S-02
08.30 - 10.00 h  Gasteig - Black Box
Track T-3 Affective disorders
Community based programs against depression and suicidality
Chairperson: Ulrich Hegerl, Munich, Germany
Co-Chairperson: Frederic Rouillon, Creteil, France

S-02-01  Title unknown
F. Rouillon, Creteil, France

S-02-02  Alcohol policy as a part of suicide prevention
A. Värnik, Tallin, Estonia

S-02-03  Depression and suicidality
J. Lönnqvist, Helsinki, Finland

S-02-04  The Nuremberg alliance against depression: Effects on suicidality
D. Althaus, Munich, Germany
G. Niklewski, A. Schmidtke, U. Hegerl

SYMPOSIUM S-05
08.30 - 10.00 h  Holiday Inn - Room 2
Track T-3 Affective disorders
Affective disorders: Traditional understanding and new approaches in psychiatry of Eastern Europe
Chairperson: Valery Krasnov, Moscow, Russia
Co-Chairperson: Roman A. Evsegeev, Minsk, Belarus

S-05-01  Borders of depression: Old and new problems of psychiatric diagnosis
V. Solojenkin, Bishkek, Kyrgyzistan
K. V. Solojenkina, T. A. Nelubova

S-05-02  The variety of depressive disorders in primary care: Case of Belarus
R. A. Evsegeev, Minsk, Belarus

S-05-03  Criteria of psychotic level of anxiety-depression syndrome
Y. Savenko, Moscow, Russia
L. N. Vinogradova

S-05-04  Transcultural specific features of affective disorders in the European North of Russia
A. B. Bogdanov, Archangelsk, Russia

S-05-05  Affective spectrum disorders: On the way to unitary concept
V. Krasnov, Moscow, Russia

SYMPOSIUM S-01
08.30 - 10.00 h  Gasteig - Carl-Orff Saal
Track T-4 Anxiety-related and eating disorders
Treatment of anxiety disorders and obsessive compulsive disorder: An update
Chairperson: Borwin Bandelow, Göttingen, Germany
Co-Chairperson: David Baldwin, Southampton, United Kingdom

S-01-01  Treatment of panic anxiety disorder: An update
B. Bandelow, Göttingen, Germany

S-01-02  Treatment of generalized disorder: An update
C. Faravelli, Firenze, Italy

S-01-03  Pharmacological treatment of social phobia: An update
D. Baldwin, Southampton, United Kingdom

S-01-04  Treatment of obsessive compulsive disorder: An update
N. Fineberg, Italy
T. M. Gale, T. Sivakumaran

SYMPOSIUM S-06
08.30 - 10.00 h  Holiday Inn - Room 3
Track T-5 Personality and behavioural disorders
Cost-effective treatment of patients with borderline personality disorder and suicidal attempt
Chairperson: Antonio Andreoli, Geneva, Switzerland
Co-Chairperson: R. Barbe, Pittsburgh, USA

S-06-01  Severe personality disorders: How organize the clinical framework for community mental health centers
M. Bassi, Bologna, Italy

S-06-02  Borderline personality disorder and suicidal attempt: A 3 year follow-up
Y. Burnand, Geneva, Switzerland
D. Maire, R. Pirrotta, C. Damsa

S-06-03  Effective ingredients of psychiatric treatment for borderline patients with suicidal attempt
A. Andreoli, Geneva, Switzerland
D. Maire, V. D Agostino
SYMPOSIUM S-52

08.30 - 10.00 h Gasteig - Bibliothek
Track T-3 Affective disorders
Can we improve treatment for depression in the medically ill?
Chairperson: Francis Creed, Manchester, United Kingdom
Co-Chairperson: Volker Arolt, Münster, Germany

S-52-01 Designing trials for the treatment of depression in the medically ill
F. Creed, Manchester, United Kingdom

S-52-02 The importance of early intervention in depression in the medically ill
V. Arolt, Münster, Germany
B. T. Baune

S-52-03 Major depression in the general hospital: Critical appraisal of different strategies to improve its treatment at the University Hospital of Lausanne
A. Berney, Lausanne, Switzerland
L. Michaud, R. Voellinger, B. Burnand, F. Stiefel

SYMPOSIUM S-04

08.30 - 10.00 h Gasteig - Room 0.131
Track T-7 Social Psychiatry
Results from most recent European studies on relatives’ burden
Chairperson: Thomas Kallert, Dresden, Germany
Co-Chairperson: Lorenza Magliano, Naples, Italy

S-04-01 Cultural differences of psychosocial burden and attitudes to disorders of relatives of chronically mentally ill persons: Methodological problems of assessment
T. Kallert, Dresden, Germany
I. Nitsche, M. Schützwohl, M. Gloeckner, L. Magliano

S-04-02 Psychosocial burden and attitudes to disorders of relatives of chronically mentally ill persons – A comparison between schizophrenic and affective disorders
I. Nitsche, Dresden, Germany

SECTION SYMPOSIUM SS-01

08.30 - 10.00 h Gasteig - Philharmonie
Track T-2 Psychotic disorders
Genes for schizophrenia: Susceptibility to what? Part I: Insights from gene-environment interactions
Chairperson: Machteld C. Marcelis, Maastricht, Netherlands
Co-Chairperson: Robin Murray, London, United Kingdom

SS-01-01 The impact of childhood trauma on co-morbid symptoms in first episode psychosis
M. Birchwood, Birmingham, United Kingdom

SS-01-02 title unknown
R. Murray, London, United Kingdom

SS-01-03 Genes that make you feel blue in the flow of daily life: A momentary assessment study of gene-stress interaction
N. Jacobs, Maastricht, Netherlands

SS-01-04 Abnormal response to metabolic stress in schizophrenia: Marker of vulnerability or acquired sensitisation?
M. C. Marcelis, Maastricht, Netherlands
E. Cavalier, J. Gielen, P. Delespaul, J. van Os
SECTION SYMPOSIUM  SS-02

08.30 - 10.00 h  Holiday Inn - Room 1
Track T-2 Psychotic disorders
New developments in functional and structural neuroimaging in schizophrenia
Chairperson: Tilo Kircher, Aachen, Germany
Co-Chairperson: Philip McGuire, London, United Kingdom

SS-02-01 Neural networks involved in hallucinations: Integrating structure and function
T. Dierks, Bern, Switzerland
D. Hubl, R. Kreis, K. Lövblad, W. Strik

SS-02-02 Brain folding in schizophrenia
J. L. Martinot, Orsay, France
A. Cachia, T. Kircher

SS-02-03 Auditory hallucinations and the brain in schizophrenia
P. McGuire, London, United Kingdom

SS-02-04 Neural correlates of thought and language processes
T. Kircher, Aachen, Germany

WORKSHOP  W-01

08.30 - 10.00 h  Holiday Inn - Room 4
Track T-6 Interdisciplinary
Driving ability and psychiatric illness
Chairperson: Gerd Laux, Wasserburg, Germany
Co-Chairperson: Michael Soyka, Munich, Germany
Speaker: A. Brunnauer, Wasserburg, Germany
G. Laux, Wasserburg, Germany
M. Soyka, Munich, Germany
A. Schale, Welzheim, Germany
R. Mager, Basel, Switzerland

WORKSHOP  W-02

08.30 - 10.00 h  Holiday Inn - Room 5
Track T-6 Interdisciplinary
Outpatient commitment - Will it change (forensic) psychiatric treatment?
Chairperson: Norbert Nedopil, Munich, Germany
Co-Chairperson: Joris Casselman, Bierbeek, Belgium
Speaker: D. Sestoft, Frederiksberg, Denmark
R. Freese, Giessen, Germany
H. Gordon, Oxford, United Kingdom

WORKSHOP  W-16

08.30 - 10.00 h  Holiday Inn - Room 6
Track T-7 Social Psychiatry
Women’s careers in academic psychiatry
Chairperson: Anita Riecher-Rössler, Basel, Switzerland
Co-Chairperson: Michaela Amering, Vienna, Austria
Speaker: A. Riecher-Rössler, Basel, Switzerland
M. Amering, Vienna, Austria
J. Angst, Zurich, Switzerland
M. L. Figueira, Lisbon, Portugal

EDUCATIONAL COURSE  C-01

08.30 - 12.00 h  Hilton - Salon Bialas
Track T-1 Substance related disorders
Early recognition and early diagnostics of addiction
Organizer: Michael Musalek, Vienna, Austria

EDUCATIONAL COURSE  C-03

08.30 - 12.00 h  Hilton - Salon Studer
Track T-2 Psychotic disorders
How to develop a programme against stigma and discrimination because of schizophrenia
Organizer: Norman Sartorius, Geneva, Switzerland
Speaker: N. Sartorius, Geneva, Switzerland
J. Arboleda-Florez, Kingston, Canada
H. Stuart, Kingston, Canada
SCIENTIFIC PROGRAM
SUNDAY, 3 APRIL 2005

EDUCATIONAL COURSE  C-02
08.30 - 12.00 h  Hilton - Salon Orff
Track T-3 Affective disorders
Teaching general practitioners about depression
Organizer: John Cooper, Nottingham, United Kingdom
Speaker: L. Gask, Manchester, United Kingdom

ORAL PRESENTATION  O-01
08.30 - 10.00 h  Holiday Inn - Room 7
Track T-3 Affective disorders
Affective disorders I
Chairperson: Marianne Kastrup, Copenhagen, Denmark
Co-Chairperson: Janusz Rybakowski, Poznan, Poland
O-01-01 Immediate switching of antidepressant therapy: Results from a clinical trial of duloxetine
M. Wohlreich, Indianapolis, USA
C. Mallinckrodt, J. Greist, P. Delgado, L. Driver, J. Watkin, M. Fava
O-01-02 Remission during treatment of first vs multiple episode of depression - results of Polish naturalistic study
J. Rybakowski, Poznan, Poland
D. Nawacka, A. Kiejna
O-01-03 Obtaining complete remission of depression: Geneva outpatients depression study
G. Bondolfi, Geneva, Switzerland
N. Gervasoni, M. Gex-Fabry, J.-M. Aubry, G. Bertschy
O-01-04 Speed-accuracy tradeoff in depression and antidepressant treatment
R. Kalb, Erlangen, Germany
M. Dörner
O-01-05 Cognitive function in unipolar depression during the depressive episode and after recovery
E. Biringer, Bergen, Norway
A. Lundervold, K. Stordal, A. Mykletun, J. Egeland, R. Bottlender, A. Lund

YP-BREAKFAST MEETING  YP-BF-01
08.45 - 09.30 h  Gasteig - Young Psych. Lounge
Track T-6 Interdisciplinary
How to write scientific papers
Chairperson: T. Schulze, Germany
Speaker: P. Munk Jorgensen, Aalborg, Denmark
PLENARY LECTURE  L-01
10.30 - 11.15 h  Gasteig - Philharmonie
Track T-2 Psychotic disorders
Understanding the similarities and differences between schizophrenia and bipolar disorder
Chairperson: Mario Maj, Naples, Italy
Speaker: R. Murray, London, United Kingdom

PLENARY LECTURE  L-02
10.30 - 11.15 h  Gasteig - Carl-Orff Saal
Track T-7 Social Psychiatry
Has a human being an own free will?
Chairperson: Henning Sass, Aachen, Germany
Speaker: W. Singer, Frankfurt, Germany

MEET-THE-EXPERT SESSION  M-01
11.15 - 12.15 h  Gasteig - Black Box
Track T-6 Interdisciplinary
Meet the experts: ADHD
Speaker: J. Krause, Ottobrunn, Germany

POSTER PRESENTATION  P-01
11.15 - 12.15 h  Gasteig - Foyers
Track T-1 Substance related disorders
Substance-related disorders I
Chairperson: Karl Mann, Mannheim, Germany
Co-Chairperson: Ulrich Preuss, Greifswald, Germany

POSTER PRESENTATION  P-02
11.15 - 12.15 h  Gasteig - Foyers
Track T-2 Psychotic disorders
Psychotic disorders II
Chairperson: Cyril Höschl, Prague, Czech Republic
Co-Chairperson: Kenneth Kaufman, New Brunswick, USA

POSTER PRESENTATION  P-03
11.15 - 12.15 h  Gasteig - Foyers
Track T-3 Affective disorders
Affective disorders I
Chairperson: Patrice Boyer, Ottawa, Canada
Co-Chairperson: K.N. Fountoulakis, Aretsou, Greece

LUNCHEON SYMPOSIUM  LS-01
12.30 - 14.00 h  Gasteig - Carl-Orff Saal
Track T-6 Interdisciplinary
Bridging the gap between schizophrenia and mood disorders
Chairperson: Hans-Jürgen Möller, Munich, Germany
LS-01-01 Biological basis of schizophrenia, bipolar disorder and mood disorder
A. Weizman, Petah Tiqva, Israel
LS-01-02 Clinical overlaps in schizophrenia, bipolar disorder and mood disorders
R. Tandon, USA
LS-01-03 Advancing the treatment of psychiatric disorders
W. Fleischhacker, Innsbruck, Austria
Supported by an unrestricted educational grant from Pfizer Inc.

SYMPOSIUM  S-08
14.15 - 15.45 h  Gasteig - Black Box
Track T-2 Psychotic disorders
The impact of genetics on schizophrenia: First schizophrenia genes
Chairperson: Dan Rujescu, Munich, Germany
Co-Chairperson: Wolfgang Maier, Bonn, Germany
S-08-01 Functional candidate genes in schizophrenia: Findings from animal models
D. Rujescu, Munich, Germany
A. Bender, M. Keck, A. M. Hartmann, F. Ohl, H. Raeder, I. Giegling, J. Genius, R. Greene, H.-J. Möller, H. Grunze
S-08-02 Genetic association studies in schizophrenia
M. Gennarelli, Brescia, Italy
S-08-03  Linkage studies in schizophrenia: New findings promise new insights  
M. Owen, Cardiff, United Kingdom

S-08-04  The impact of first schizophrenia genes: Focus on dysbindin  
W. Maier, Bonn, Germany

S-11-01  MRI findings in persons at risk for psychosis  
S. Ruhrmann, Cologne, Germany  
R. Tepest, P. Falkai, F. Schultze-Lutter,  
J. Klosterkötter, K. Vogeley, EPOS Group

S-11-02  Title unknown  
P. M. Dingemans, Amsterdam, Netherlands  
D. Linszen, M. Birchwood

S-11-03  ERP findings and antisaccades in the initial prodromal state  
A. Brockhaus-Dumke, Cologne, Germany  
F. Schultze-Lutter, R. Pukrop,  
J. Klosterkötter, S. Ruhrmann

S-11-04  Biology of psychosis vulnerability - positron emission tomography studies in first-degree relatives of patients with schizophrenia  
J. Hietala, Turku, Finland

S-11-05  MR-spectroscopy in prodromal and first-episode patients with schizophrenia  
G. Juckel, Berlin, Germany
### SYMPOSIUM S-12

**14.15 - 15.45 h**  
Holiday Inn - Room 2  
Track T-3 Affective disorders  
**Stress, glucocorticoids and affective disorders: From bench to bedside**

**Chairperson:** Peter Gass, Mannheim, Germany  
**Co-Chairperson:** Isabella Heuser, Berlin, Germany

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| S-12-01 | Stress system regulation, glucocorticoid receptors and traumatic early life events | M. Oitzl, Leiden, Netherlands  
E. Leo, D. K. Ron |
| S-12-02 | Glucocorticoid receptor transgenic mice as models of depression | P. Gass, Mannheim, Germany |
| S-12-03 | Genetic factors have an impact on cortisol and ACTH responses to psychosocial stress | S. Wüst, Trier, Germany  
| S-12-04 | Glucocorticoid-antagonists as a new strategy in hypercortisolemic depression | I. Heuser, Berlin, Germany |
| S-12-05 | Using cellular systems to understand glucocorticoid resistance in depression | C. Pariante, London, United Kingdom |

### SYMPOSIUM S-10

**14.15 - 15.45 h**  
Holiday Inn - Room 3  
Track T-4 Anxiety-related and eating disorders  
**OCD dimension: From clinical psychopharmacology to psychopathology**

**Chairperson:** Stefano Pallanti, Florence, Italy  
**Co-Chairperson:** Alessandro Rossi, L’Aquila, Italy

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-10-01</td>
<td>Neuroleptic augmentation in OCD: Clinic and neuroimaging of risperidone</td>
<td>S. Pallanti, Florence, Italy</td>
</tr>
<tr>
<td>S-10-02</td>
<td>Defining a role for antipsychotics in the treatment of obsessive compulsive disorder</td>
<td>N. Fineberg, Italy</td>
</tr>
<tr>
<td>S-10-03</td>
<td>The OCD disorder and its relationship with the schizotypal features: A clinical study with temperament and character inventory and schizotypal personality questionnaire</td>
<td>A. Rossi, L’Aquila, Italy</td>
</tr>
</tbody>
</table>
| S-10-04 | Antipsychotics in OCD | F. Bogetto, Turin, Italy  
G. Maina |
| S-10-05 | Immunological alterations in obsessive-compulsive disorder before and after pharmacological treatment | D. Marazziti, Pisa, Italy  
F. Mungai, L. Vivarelli, M. Catena, S. Baroni |

### SYMPOSIUM S-18

**14.15 - 15.45 h**  
Holiday Inn - Room 8  
Track T-4 Anxiety-related and eating disorders  
**Trauma and posttraumatic disorders in psychiatric patients**

**Chairperson:** Anne-Marie Pezous, Paris, France  
**Co-Chairperson:** Wim van den Brink, Amsterdam, Netherlands

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| S-18-01 | Childhood trauma in patients with psychotic disorders | I. Schäfer, Hamburg, Germany  
T. Harfst, P. Briken, V. Aderhold |
| S-18-02 | Influence of Trauma on Axis I Disorders among a population of Khmer Refugees | P. Auby, Paris, France  
L. Michel, A. Sebille, C. Netillard |
| S-18-03 | Title unknown | A.-M. Pezous, Paris, France |
| S-18-04 | Trauma, PTSD and dissociation in alcohol dependent patients | W. Langeland en Gertjan Dijkstra, Amsterdam, Netherlands |
| S-18-05 | Trauma therapeutic approach through associative process: “Algerian Experience” | B. Chawki, Tebessa, Algeria |
30

SCIENTIFIC PROGRAM  
SUNDAY, 3 APRIL 2005

SYMPOSIUM  S-13

14.15 - 15.45 h  Holiday Inn - Room 6  
Track T-7 Social Psychiatry  
Research on mental health sequelae of war and migration in the Balkans  
Chairperson: Stefan Priebe, London, United Kingdom  
Co-Chairperson: Dusica Lecic-Tosevski, Belgrad, Serbia + Montenegro

S-13-01  Barriers to treatment for people suffering from posttraumatic stress: Quantitative and qualitative findings  
J. Jankovic Gavrilovic, London, United Kingdom  
M. Schuetzwohl, A. Matanov, M. Bogic, S. Priebe

S-13-02  A new instrument to assess health care and social interventions for patients with posttraumatic stress  
G. M. Galeazzi, Sassuolo, Italy  

S-13-03  Assessment for long-term outcomes following potentially traumatic events - the CONNECT study  
S. Priebe, London, United Kingdom  
D. Lecic-Tosevski, T. Franciskovic, M. Schützwohl, D. Ajdukovic, M. Popovski, G. M. Galeazzi, M. Bogic, A. Kucukalic

S-13-04  Outcomes of specialised treatments for posttraumatic stress in specialised centres in three Balkans countries  
T. Franciskovic, Rijeka, Croatia

S-13-05  Characteristics of non-treatment seekers with posttraumatic stress: Differences between groups in former Yugoslavia and refugees in Western Europe  
M. Schützwohl, Dresden, Germany

SECTION SYMPOSIUM  SS-03

14.15 - 15.45 h  Gasteig - Philharmonie  
Track T-1 Substance related disorders  
Neuroimaging in addiction research  
Chairperson: Andreas Heinz, Berlin, Germany  
Co-Chairperson: Sophia Frangou, London, United Kingdom

SS-03-01  Structural neuroimaging and neuropsychological impairment in alcohol dependence  
L. Reed, London, United Kingdom

SS-03-02  Severity of nicotine dependence modulates cue-induced brain activity in regions involved in motor preparation and imagery  
M. Smolka, Mannheim, Germany

SS-03-03  Title unknown  
A. Lingford-Hughes, Bristol, United Kingdom

SS-03-04  Neuroimaging and addiction  
I. Crome, Harpfields, Stoke-on-Trent, United Kingdom  
C. Newman, M. Frisher

SS-03-05  Cue-induced craving in alcohol dependent patients: Modality specific fMRI of therapeutic intervention  
F. Schneider, Aachen, Germany  
W. Wölwer, V. Backes, K. Zilles, N. J. Shah

WORKSHOP  W-04

14.15 - 15.45 h  Holiday Inn - Room 4  
Track T-6 Interdisciplinary  
Bridging the gap between evidence-based treatment and complementary and alternative medicine  
Chairperson: Christoph Lauber, Zurich, Switzerland  
Co-Chairperson: Wulf Rössler, Zurich, Switzerland

Speaker: W. Fleischhacker, Innsbruck, Austria  
W. Rössler, Zurich, Switzerland  
H.-J. Assion, Bochum, Germany

WORKSHOP  W-05

14.15 - 15.45 h  Holiday Inn - Room 5  
Track T-6 Interdisciplinary  
Prediction of treatment response in psychiatry: Integration of concepts and methods  
Chairperson: Oliver Pogarell, Munich, Germany  
Co-Chairperson: Silvana Galderisi, Napoli, Italy

Speaker: T. Dierks, Bern, Switzerland  
O. Pogarell, Munich, Germany  
C. Mulert, Munich, Germany  
S. Galderisi, Napoli, Italy  
U. Hegerl, Munich, Germany
### SCIENTIFIC PROGRAM

**SUNDAY, 3 APRIL 2005**

<table>
<thead>
<tr>
<th><strong>EDUCATIONAL COURSE</strong></th>
<th><strong>C-04</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14.15 - 17.45 h</strong></td>
<td>Hilton - Salon Bialas</td>
</tr>
<tr>
<td><strong>Track T-3</strong></td>
<td>Affective disorders</td>
</tr>
<tr>
<td><strong>Introduction to cognitive psychotherapy</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Organizer:</strong></td>
<td>S. Moorey, London, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>EDUCATIONAL COURSE</strong></th>
<th><strong>C-05</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14.15 - 17.45 h</strong></td>
<td>Hilton - Salon Orff</td>
</tr>
<tr>
<td><strong>Track T-7</strong></td>
<td>Social Psychiatry</td>
</tr>
<tr>
<td><strong>Liaison psychiatry: Identifying and treating psychiatric problems in a medical population</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Organizer:</strong></td>
<td>F. Creed, Manchester, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>EDUCATIONAL COURSE</strong></th>
<th><strong>C-06</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14.15 - 17.45 h</strong></td>
<td>Hilton - Salon Studer</td>
</tr>
<tr>
<td><strong>Track T-7</strong></td>
<td>Social Psychiatry</td>
</tr>
<tr>
<td><strong>Care and custody of children by mothers with psychiatric illness</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Organizer:</strong></td>
<td>I. Brockington, Hereforeshire, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>DEBATE</strong></th>
<th><strong>D-01</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14.15 - 17.45 h</strong></td>
<td>Gasteig - Carl-Orff-Hall</td>
</tr>
<tr>
<td><strong>Track T-6</strong></td>
<td>Interdisciplinary</td>
</tr>
<tr>
<td><strong>Monotherapy vs. Polytherapy</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chairperson:</strong></td>
<td>Julio Bobes, Oviedo, Spain</td>
</tr>
<tr>
<td><strong>From a psychiatric view</strong></td>
<td>S. Kaspar, Vienna, Austria</td>
</tr>
<tr>
<td><strong>From a pharmacological view</strong></td>
<td>W. Müller, Frankfurt, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>YP-MEET-THE-EXPERT SESSION</strong></th>
<th><strong>YP-M-01</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14.15 - 15.15 h</strong></td>
<td>Gasteig - Young Psych. Lounge</td>
</tr>
<tr>
<td><strong>Track T-6</strong></td>
<td>Interdisciplinary</td>
</tr>
<tr>
<td><strong>Meet-the-Expert</strong></td>
<td>N. Satorius, Geneva, Switzerland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>ORAL PRESENTATION</strong></th>
<th><strong>O-02</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14.15 - 15.45 h</strong></td>
<td>Holiday Inn - Room 7</td>
</tr>
<tr>
<td><strong>Track T-5</strong></td>
<td>Personality and behavioural disorders</td>
</tr>
<tr>
<td><strong>Personality and behavioural disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chairperson:</strong></td>
<td>Paul Cosyns, Edegem, Belgium</td>
</tr>
<tr>
<td><strong>Co-Chairperson:</strong></td>
<td>Arnstein Mykletun, Bergen, Norway</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>O-02-01</strong></th>
<th>Risk of suicide after attempted suicide</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ziherl, Ljubljana, Slovenia</strong></td>
<td>B. Zalar</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>O-02-02</strong></th>
<th>Suicide attempts in Basel (Switzerland) 2003-2004</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P. Berger, Basel, Switzerland</strong></td>
<td>M. Eichhorn, A. Riecher-Rössler</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>O-02-03</strong></th>
<th>Homicide of women by intimate partners - femicide</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>R. Kovacevic, Belgrad, Serbia + Montenegro</strong></td>
<td>B. Kecman</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>O-02-04</strong></th>
<th>Newer antidepressants - a principal factor in preventing suicide</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>L. Sondergard, Copenhagen, Denmark</strong></td>
<td>L. Kessing, K. Kvist, P. K. Andersen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>O-02-05</strong></th>
<th>Mortality in relation to anxiety and depression</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A. Mykletun, Bergen, Norway</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>O-02-06</strong></th>
<th>Severe personality disorders in the offspring of antenatally depressed mothers - a 31 year follow-up of the Northern Finland 1966 Birth Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P. Maki, Oulu, Finland</strong></td>
<td>P. Mäki, J. Veijola, M. Joukamaa, P. Rantakallio, J. Jokelainen, L. Kantojärvi, M. Isohanni</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>O-02-07</strong></th>
<th>Outcome and follow up of treatment of personality disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E. Fabian, Munich, Germany</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>O-02-08</strong></th>
<th>Anticipatory fear in violent schizophrenia and personality disorder subjects: A functional mri study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>D. Mrigendra, Crowthorne, United Kingdom</strong></td>
<td>V. Kumari, I. Barkakati, P. Taylor, T. Sharma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>O-02-09</strong></th>
<th>Amygdala and emotions – investigation of gender and cultural differences in facial emotion recognition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B. Hoheisel, Vienna, Austria</strong></td>
<td>U. Habel, C. Windischberger, S. Robinson, I. Kryspin-Exner, E. Moser</td>
</tr>
</tbody>
</table>
O-02-10 The serotonin transporter polymorphism may modulate severity of adult ADHD symptoms in conjunction with adverse life events
D. J. Müller, Berlin, Germany
C. G. DeYoung, T. Sicard, S. Tharmalan-gam, P. Muglia, U. Jain, J. L. Kennedy

O-02-11 Haplotype association study between DRD1 gene and parasuicide in bipolar disorder: Analysis of two samples from Canada and Sardinia
V. De Luca, Toronto, Canada
V. De Luca, G. Severino, X. Ni,
P. Picardi, A. de Batolomeis,
A. Squassina, G. Muscettola,
J. L. Kennedy, M. Del Zompo, D. Congiu

S-17-01 Experimental psychology of delusions
T. Kircher, Aachen, Germany
S-17-02 The effects of angry and happy expressions on recognition memory for unfamiliar faces in delusion-prone subjects
F. Laroi, Liege, Belgium
A. D’Argembeau, M. van der Linden,
C. Bertoni
S-17-03 Knowledge corruption in paranoid schizophrenia
S. Moritz, Hamburg, Germany
S-17-04 Theoretical and clinical implications of an attribution model of paranoia
P. Kinderman, Liverpool, United Kingdom
S-17-05 Testing a cognitive model of persecutory delusions using virtual reality
D. Freeman, London, United Kingdom

S-16-01 Evaluation of phosphorylated-tau protein as a core biomarker of Alzheimer’s disease
H. Hampel, Munich, Germany
S-16-02 Proteome analysis of potential protein markers for Alzheimer’s disease
U. Ruetschi, Mölndal, Sweden
S-16-03 Peptide Screening in Cerebrospinal Fluid
H. Selle, Hannover, Germany
S-16-04 Antibodies against amyloid-beta peptide
R. Dodel, Bonn, Germany
Y. Du
S-16-05 Kynurenine metabolites in pathophysiology and diagnosis of Alzheimer’s dementia
M. J. Schwarz, Munich, Germany
K. Bürger, J. Teipel, J. Zach, H. Hampel
S-16-06 CSF phosphorylated tau protein correlates with protein expression in brain as well as neocorti-cal neurofibriillary tangles in Alzheimer’s disease
K. Bürger, Munich, Germany
S. J. Teipel, H.-J. Möller, P. Davies,
H. Hampel, R. Zinkowski, J. De Bernardis,
D. Kerkman, T. Pirritilä, I. Alafuzoff, H.
Soininen

S-15-01 Genetic polymorphisms of psychotropic drug metabolizing enzymes: Clinical relevance
P. Baumann, Prilly-Lausanne, Switzerland
E. Jaquenoud, C. Eap
S-15-02 The pharmacogenetics of antipsychotics
J. Scharfetter, Vienna, Austria
S-15-03 The influence of ABCB1 transport proteins (MDR1, P-glycoprotein) on the blood-brain barrier function: Therapeutic implications
M. Uhr, Munich, Germany
S-15-04 Adverse drug reactions: Role of pharmaco-genomics
P. Zill, Munich, Germany
SYMPOSIUM S-19

16.15 - 17.45 h Holiday Inn - Room 4
Track T-4 Anxiety-related and eating disorders
Update on treatment and prevention of eating disorders
Chairperson: Manfred M. Fichter, Prien, Germany
Co-Chairperson: Fernando Fernandez-Aranda, Barcelona, Spain
S-19-01 Risk factors for eating disorders (genetics and environment)
A. Karwautz, Vienna, Austria
S-19-02 Psychotherapy of eating disorders
F. Fernandez-Aranda, Barcelona, Spain
S-19-03 What we know and what we don't know about the pharmacotherapy of eating disorders
A. Favaro, Padova, Italy
S-19-04 Prevention of eating disorders
M. M. Fichter, Prien, Germany

SYMPOSIUM S-14

16.15 - 17.45 h Gasteig - Black Box
Track T-6 Interdisciplinary
Polypharmacy in psychiatry
Chairperson: Siegfried Kasper, Vienna, Austria
Co-Chairperson: Eduard Vieta, Barcelona, Spain
S-14-01 Polypharmacy in schizophrenia
S. Kasper, Vienna, Austria
A. Konstantinidis
S-14-02 Polypharmacy in bipolar disorder
E. Vieta, Barcelona, Spain
S-14-03 Combinations of antidepressants with other psychototropic drugs: Evidence from naturalistic studies and randomised controlled trials
D. Baldwin, Southampton, United Kingdom
S-14-04 Is there a psychopharmacological rationale for polypharmacy?
W. Müller, Frankfurt, Germany

SYMPOSIUM S-64

16.15 - 17.45 h Holiday Inn - Room 8
Track T-7 Social Psychiatry
It’s the people, stupid: Taking care of the mental health workforce
Chairperson: Peter Huxley, London, United Kingdom
Co-Chairperson: Sherrill Evans, London, United Kingdom
S-64-01 Morale and job perception of community mental health professionals in Berlin and London
S. Priebe, London, United Kingdom
K. Hoffman, R. Powell, W. Fakhoury
S-64-02 A national survey of mental health social workers in England and Wales: Decision latitude, organisational justice and mental health
S. Evans, London, United Kingdom
S-64-03 Social workers in adult mental health - survey results from the Republic of Ireland
P. Quinn, Dublin, Ireland
S-64-04 Consultant psychiatrists working patterns: Are progressive approaches the key to staff retention?
A. Mears, London, United Kingdom
S-64-05 Morale of staff in community mental health care in a province in Northern Italy
G. M. Galeazzi, Sassuolo, Italy
S. Priebe, S. Delmonte, W. Fakhoury

SECTION SYMPOSIUM SS-05

16.15 - 17.45 h Gasteig - Philharmonie
Track T-2 Psychotic disorders
Genes for schizophrenia: Susceptibility to what? Part II: Insights from neuroimaging
Chairperson: Stephen Lawrie, Edinburgh, United Kingdom
Co-Chairperson: Wolfgang Fleischhacker, Innsbruck, Austria
SS-05-02 Neuroimaging in people vulnerable to psychosis
P. McGuire, London, United Kingdom
SS-05-03 Insights from neuroimaging
H. Schnack, Utrecht, Netherlands
SS-05-04 Brain dopamine d1 receptors in monozygotic and dizygotic twin pairs discordant for schizophrenia
J. Hietala, Turku, Finland
SS-05-05 What is genetically mediated in subjects at high genetic risk?
S. Lawrie, Edinburgh, United Kingdom
### SCIENTIFIC PROGRAM

**SUNDAY, 3 APRIL 2005**

#### WORKSHOP

##### W-03

16.15 - 17.45 h  
**Holiday Inn - Room 2**  
**Track T-7 Social Psychiatry**  
**Core competences for the psychiatrist of the future - a comparison between Europe and US**  
Chairperson: Anne Lindhardt, Copenhagen, Denmark  
Co-Chairperson: Allan Tasman, Louisville, USA  
Speaker: Allan Tasman, Louisville, USA  
A. Lindhardt, Copenhagen, Denmark  
L. Küey, Istanbul, Turkey  
M. Musalek, Vienna, Austria  
F. Hohagen, Lübeck, Germany  

##### W-06

16.15 - 17.45 h  
**Holiday Inn - Room 5**  
**Track T-3 Affective disorders**  
**Neuropsychological and neuroanatomical correlates of affective-cognitive interaction in major depression**  
Chairperson: Georg Northoff, Magdeburg, Germany  
Co-Chairperson: Heinz Boeker, Zurich, Switzerland  
Speaker: H. Boeker, Zurich, Switzerland  
F. Bermpehl, Boston, USA  
S. Grimm, Zurich, Switzerland  
G. Northoff, Magdeburg, Germany  

##### W-07

16.15 - 17.45 h  
**Holiday Inn - Room 6**  
**Track T-6 Interdisciplinary**  
**Cycloid psychoses**  
Chairperson: Willem Verhoeven, Venray, Netherlands  
Co-Chairperson: Siegfried Tuinier, Venray, Netherlands  
Speaker: F. Van der Heijden, Venray, Netherlands  
E. Franzek, Poortugaal, Netherlands  
G. Stoer, Würzburg, Germany  
B. Pfuhlmann, Würzburg, Germany  

#### DEBATE

##### D-02

16.15 - 17.45 h  
**Gasteig - Carl-Orff-Hall**  
**Track T-6 Interdisciplinary**  
**Current classifications are not relevant to biological psychiatry**  
Chairperson: Hanns Hippius, Munich, Germany  
From a more biological point of view  
M. Ackenheil, Munich, Germany  
From a more clinical point of view  
D. Goldberg, London, United Kingdom  

---

#### SECTION SYMPOSIUM

##### SS-06

16.15 - 17.45 h  
**Holiday Inn - Room 3**  
**Track T-5 Personality and behavioural disorders**  
The interface between biological and social factors in borderline personality disorder  
Chairperson: Sabine Christiane Herpertz, Rostock, Germany  
Co-Chairperson: Henning Sass, Aachen, Germany  

<table>
<thead>
<tr>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| SS-06-01 | Title unknown  
E. Seifritz, Bern, Switzerland |
| SS-06-02 | Dissociative experiences in borderline personality disorder and other trauma disorders  
E. Vermetten, CX Utrecht, Netherlands  
C. Schmahl, J. D. Bremner, R. Loewenstein |
| SS-06-03 | Perception of facial affect in borderline personality disorder (BPD)  
G. Domes, Rostock, Germany  
S. Herpertz |
| SS-06-04 | Biological and psychological aspects of self-injurious behavior in borderline personality disorder  
C. Schmahl, Mannheim, Germany  
P. Ludaescher, A. Jochims, K. Kuenkele, M. Bohus |

---

### WORKSHOP

##### W-07

16.15 - 17.45 h  
**Holiday Inn - Room 6**  
**Track T-6 Interdisciplinary**  
**Cycloid psychoses**  
Chairperson: Willem Verhoeven, Venray, Netherlands  
Co-Chairperson: Siegfried Tuinier, Venray, Netherlands  
Speaker: F. Van der Heijden, Venray, Netherlands  
E. Franzek, Poortugaal, Netherlands  
G. Stoer, Würzburg, Germany  
B. Pfuhlmann, Würzburg, Germany  

---

### WORKSHOP

##### W-06

16.15 - 17.45 h  
**Holiday Inn - Room 5**  
**Track T-3 Affective disorders**  
**Neuropsychological and neuroanatomical correlates of affective-cognitive interaction in major depression**  
Chairperson: Georg Northoff, Magdeburg, Germany  
Co-Chairperson: Heinz Boeker, Zurich, Switzerland  
Speaker: H. Boeker, Zurich, Switzerland  
F. Bermpehl, Boston, USA  
S. Grimm, Zurich, Switzerland  
G. Northoff, Magdeburg, Germany  

---

### WORKSHOP

##### W-03

16.15 - 17.45 h  
**Holiday Inn - Room 2**  
**Track T-7 Social Psychiatry**  
**Core competences for the psychiatrist of the future - a comparison between Europe and US**  
Chairperson: Anne Lindhardt, Copenhagen, Denmark  
Co-Chairperson: Allan Tasman, Louisville, USA  
Speaker: Allan Tasman, Louisville, USA  
A. Lindhardt, Copenhagen, Denmark  
L. Küey, Istanbul, Turkey  
M. Musalek, Vienna, Austria  
F. Hohagen, Lübeck, Germany  

---

### DEBATE

##### D-02

16.15 - 17.45 h  
**Gasteig - Carl-Orff-Hall**  
**Track T-6 Interdisciplinary**  
**Current classifications are not relevant to biological psychiatry**  
Chairperson: Hanns Hippius, Munich, Germany  
From a more biological point of view  
M. Ackenheil, Munich, Germany  
From a more clinical point of view  
D. Goldberg, London, United Kingdom
SCIENTIFIC PROGRAM
SUNDAY, 3 APRIL 2005

ORAL PRESENTATION  O-03

16.15 - 17.45 h  Holiday Inn - Room 7
Track T-6 Interdisciplinary
Interdisciplinary
Chairperson: Povl Munk-Jörgensen, Aalborg, Denmark
Co-Chairperson: Juha Veijola, Oulu, Finland

O-03-01  Experiences from the first Assertive Community Treatment (ACT) programme in Denmark
J. Aagaard, Risskov, Denmark
C. Müller-Nielsen

O-03-02  Nonparticipants have more commonly mental disorders than participants
J. Veijola, Oulu, Finland
M. Haapea, M. Joukamaa, K. Läksy, J. Miettunen

O-03-03  Group treatment of depression: Psycho-education vs. behavior therapy
F. Caspar, Freiburg, Germany
W. Greil, T. Dopmann, T. Berger

O-03-04  Measuring social capital in mental health research: A new approach
M. Webber, London, United Kingdom

O-03-05  Having mentally ill parents: Impact on spare time activity, school performance and familial relationship
S. Rothen, Prilly, Switzerland
F. Ferrero, O. Chouchena, M. Preisig

O-03-06  New perspectives on reducing stigma: Fighting burnout to enhance provider attitudes of recovery
B. Schulze, Zurich, Switzerland

O-03-07  Study on mental health status in hemodialysis patient
A. Navidian, Iran

O-03-08  When is the most appropriate moment for psychotherapeutic intervention following autologous peripheral blood stem cell transplantation?
E. Frick, Munich, Germany
M. Tyroler, N. Fischer, R. Busch, B. Emmerich, I. Bumeder

ORAL PRESENTATION  O-03

0-03-09  Religious coping with a life-threatening disease
O. Seidl, Munich, Germany
E. Frick

0-03-10  Ethics in psychiatry: From hippocrates to the WPA Declaration on Ethics
G. Christodoulou, Athens, Greece

0-03-11  Adult ADHD and substance abuse
M. Casas, Barcelona, Spain
R.-Q. Josep A, B. Rosa, E. Gemma, M. Xavier

POSTER PRESENTATION  P-04

18.00 - 19.30 h  Gasteig - Foyers
Track T-2 Psychotic disorders
Psychotic disorders I
Chairperson: Anita Riecher-Rössler, Basel, Switzerland
Co-Chairperson: Eva Meisenzahl, Munich, Germany

POSTER PRESENTATION  P-05

18.00 - 19.30 h  Gasteig - Foyers
Track T-4 Anxiety-related and eating disorders
Anxiety-related disorders
Chairperson: Donatella Marazziti, Pisa, Italy
Co-Chairperson: Stuart Montgomery, London, United Kingdom

POSTER PRESENTATION  P-06

18.00 - 19.30 h  Gasteig - Foyers
Track T-6 Interdisciplinary
Interdisciplinary II
Chairperson: Marianne Kastrup, Copenhagen, Denmark
Co-Chairperson: Borys Mykhaylov, Kharkov, Ukraine
SCIENTIFIC PROGRAM
MONDAY, 4 APRIL 2005

SYMPOSIUM S-23
08.30 - 10.00 h  Gasteig - Black Box
Track T-1 Substance related disorders
Psychopharmacology of opiate addiction
Chairperson:  Markus Gastpar, Essen, Germany
S-23-01 Evaluation of drug consumption rooms for drug addicts
N. Scherbaum, Essen, Germany
S-23-02 Results of the dutch heroin trial
W. van den Brink, Amsterdam, Netherlands
S-23-03 Drug monitoring during substitution treatment
C. Eap, Prilly-Lausanne, Switzerland

SYMPOSIUM S-22
08.30 - 10.00 h  Gasteig - Carl-Orff Saal
Track T-2 Psychotic disorders
Brain morphology in schizophrenia: New findings and perspectives
Chairperson:  Ralf Schloesser, Jena, Germany
Co-Chairperson:  Steven Chance, Oxford, United Kingdom
S-22-01 Schizophrenia as a misconnexion syndrome
S. Chance, Oxford, United Kingdom
S-22-02 Focal white matter density changes in schizophrenia
H. Schnack, Utrecht, Netherlands
S-22-03 Magnetisation Transfer Ratio (MTR) abnormalities in schizophrenia
M. Bagary, London, United Kingdom
J. Foong, M. Symms, G. Barker, E. Joyce, M. Ron
S-22-04 Novel morphometric approaches in schizophrenia: Methods and applications
C. Gaser, Jena, Germany

SYMPOSIUM S-27
08.30 - 10.00 h  Holiday Inn - Room 6
Track T-2 Psychotic disorders
Catatonia - a neuropsychiatric syndrome across psychiatric diagnoses
Chairperson:  Stephanie Krüger, Dresden, Germany
Co-Chairperson:  Peter Bräunig, Chemnitz, Germany
S-27-01 Catatonia in affective disorder
S. Krüger, Dresden, Germany
S-27-02 Catatonic schizophrenia
G. Ungvari, Hungary
S. K. Leung, F. S. Ng, H.-K. Cheung, T. Leung
S-27-03 Malignant catatonia
S. Mann, Harleysville, USA
S. Caroff
S-27-04 Malignant neuroleptic syndrome vs. catatonia
G. Petrides, Greece
S-27-05 Pathophysiology in catatonia: Orbitofrontal cortical dysfunction?
G. Northoff, Magdeburg, Germany

SYMPOSIUM S-21
08.30 - 10.00 h  Gasteig - Philharmonie
Track T-3 Affective disorders
Anxiety and depression, first results of the DSM-5 steering group
Chairperson:  David Goldberg, London, United Kingdom
S-21-01 Rethinking the duration criterion for DSM-IV Generalized Anxiety Disorder: Evidence from the National Comorbidity Survey Replication
R. Kessler, Cambridge, USA
S-21-02 Is there mental disorder beyond ICD-10?
M. Prince, London, United Kingdom
S-21-03 The comparison of latent variable models of common mental disorders in developing countries
K. S. Jacob, Vellore, India
S-21-04 Differences during childhood that differentiate the two groups of disorder
M. Richards, London, United Kingdom
**SYMPOSIUM S-25**

08.30 - 10.00 h  Holiday Inn - Room 2
Track T-4 Anxiety-related and eating disorders
Future perspectives in the treatment of anxiety: Targeting the GABA system
Chairperson:  Rainer Rupprecht, Munich, Germany
Co-Chairperson:  Siegfried Kasper, Vienna, Austria

S-25-01  Title unknown
  A. Bateson, Leeds, United Kingdom

S-25-02  Title unknown
  Z. Bhagwagar, Oxford, United Kingdom

S-25-03  Selective GABA-ERGIC treatment for human anxiety – Is there a new class of anxiolytics?
  P. Zwanzger, Munich, Germany

S-25-04  Current state of the art in the pharmacotherapy of anxiety disorders
  S. Kasper, Vienna, Austria
  M. Stamenkovic

**SYMPOSIUM S-26**

08.30 - 10.00 h  Holiday Inn - Room 3
Track T-5 Personality and behavioural disorders
Neurobiological, genetic and developmental aspects of personality disorders
Chairperson:  Kristina Fast, Munich, Germany
Co-Chairperson:  Birgit Völlm, Manchester, United Kingdom

S-26-01  On the interface of genetic and environmental factors in the neurobiology of antisocial personality disorder
  S. C. Herpertz, Rostock, Germany

S-26-02  The influence of juvenile socio-emotional experiences on the functional development of limbic brain systems
  J. Bock, Magdeburg, Germany

S-26-03  Neurobiology of patients with borderline personality disorder: CNS imaging, neuropsychological and clinical symptoms
  T. Zetzsche, Munich, Germany

S-26-04  Neuronal correlates of Cluster B personality disorders
  B. Völlm, Manchester, United Kingdom

S-26-05  The neuropsychology and functional neuroimaging of personality traits and dimensions
  C. van Heeringen, Gent, Belgium
  K. Bernagie, M. Vervaet, I. Goethals, K. Audenaert

**SYMPOSIUM S-28**

08.30 - 10.00 h  Holiday Inn - Room 8
Track T-4 Anxiety-related and eating disorders
Psychopathological consequences of the 11 M terrorists attacks
Chairperson:  Laura Ferrando, Madrid, Spain

S-28-01  Comparison dates among New York 11S and Madrid 11M
  S. Galea, New York, USA

S-28-02  Methodology of the study psychopathological consequences of the 11M terrorist attacks
  R. Gabriel, Madrid, Spain

S-28-03  Results of the study psychopathological consequences of the 11 M terrorist attacks - 1a
  L. Ferrando, Madrid, Spain

**YP-SYMPOSIUM YP-S-01**

08.30 - 10.00 h  Holiday Inn - Room 4
Track T-6 Interdisciplinary
New challenges for young psychiatrists in Europe
Chairperson:  Iris Callies, Hannover, Germany
Co-Chairperson:  Kai Treichel, Berlin, Germany

YP-S-01-01  Ensuring good practice in Psychiatric Training - a European challenge
  J. Strachan, United Kingdom

YP-S-01-02  Challenges for Young Psychiatrists and Trainees under the viewpoint of the Union of European Medical Specialists (UEMS)
  A. Lindhardt, Copenhagen, Denmark
SCIENTIFIC PROGRAM
MONDAY, 4 APRIL 2005

YP-SYMPOSIUM YP-S-01

YP-S-01-03 Trends and perspectives for Young Psychiatrists and Trainees in Europe
A. Heinz, Berlin, Germany

YP-S-01-04 The networks of New Consultants in Great Britain and the representation of Young Psychiatrists and Trainees in the Royal College of Psychiatry
J. Beezold, United Kingdom

SYMPOSIUM S-24

08.30 - 10.00 h Gasteig - Bibliothek
Track T-7 Social Psychiatry
Adjusting to cultural differences for interventions in mental health care
Chairperson: Christian Haasen, Hamburg, Germany
Co-Chairperson: Marianne Kastrup, Copenhagen, Denmark

S-24-01 Cultural sensitivity for institutions of mental health
C. Haasen, Hamburg, Germany

S-24-02 Cultural aspects of psychosocial interventions
M. Kastrup, Copenhagen, Denmark

S-24-03 Ethnic factors in pharmacology and pharmacogenetics
A.-M. Pezous, Paris, France

S-24-04 Cultural mediators for mental health services
W. Machleidt, Hannover, Germany
R. Salman

S-24-05 Cultural competency training in mental health
A. Qureshi, Barcelona, Spain
F. Collazos

SECTION SYMPOSIUM SS-07

SS-07-02 Skill-based objectives for specialist training in old age psychiatry
R. Mateos, Santiago de Compostela, Spain

SS-07-03 Late-life depression as a cause of social disability
J. Leszek, Wroclaw, Poland

SS-07-04 Romanian perspectives on old age psychiatry
N. Tataru, Oradea, Romania

SS-07-05 An initiative to promote exchange between professionals in old age psychiatry
M. Aartsen, Zeist, Netherlands

SECTION SYMPOSIUM SS-08

08.30 - 10.00 h Holiday Inn - Room 1
Track T-2 Psychotic disorders
Schizophrenia - Nature and narratives
Chairperson: Michael Musalek, Vienna, Austria
Co-Chairperson: Christoph Mundt, Heidelberg, Germany

SS-08-01 Self and identity in schizophrenia
G. Stanghellini, Florenz, Italy

SS-08-02 Change of schizophrenic syndromes?
C. Mundt, Heidelberg, Germany

SS-08-03 Present status of cycloid psychoses
I. Brockington, Hereforshire, United Kingdom

SS-08-04 Schizophrenia - what for?
M. Musalek, Vienna, Austria

SS-08-05 New phenotypes as basis for treatment
S. Opjordsmoen, Oslo, Norway

WORKSHOP W-08

08.30 - 10.00 h Holiday Inn - Room 5
Track T-7 Social Psychiatry
Semiotics between neuro-myths and social romanticism - Part I
Semiotics and neuro-sciences
Chairperson: Hans Pfefferer-Wolf, Hannover, Germany
Speaker: S. Debus, Germany
A. Heinz, Berlin, Germany
H. Pfefferer-Wolf, Hannover, Germany
R. Posner, Germany
G. Schulte, Germany
EDUCATIONAL COURSE C-07

08.30 - 12.00 h Hilton - Salon Bialas
Track T-6 Interdisciplinary
Therapeutic drug monitoring of psychotropic drugs and pharmacogenetic tests in psychiatry
Organizer: P. Baumann, Prilly-Lausanne, Switzerland
Speaker: P. Baumann, Prilly-Lausanne, Switzerland
C. Hiemke, Mainz, Germany
F. Bengsston, Linköping, Sweden

EDUCATIONAL COURSE C-08

08.30 - 12.00 h Hilton - Salon Orff
Track T-6 Interdisciplinary
Prevention of suicide
Organizer: D. Wassermann, Stockholm, Sweden

EDUCATIONAL COURSE C-22

08.30 - 12.00 h Hilton - Salon Studer
Track T-7 Social Psychiatry
Taking care of ourselves: Managing stress, preventing burnout
Organizer: W. Rössler, Zurich, Switzerland
Speaker: B. Schulze, Zurich, Switzerland

ORAL PRESENTATION O-04

08.30 - 10.00 h Holiday Inn - Room 7
Track T-3 Affective disorders
Affective disorders II
Chairperson: Fritz Hohagen, Lübeck, Germany
Co-Chairperson: Christine Norra, Aachen, Germany

O-04-01 Functional status of patients with acute mania
I. Goetz, Windlesham, United Kingdom
C. Reed, H. Grunze, E. Vieta

O-04-02 Short psychoeducation for bipolar patients
A. Erfurth, Augsburg, Germany
M. Dobmeier, M. Zechendorff

O-04-03 Effects of lithium on the HPA axis in patients with unipolar major depression
T. Bschor, Berlin, Germany
D. Ritter, U. Lewitzka, M. Bauer,
M. Adli, C. Baethge, M. Uhr, M. Ising

O-04-04 Parental bonding attitudes of bipolar, depressive, and substance dependent subjects as assessed by parent and offspring
Y. Lustenberger, Prilly, Switzerland
S. Rothen, M. Preisig, F. Ferrero

O-04-05 Phenomenon of loneliness in structure of anxious-depressive disorders of an out-patient level
A. S. Kim, Russia
S. M. Karypbaeva

O-04-06 Depressive mood and quality of life in patients with chronic heart failure (CHF): Impact of sleep related breathing disorder and cardiac resynchronisation therapy
C. Norra, Aachen, Germany
A.-M. Sinha, E. C. Skobel

O-04-07 Depression and anxiety during the climacteric period - The HUNT-II study
T. T. Haug, Bergen, Norway
A. Mykletun

O-04-08 The association between eczema, anxiety, and depression: Exploring etiological models
M. K. Fremstad, Alesund, Norway
A. Mykletun

O-04-09 Help-seeking behaviour in patients with anxiety disorder and depression
A. Roness, Bergen, Norway
A. Mykletun, A. A. Dahl

O-04-10 Hypericum possibility in Lithuania
B. Burba, Kaunas, Lithuania
A. Gendrolis, O. Jankuviene
10.30 - 11.15 h  Gasteig - Philharmonie
Track T-7 Social Psychiatry
AEP Presidential Symposium on ethical issues:
Ethics in psychiatry
Chairperson: Henning Saß, Aachen, Germany
Co-Chairperson: Norman Sartorius, Geneva, Switzerland

S-29-01 Conflicts of interests in psychiatric research and practice
M. Maj, Naples, Italy

S-29-02 The psychiatric profession and its human rights aspects: Should they vary from culture to culture?
M. Kastrup, Copenhagen, Denmark

S-29-03 Ethical implications of sponsoring
H. Helmchen, Berlin, Germany

S-29-04 Forensic psychiatry: Two masters, one ethics
J. Arboleda-Florez, Kingston, Canada

S-29-05 To irritate, to soothe, to scrutinize and to harmonize: the challenges of an ethical education in European medical schools
D. Bowman, London, United Kingdom

11.15 - 12.15 h  Gasteig - Black Box
Track T-6 Interdisciplinary
Meet the experts: Forensic Psychiatry
Speaker: J. Arboleda-Florez, Kingston, Canada

11.15 - 12.15 h  Gasteig - Foyers
Track T-1 Substance related disorders
Substance-related disorders II
Chairperson: Valery Krasnov, Moscow, Russia
Co-Chairperson: Johanna Koskinen, Oulu, Finland

11.15 - 12.15 h  Gasteig - Foyers
Track T-2 Psychotic disorders
Psychotic disorders III
Chairperson: Hans-Jürgen Möller, Munich, Germany
Co-Chairperson: Dieter Naber, Hamburg, Germany

12.30 - 14.00 h  Gasteig - Philharmonie
Track T-3 Affective disorders
Antidepressant myths and facts:
Do the data reflect clinical reality?
Chairperson: David Sheehan, Tampa, USA

LS-02-04 Treating anxiety disorders: Efficacy and safety considerations
B. Bandelow, Göttingen, Germany

LS-02-01 Diagnosis and treatment of spectrum depression and anxiety disorders
G. Cassano, Pisa, Italy

LS-02-02 The importance of actively treating depression in medically ill patients
R. Krishnan, Durham, USA

LS-02-03 First and second line antidepressants: Evidence-based considerations
D. Sheehan, Tampa, USA

Chair’s closing remarks
D. Sheehan, Tampa, USA

Supported by an unrestricted educational grant from Pfizer Inc.

LS-03-01 Biological rhythm disturbances in mood disorders
A. Wirz-Justice, Basel, Switzerland

LS-03-02 Insights into the pharmacology of agomelatine: The first melatonergic antidepressant
E. Fuchs, Göttingen, Germany

LS-03-03 Antidepressant efficacy of agomelatine: Clinical implications
P. Boyer, Ottawa, Canada
LUNCH SYMPOSIUM LS-03

LS-03-04  Sleep as a marker of disrupted circadian rhythms in depression  
C. Guilleminault, Stanford, USA

LS-03-05  Benefits and tolerability evaluation of agomelatine: A new approach to the treatment of depressed patients  
S. Montgomery, London, United Kingdom

Conclusion  
D. Naber, Hamburg, Germany

Supported by an unrestricted educational grant from Servier International

LUNCH SYMPOSIUM LS-04

12.30 - 14.00 h  Holiday Inn - Room 1
Track T-3 Affective disorders
Overcoming common barriers to treatment adherence in bipolar disorder
Chairperson: Siegfried Kasper, Vienna, Austria

LS-04-01  Medical comorbidities and bipolar disorder  
S. Kasper, Vienna, Austria

LS-04-02  Drug abuse and bipolar disorder  
S. Stakowski, Germany

LS-04-03  Depression and bipolar disorder  
H.-J. Möller, Munich, Germany

Supported by an unrestricted educational grant from Eli Lilly Company

SYMPOSIUM S-30

14.15 - 15.45 h  Holiday Inn - Room 1
Track T-2 Psychotic disorders
New challenges to the dichotomy schizophrenia versus affective disorder - Part I
Chairperson: Heinz Häfner, Mannheim, Germany
Co-Chairperson: Wolfgang Maier, Bonn, Germany

S-30-01  Depression as prodrome of schizophrenia  
H. Häfner, Mannheim, Germany

S-30-02  The epidemiology of subclinical mania and subclinical psychosis comorbidity in the general population  
M. C. Marcelis, Maastricht, Netherlands
N. Kaymaz, J. van Os, R. de Graaf, W. Vollebergh, L. Krabbeendam

S-30-03  Prediction of psychosis by depressive symptoms among high-risk subjects  
S. Lawrie, Edinburgh, United Kingdom
P. Miller, D. Owens, E. Johnstone

S-30-04  Current status of molecular genetics of schizophrenia and bipolar disorder  
N. Craddock, Cardiff, United Kingdom

S-30-05  Anomalous asymmetry as the key to the pathophysiology of schizophrenia and bipolar disorder  
T. Crow, Oxford, United Kingdom
P. Falkai

SYMPOSIUM S-33

14.15 - 15.45 h  Holiday Inn - Room 1
Track T-2 Psychotic disorders
Molecular foundations of schizophrenic psychoses
Chairperson: Gavin Reynolds, Belfast, United Kingdom

S-33-01  Genetics of electrophysiological endophenotypes in schizophrenia  
G. Juckel, Berlin, Germany

S-33-03  Neurotransmitter pathology of schizophrenia  
G. Reynolds, Belfast, United Kingdom
SYMPOSIUM S-34

14.15 - 15.45 h Holiday Inn - Room 2
Track T-3 Affective disorders
Neurobiology of suicidal behaviour
Chairperson: Cornelis van Heeringen, Gent, Belgium
Co-Chairperson: Ina Giegling, Munich, Germany
S-34-01 Genetic risk factors as possible causes of the variation in European suicide rates
A. Marusic, Ljubljana, Slovenia
S-34-02 In vivo functional neuro-imaging provides new insights into the suicidal brain
C. van Heeringen, Gent, Belgium
K. Bernagie, M. Vervaet, K. Audenaert
S-34-03 Serotonergic genes influence suicidal behaviour
A. Malafosse, Chêne-Bourg, Switzerland
S-34-04 Aggression-related genes in suicidal behavior: An intermediate phenotype strategy in the search for genetic susceptibility factors
I. Giegling, Munich, Germany
I. Dietrich, A. M. Hartmann, H. J. Möller, D. Rujescu
S-34-05 Transmission of suicidal behaviour: Non-genetic factors
D. L. Diego, Mount Gravatt, Australia

SYMPOSIUM S-35

14.15 - 15.45 h Holiday Inn - Room 6
Track T-3 Affective disorders
Psychosocial aspects of depressive disorders in ethnic minority groups
Chairperson: Francis Creed, Manchester, United Kingdom
Co-Chairperson: Christian Haasen, Hamburg, Germany
S-35-01 Prevalence of depression in people of Pakistani origin in U.K.
F. Creed, Manchester, United Kingdom
S-35-02 Depression among migrants of Turkish and Russian origin living in Germany
C. Haasen, Hamburg, Germany

SYMPOSIUM S-32

14.15 - 15.45 h Gasteig - Room 0.131
Track T-4 Anxiety-related and eating disorders
Biological background and psychopathological targets of therapeutic approaches to eating disorders
Chairperson: Francesca Brambilla, Naples, Italy
Co-Chairperson: Palmiero Monteleone, Naples, Italy
S-32-01 Genetic predictivity of the clinical and psychological effects of sSri treatments in disorders of eating behavior
P. Monteleone, Naples, Italy
A. Tortorella, M. Fabrazzo, E. Castaldo, A. Fuschino, C. Di Filippo, M. Maj
S-32-02 Biological background of the psychological effects of cognitive-behavioural therapy in anorexia nervosa
F. Brambilla, Naples, Italy
R. Dalle Grave, T. Todesco, D. Marazziti, P. Monteleone, S. Caluggi
S-32-03 Implications of biological research for our understanding and definition of anorexia nervosa
J. Hebebrand, Marburg, Germany
S-32-04 Guided self-help for bulimic anorexia nervosa to reduce time in intensive treatment: A controlled study
M. M. Fichter, Prien, Germany
M. Cebulla, N. Kränzlin, M. Fumi, S. Naab
**SCIENTIFIC PROGRAM**  
**MONDAY, 4 APRIL 2005**

---

**SYMPOSIUM**  
**S-31**

14.15 - 15.45 h  
Gasteig - Bibliothek  
Track T-7 Social Psychiatry

Future of education in ethics in psychiatry: Evidence based medicine (EBM) or values based medicine (VBM)?

Chairperson: Paul Cosyns, Edegem, Belgium  
Co-Chairperson: Driss Moussaoui, Casablanca, Morocco

- S-31-01 Values in diagnosis and treatment in psychiatry  
P. Cosyns, Edegem, Belgium

- S-31-02 Values-Based Practice in psychiatry  
B. Fulford, Coventry, United Kingdom

- S-31-03 Teaching ethics in psychiatry to post-graduates  
D. Moussaoui, Casablanca, Morocco

- S-31-04 Teaching ethics in psychiatry: Does it work?  
J. Arboleda-Florez, Kingston, Canada

---

**SECTION SYMPOSIUM**  
**SS-09**

14.15 - 15.45 h  
Gasteig - Philharmonie  
Track T-2 Psychotic disorders

**Antipsychotics: Effectiveness beyond mere symptom control in schizophrenia patients**

Chairperson: Manfred Ackenheil, Munich, Germany  
Co-Chairperson: Wolfgang Fleischhacker, Innsbruck, Austria

- SS-09-01 Evaluating antipsychotics: Methodological challenges  
W. Fleischhacker, Innsbruck, Austria

- SS-09-02 Efficacy beyond the PANSS  
H.-J. Möller, Munich, Germany

- SS-09-03 EUFEST: A randomized pragmatic long-term trial in first episode schizophrenia  
R. Kahn, GA Utrecht, Netherlands  
H. Boter

- SS-09-04 Quality of life as an important outcome parameter  
J. Bobes Garcia, Oviedo, Spain

---

**WORKSHOP**  
**W-09**

14.15 - 15.45 h  
Holiday Inn - Room 4  
Track T-2 Psychotic disorders

**Schizophrenia, thalamus and the cortex: Molecular and functional neuroimaging studies**

Chairperson: Peter Danos, Giessen, Germany  
Co-Chairperson: Mirjam Talvik, Stockholm, Sweden

Speaker  
M. Talvik, Stockholm, Sweden  
V. Kumari, London, United Kingdom  
R. Schloesser, Jena, Germany  
P. Delamillieure, Caen, France  
M. Kromkamp, Utrecht, Netherlands

---

**WORKSHOP**  
**W-10**

14.15 - 15.45 h  
Holiday Inn - Room 5  
Track T-6 Interdisciplinary

**Ligand-gated ion channels as targets for psychotropic drugs**

Chairperson: Rainer Rupprecht, Munich, Germany  
Co-Chairperson: Johannes Kornhuber, Erlangen, Germany

Speaker  
G. Biggio, Cagliari, Italy  
G. Collingridge, Bristol, United Kingdom  
R. Rupprecht, Munich, Germany  
J. Kornhuber, Erlangen, Germany

---

**PRO-AND CON-DEBATE**  
**D-03**

14.15 - 15.45 h  
Gasteig - Carl-Orff-Hall  
Track T-3 Affective Disorders

**Anticonvulsants are fully sufficient for treatment of acute bipolar disorder**

Chairperson: Patrice Boyer, Ottowa, Canada

Pro-Author: H. Grunze, Munich, Germany  
Con-Author: E. Vieta, Barcelona, Spain
**YP-WORKSHOP YP-W-01**

14.15 - 15.45 h  Holiday Inn - Room 8
Track T-6 Interdisciplinary
European and International networks of young psychiatrists and trainees
Chairperson: Kai Treichel, Berlin, Germany
Co-Chairperson: I.T. Calliess, Hannover, Germany

YP-W-01-01  The history and development of EFPT as a prototype of an international network of young psychiatrists and trainees
J. Beezold, United Kingdom

YP-W-01-02  The current role of EFPT for the harmonization of psychiatric training in Europe
D. Eraslan, Turkey

YP-W-01-03  Possibilities for a worldwide representation of young psychiatrists and trainees
V. Buwalda, Netherlands

YP-W-01-04  The situation of Eastern European young psychiatrists and trainees and the process of self-organization within a scientific network
N. Maric, Belgrad, Serbia + Montenegro

**EDUCATIONAL COURSE C-09**

14.15 - 17.45 h  Hilton - Salon Bialas
Track T-4 Anxiety-related and eating disorders
Cognitive behaviour therapy in anxiety disorders
Organizer: L.G. Öst, Stockholm, Sweden

**EDUCATIONAL COURSE C-10**

14.15 - 17.45 h  Hilton - Salon Orff
Track T-5 Personality and behavioural disorders
ADHD through the life span
Organizer: S. Tyano, Petah-Tiqvah, Israel

**EDUCATIONAL COURSE C-11**

14.15 - 17.45 h  Hilton - Salon Studer
Track T-5 Personality and behavioural disorders
Psychoeducation and risk management strategies with borderline personality disorder patients
Organizer: S. Herpertz, Rostock, Germany
A. Andreoli, Geneva, Switzerland

Speaker: A. Andreoli, Geneva, Switzerland
V. Habermeyer, Rostock, Germany
S. Herpertz, Rostock, Germany

**ORAL PRESENTATION 0-05**

14.15 - 15.45 h  Holiday Inn - Room 7
Track T-0 Dementia
Dementia / Gerontopsychiatry
Chairperson: Nicoleta Tataru, Oradea, Romania
Co-Chairperson: Michael Rapp, New York, USA

0-05-01  Functional abnormalities of the visual attention system in mild cognitive impaired subjects
A. Bokde, Munich, Germany
P. Lopez-Bayo, C. Born, T. Meindl, W. Dong, S. Teipel, M. Reiser, H.-J. Möller, H. Hampel

0-05-02  Decision making in dementia
R. Ihl, Düsseldorf, Germany
V. Stihl, S. Brieber, B. Grass-Kapanke

0-05-03  Correlation of neuropsychological evaluation and SPECT in patients with dementia
M. L. Onor, Trieste, Italy
E. Aguglia

0-05-04  Evaluation of shunting in idiopathic normal pressure hydrocephalus: Psychometric testing, gait analysis and PET
B. Grass-Kapanke, Düsseldorf, Germany

0-05-05  Increased hippocampal plaques and tangles in Alzheimer’s disease patients with a lifetime history of major depression
M. Rapp, New York, NY, USA
V. Haroutunian, J. Gorman

0-05-06  Pain experience in demented patients as indicated by facial responses
M. Kunz, Marburg, Germany
V. Mylius, S. Scharmann, K. Schepelmann, U. Hemmeter, S. Lautenbacher

0-05-07  Quality of life assessment in Alzheimer disease
D. Vasile, Bukarest, Romania
M. Gheorghe

0-05-08  Psycho-social and biological aspects of alcoholism of elderly people in the North of Russia
A. Soloviev, Arkhangelsk, Russia
P. Sidorov, A. Garazha

0-05-09  Glial-neuronal Interrelations in motor neocortex of rats genetically predisposed to epilepsy
N. Pasikova, Moscow, Russia
V. Mats, G. Kuznetsova
SCIENTIFIC PROGRAM
MONDAY, 4 APRIL 2005

SYMPOSIUM S-41

16.15 - 17.45 h
Holiday Inn - Room 6
Track T-1 Substance related disorders
The Addictions: Young Researchers Symposium
Chairperson: Falk Kiefer, Mannheim, Germany
Co-Chairperson: Andreas Heinz, Berlin, Germany

S-41-01 Videotapes exposure of delirium tremens reduce the relapse rate in alcohol dependence
A. Mihai, Tg. Mures, Romania

S-41-02 Cue-exposure treatment for alcohol dependent patients: Analysis of patients’ characteristics associated with beneficial treatment effects
S. Löber, Mannheim, Germany
B. Croissant, A. Heinz, H. Flor, K. Mann

S-41-03 Genetic variation in the Dopamine Transporter gene is associated with Cocaine Addiction
G. Breen, London, United Kingdom

S-41-04 What can imaging studies contribute to illuminate alcohol relapse?
J. Wrase, Berlin, Germany
T. Kienast, T. Siessmeier, P. Bartenstein, D. F. Baus, N. Makris, K. Mann,
H. C. Breiter, A. Heinz

S-41-05 A comparative study of young, and elderly patients suffering from "alcoholism"
H. Shahpesandy, Palucanska, Slovakia

SYMPOSIUM S-37

16.15 - 17.45 h
Holiday Inn - Room 1
Track T-2 Psychotic disorders
Pharmacogenetics of antipsychotic treatment: Predicting clinical efficacy and side effects
Chairperson: Joachim Klosterkötter, Cologne, Germany
Co-Chairperson: A. Yung, Victoria, Australia

S-37-02 Towards pharmacogenomics: A large scale association study on response to haloperidol
D. Rujescu, Munich, Germany
I. Giegling, M. Schafer, N. Dahmen, T. Sander, A. Szegedi, M. R. Toliat,
B. Bondy, A. M. Hartmann, H. H. Stassen, H. J. Möller

S-37-03 Genetic predictors of response to clozapine and other atypical antipsychotics: Current status and implications of pharmacogenomics
R. Kerwin, London, United Kingdom
M. J. Arranz

S-37-04 Genetic markers and mechanisms of antipsychotic drug-induced weight gain
G. Reynolds, Belfast, United Kingdom

SYMPOSIUM S-39

16.15 - 17.45 h
Holiday Inn - Room 1
Track T-2 Psychotic disorders
Early recognition of psychoses
Chairperson: Joachim Klosterkötter, Cologne, Germany
Co-Chairperson: A. Yung, Victoria, Australia

S-39-01 Title unknown
W. Maier, Bonn, Germany

S-39-02 The development of schizophrenia and depression from onset until remission of the first psychotic episode
H. Häfner, Mannheim, Germany

S-39-03 Predictors of psychotic disorders in an Ultra High Risk Group
A. Yung, Victoria, Australia

S-39-04 Neuroimaging in the at risk mental state
P. McGuire, London, United Kingdom

S-39-05 Early recognition and indicated prevention
J. Klosterkötter, Cologne, Germany
S. Ruhrmann, A. Bechdolf, M. Wagner, W. Maier
### SYMPOSIUM S-36

**16.15 - 17.45 h**  
Gasteig - Philharmonie  
Track T-3 Affective disorders  
German depression research network: Results from naturalistic and intervention studies  
Chairperson: Hans-Jürgen Möller, Munich, Germany  
Co-Chairperson: Ulrich Hegerl, Munich, Germany  

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-36-01</td>
<td>Diagnostic and treatment issues in primary care</td>
<td>U. Hegerl, Munich, Germany</td>
</tr>
<tr>
<td>S-36-02</td>
<td>Results of the algorithm study in acute depression</td>
<td>M. Bauer, Berlin, Germany; K. Wiethoff, D. Schlath, T. Baghai, H.-J. Möller, M. Adli</td>
</tr>
<tr>
<td>S-36-03</td>
<td>Lithium treatment as prevention strategy</td>
<td>W. Felber, Dresden, Germany</td>
</tr>
<tr>
<td>S-36-04</td>
<td>Short- and long-term outcome of hospitalised unipolar depressive patients</td>
<td>H.-J. Möller, Munich, Germany; W. Gaebel, R. Bottlender, G. Laux, M. Schmauß, H. Pfeiffer</td>
</tr>
<tr>
<td>S-36-05</td>
<td>Follow up imaging in major depression: New insight in the neurobiology of affective disorders?</td>
<td>E. Meisenzahl, Munich, Germany; T. Frodl, C. Born, M. Reiser, H.-J. Möller</td>
</tr>
</tbody>
</table>

### SYMPOSIUM S-38

**16.15 - 17.45 h**  
Gasteig - Room 0.131  
Track T-4 Anxiety-related and eating disorders  
Psychotherapy and pharmacotherapy of obsessive-compulsive disorder: New findings  
Chairperson: Ulrich Voderholzer, Freiburg, Germany  
Co-Chairperson: Damiaan Denys, Utrecht, Netherlands  

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-38-01</td>
<td>Neuropsychological deficits in OCD as a correlate of a neurobiological dysfunction: Do these deficits change by successful cognitive behavioral treatment?</td>
<td>U. Voderholzer, Freiburg, Germany; A. K. Kuelz</td>
</tr>
<tr>
<td>S-38-02</td>
<td>Brain imaging findings in patients with obsessive-compulsive disorder and their impact on cognitive behavioral therapy</td>
<td>A. Kordon, Lübeck, Germany; F. Hohagen</td>
</tr>
<tr>
<td>S-38-03</td>
<td>Pharmacotherapy of treatment resistant OCD: A summary of recent findings</td>
<td>D. Denys, Utrecht, Netherlands</td>
</tr>
<tr>
<td>S-38-04</td>
<td>Cognitive treatment of OCD: Current developments</td>
<td>P. Salkovskis, London, United Kingdom</td>
</tr>
</tbody>
</table>

### SYMPOSIUM S-40

**16.15 - 17.45 h**  
Holiday Inn - Room 3  
Track T-5 Personality and behavioural disorders  
Pathological cruelty against animals and people: Contributions from Russia and the USA  
Chairperson: Aleksandr Bukhanovsky, Rostov on Don, Russia  
Co-Chairperson: Alan Felthouse, USA  

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-40-01</td>
<td>Psychotherapy of cruel sadism: A family systemic approach</td>
<td>N. M. Turchenko, Rostov on Don, Russia</td>
</tr>
<tr>
<td>S-40-02</td>
<td>Animal cruelty and psychiatric disorders</td>
<td>R. Gleyzer, Tacoma, USA; R. Gleyzer, A. R. Felthouse</td>
</tr>
<tr>
<td>S-40-03</td>
<td>Animal cruelty: A prodrome of antisocial and aggressive behavior or not?</td>
<td>A. Felthouse, Chester, USA; A. Felthouse, R. Gleyzer</td>
</tr>
<tr>
<td>S-40-04</td>
<td>Cruel criminal sadism: Origination and development</td>
<td>A. Bukhanovsky, Rostov on Don, Russia</td>
</tr>
<tr>
<td>S-40-05</td>
<td>Brain of serial killers</td>
<td>O. Bukhanovskaya, Rostov on Don, Russia</td>
</tr>
</tbody>
</table>
SCIENTIFIC PROGRAM  
MONDAY, 4 APRIL 2005

SYMPOSIUM  
S-42

16.15 - 17.45 h  Holiday Inn - Room 8
Track T-5 Personality and behavioural disorders
Alexithymia - interaction with psychiatric and psychosomatic disorders
Chairperson: Hans Jörgen Grabe, Stralsund, Germany
Co-Chairperson: Matti Joukamaa, Tampere, Finland
S-42-01 Alexithymia across the life span
M. Joukamaa, Tampere, Finland
S-42-02 The role of alexithymia in the natural history of the functional gastrointestinal disorders
P. Porcelli, Castellana Grotte, Italy
S-42-03 Alexithymia in obsessive compulsive disorder – Results from a family study
H. J. Grabe, Stralsund, Germany
S. Ettelt, S. Ruhrmann, M. Wagner
S-42-04 Alexithymia and psychological distress - a 5 year follow-up study in general population
J. Salminen, Turku, Finland
S. Saarijärvi, T. Toikka, J. Kauhanen

SECTION SYMPOSIUM  
SS-10

16.15 - 17.45 h  Gasteig - Bibliothek
Track T-3 Affective disorders
Mood disorders and somatic syndromes
Chairperson: Martin Preisig, Prilly, Switzerland
Co-Chairperson: Jules Angst, Zurich, Switzerland
SS-10-01 Neurasthenia and atypical depression
J. Angst, Zurich, Switzerland
F. Benazzi, V. Ajdacic-Gross,
D. Eich-Höchli, W. Rössler, A. Gamma
SS-10-02 Diabetes and comorbid depression
C. Kuehner, Mannheim, Germany
F. Lederbogen, M. Deuschle
SS-10-03 Depression in neurological diseases: Emphasis on Parkinson's disease
F. Morkeberg Nilsson, Copenhagen, Denmark
M. Brandt-Christensen
SS-10-04 Comorbidity of mood disorders and migraine
M. Preisig, Prilly, Switzerland
SS-10-05 Somatic health and illness and depressive symptomatology: Data from a population health survey
M. Kovacs, Budapest, Hungary
M. Kopp

SECTION SYMPOSIUM  
SS-11

16.15 - 17.45 h  Holiday Inn - Room 2
Track T-6 Interdisciplinary Psychotherapy in postpartum
Chairperson: Christiane Hornstein, Wiesloch, Germany
Co-Chairperson: Anette Kersting, Münster, Germany
SS-11-01 Interaction focussed psychotherapy for postpartum disorders
C. Hornstein, Wiesloch, Germany
SS-11-02 Outcome of brief mother-infant psychotherapies as a function of maternal depression
C. Robert-Tissot, Switzerland
SS-11-03 Psychotherapy of parents after the birth of a dead child
A. Kersting, Münster, Germany

WORKSHOP  
W-11

16.15 - 17.45 h  Holiday Inn - Room 4
Track T-7 Social Psychiatry
New forms of cooperation between mental health care professionals and users of services
Chairperson: Michaela Amering, Vienna, Austria
Co-Chairperson: Stefan Priebe, London, United Kingdom
Speaker: S. Priebe, London, United Kingdom
M. Zaumseil, Berlin, Germany
M. Amering, Vienna, Austria
R.C. Handerson, New York, USA
D. Rose, London, United Kingdom

WORKSHOP  
W-12

16.15 - 17.45 h  Holiday Inn - Room 5
Track T-7 Social Psychiatry
Mental health in Eastern Europe and the Balkans
Chairperson: George Christodoulou, Athens, Greece
Co-Chairperson: Valery Krasnov, Moscow, Russia
Speaker: V. Krasnov, Moscow, Russia
D. Lecic-Tosevski, Belgrade, Serbia + Montenegro
G. Christodoulou, Athens, Greece
DEBATE

16.15 - 17.45 h  Gasteig - Carl-Orff-Hall
Track T-2 Psychotic Disorders
The concept of schizophrenia is not useless anymore
Chairperson: Norman Sartorius, Geneva, Switzerland

From a biological psychiatry view
W. Fleischhacker, Innsbruck, Austria

From a clinical psychiatry view
M. Musalek, Vienna, Austria

ORAL PRESENTATION O-06

16.15 - 17.45 h  Holiday Inn - Room 7
Track T-4 Anxiety-related and eating disorders
PTDS and somatoform disorders
Chairperson: Ian Brockington, Hereforshire, United Kingdom
Co-Chairperson: Michael Linden, Teltow/Berlin, Germany

O-06-01 Risperidone treatment for chronic PTSD
M. Simonovic, Serbia + Montenegro

O-06-02 PTSD problem in Ukraine
B. Mykhaylov, Kharkov, Ukraine

O-06-03 Impact of comorbid ptsd on course and familial aggregation of mood disorders
C. Vandeleur, Chene-Bourg, Geneva, Switzerland
F. Ferrero, M. Preisig

O-06-04 Refugees and healing: Possible barriers
N. Makhashvili, Tbilisi, Georgian

O-06-05 Stress reactions in victims of terrorism in Beslan
D. Veltishchev, Moscow, Russia

O-06-06 The psychopathology of posttraumatic embitterment disorders (PTED)
M. Linden, Teltow/Berlin, Germany

ORAL PRESENTATION O-06

16.15 - 17.45 h  Gasteig - Carl-Orff-Hall
Track T-2 Psychotic Disorders
The concept of schizophrenia is not useless anymore
Chairperson: Norman Sartorius, Geneva, Switzerland

From a biological psychiatry view
W. Fleischhacker, Innsbruck, Austria

From a clinical psychiatry view
M. Musalek, Vienna, Austria

ORAL PRESENTATION O-06

16.15 - 17.45 h  Holiday Inn - Room 7
Track T-4 Anxiety-related and eating disorders
PTDS and somatoform disorders
Chairperson: Ian Brockington, Hereforshire, United Kingdom
Co-Chairperson: Michael Linden, Teltow/Berlin, Germany

O-06-01 Risperidone treatment for chronic PTSD
M. Simonovic, Serbia + Montenegro

O-06-02 PTSD problem in Ukraine
B. Mykhaylov, Kharkov, Ukraine

O-06-03 Impact of comorbid ptsd on course and familial aggregation of mood disorders
C. Vandeleur, Chene-Bourg, Geneva, Switzerland
F. Ferrero, M. Preisig

O-06-04 Refugees and healing: Possible barriers
N. Makhashvili, Tbilisi, Georgian

O-06-05 Stress reactions in victims of terrorism in Beslan
D. Veltishchev, Moscow, Russia

O-06-06 The psychopathology of posttraumatic embitterment disorders (PTED)
M. Linden, Teltow/Berlin, Germany

POSTER PRESENTATION P-09

18.00 - 19.30 h  Gasteig - Foyers
Track T-3 Affective disorders
Affective disorders III
Chairperson: Filip Rybakowski, Poznan, Poland
Co-Chairperson: Verena Henkel, Munich, Germany

POSTER PRESENTATION P-10

18.00 - 19.30 h  Gasteig - Foyers
Track T-3 Affective disorders
Affective disorders III
Chairperson: Filip Rybakowski, Poznan, Poland
Co-Chairperson: Verena Henkel, Munich, Germany

POSTER PRESENTATION P-11

18.00 - 19.30 h  Gasteig - Foyers
Track T-6 Interdisciplinary
Interdisciplinary I
Chairperson: Jiri Raboch, Prague, Czech Republic
Co-Chairperson: Michael Linden, Teltow/Berlin, Germany
Concert at the Residenz, Max-Joseph Hall

German Psychiatrists play for European Psychiatrists

Monday, 4 April 2005, 19.30 h

Part I: Famous chamber music

**Ludwig van Beethoven (1770 - 1827)**
Sonata in G minor for Violoncello and Piano, op. 5 No.2
Adagio sostenuto et espressivo - Allegro molto piu
tosto presto - Rondo allegro

**Johannes Brahms (1833 - 1897)**
Sonata in A Major for Violin and Piano, op. 100
Allegro amabile - Andante tranquillo-Vivace - Allegretto grazioso

Klaus Toyka, violin
Konrad Maurer, violoncello
Rainer Rupprecht, piano
Wilfried Günther, piano

Part II: Arias of Madness from Italian Belcanto Operas of the 19th Century

**Gaetano Donizetti (1797-1848)**
Piangete voi – Al dolce guidami (Anna Bolena)

**Vincenzo Bellini (1801-1835)**
Col sorriso (I Pirati)
Ah! Non credea mirarti (La Sonnambula)
O rendetemi la speme (I Puritani)

**Gaetano Donizetti (1797-1848)**
Regnava nel silenzio (Lucia di Lammermoor)
Ardon gl’incensi (Lucia di Lammermoor)

Anna Maria Möller-Leimkühler, soprano
Wilfried Günther, piano

Residenz, Max-Joseph-Hall, Residenzstraße 1
**SYMPOSIUM S-45**

08.30 - 10.00 h Gasteig - Bibliothek
Track T-1 Substance related disorders
Genetic analyses of treatment-relevant phenotypes in alcohol dependence
Chairperson: Gunter Schumann, Mannheim, Germany
Co-Chairperson: Michael Soyka, Munich, Germany

S-45-01 Candidate genes in alcohol withdrawal process: A relevant phenotype?
P. Gorwood, Colombes, France
P. Pickering, C. Boni

S-45-02 NPY gene in anxiety-related phenotypes and alcohol dependence
M. Heilig, Bethesda, USA

S-45-03 Glutamatergic signalling genes and their association with alcohol dependence and associated phenotypes
G. Schumann, Mannheim, Germany

S-45-04 Genetic analysis of treatment-relevant phenotypes in alcohol dependence
M. Soyka, Munich, Germany
V. Hesselbrock, U. W. Preuss, G. Koller, P. Zill, B. Bondy

**SYMPOSIUM S-43**

08.30 - 10.00 h Gasteig - Philharmonie
Track T-2 Psychotic disorders
German schizophrenia research network: Results from clinical follow-up and intervention studies
Chairperson: Hans-Jürgen Möller, Munich, Germany
Co-Chairperson: Wolfgang Gaebel, Düsseldorf, Germany

S-43-01 Therapeutic results of early intervention in schizophrenia
J. Klosterkötter, Cologne, Germany
S. Ruhrmann, A. Bechdolf, M. Wagner, W. Maier

S-43-02 Outcome of acute treatment with haloperidol or risperidone in first episode schizophrenics
H.-J. Möller, Munich, Germany
W. Gaebel, R. Bottlender, G. Buchkremer, J. Klosterkötter, W. Maier

**SYMPOSIUM S-46**

08.30 - 10.00 h Holiday Inn - Room 1
Track T-2 Psychotic disorders
Neurophysiological indicators of vulnerability to schizophrenia – endophenotypes of the disease
Chairperson: Anke Brockhaus-Dumke, Cologne, Germany
Co-Chairperson: Dorien Nieman, Amsterdam, Netherlands

S-46-01 Raw eeg and erp in twins discordant for schizophrenia
M. Weisbrod, Heidelberg, Germany

S-46-02 Is the P300 wave an endophenotype for schizophrenia?
E. Bramon, London, United Kingdom
E. Bramon, C. McDonald, R. Croft, P. Sham, S. Frangou, R. Murray

S-46-03 P300 and eye movement abnormalities in patients at risk for developing psychosis
D. Nieman, Amsterdam, Netherlands
L. J. Bour, H. E. Becker, J. R. van de Fliert, N. Plat, M. Niessen,
M. C. Klaassen, P. M. Dingemans, D. H. Linszen

S-46-04 Intermediate phenotypes in schizophrenia research: P300 and Theta activity
J. Gallinat, Berlin, Germany
M. Bajbouj, T. Sander, K. Xu, D. Goldman, G. Winterer

S-46-05 Abnormalities of auditory information processing in patients at risk for psychosis
A. Brockhaus-Dumke, Cologne, Germany
F. Schultze-Lutter, R. Pukrop, I. Tendolkar,
J. Klosterkötter, S. Ruhrmann
**SYMPOSIUM S-44**

08.30 - 10.00 h  Gasteig - Black Box
Track T-3 Affective disorders
Sleep, depression and antidepressants
Chairperson: Axel Steiger, Munich, Germany
Co-Chairperson: Edith Holsboer-Trachsler, Switzerland

S-44-01  Sleep debt, reasons and consequences
J. Hetta, Stockholm, Sweden
J.-E. Broman

S-44-02  The role of peptides and steroids in normal and disturbed sleep regulation
A. Steiger, Munich, Germany

S-44-03  Sleep EEG and HPA axis regulation changes under antidepressant treatment and prediction of long-term outcome
M. Hatzinger, Basel, Switzerland
U. Hemmeter, S. Brand, M. Ising, E. Holsboer-Trachsler

S-44-04  Sleep EEG alterations as surrogate markers of serotonin and noradrenaline neurotransmission in healthy subjects: Relationship to the neurobiology of depression
L. Staner, Rouffach, France
L. Staner, F. Cornette, D. Osbild,
C. Staner, C. Gilles, R. Luthringer

**SYMPOSIUM S-47**

08.30 - 10.00 h  Holiday Inn - Room 2
Track T-3 Affective disorders
Relationship between dose and response in trials of antidepressants
Chairperson: Per Bech, Hillerod, Denmark
Co-Chairperson: Lars F. Gram, Odense, Denmark

S-47-01  Pharmacokinetics and -dynamics in dose-response trials with antidepressants
L. F. Gram, Odense, Denmark

S-47-02  Receptor binding problems in dose-response trials of antidepressants
B. Leonhard, Ireland

S-47-03  A linear dose-response relationship of venlafaxine in major depression
P. Boyer, Ottawa, Canada

S-47-04  Dose-response relationship of other antidepressants using unidimensional depression scales
P. Bech, Hillerod, Denmark

**SYMPOSIUM S-48**

08.30 - 10.00 h  Holiday Inn - Room 3
Track T-5 Personality and behavioural disorders
Social brain and psychopathology
Chairperson: Martin Brüne, Bochum, Germany
Co-Chairperson: Shigenobu Kanba, Fukuoka, Japan

S-48-01  Evolutionary perspectives on schizophrenia
J. Polimeni, Winnipeg, Canada

S-48-02  Theory of mind and linguistic skills in patients with schizophrenia
M. Brüne, Bochum, Germany
SCIENTIFIC PROGRAM
TUESDAY, 5 APRIL 2005

SYMPOSIUM S-48

S-48-03 Non-verbal communication processes predict onset and course of depression - ethological analyses of depressed patients' and interviewers' interpersonal behaviour
E. Geerts, Groningen, Netherlands
A. L. Bouhuys, T. W. van Os

S-48-04 Deficit of theory of mind found in remitted depression: Practical implication
S. Kanba, Fukuoka, Japan
Y. Inoue, K. Yamada

SYMPOSIUM S-49

08.30 - 10.00 h Holiday Inn - Room 6
Track T-5 Personality and behavioural disorders
ADHD, autism and personality disorders: Cookbook diagnoses?
Chairperson: Susanne Bejerot, Stockholm, Sweden
Co-Chairperson: Willem Verhoeven, Venray, Netherlands

S-49-01 Comorbidity and spectrum disorders: Diagnostic confusion?
S. Tuinier, Venray, Netherlands
W. Verhoeven, J. I. Egger

S-49-02 Self-assessed personality traits in adults with ADHD or autism spectrum disorders (ASD) - relevance for diagnosis?
L. Nylander, Lund, Sweden

S-49-03 Genetic research in autism: What do we learn from it?
J. Steyaert, Leuven, Belgium
J.-P. Fryns, K. Devriendt

S-49-04 How to create brief and meaningful psychotherapy from assessing psychiatric symptoms, minor physical abnormalities and soft neurological signs
S. Bejerot, Stockholm, Sweden

S-49-05 Comorbidity and spectrum disorders: Diagnostic confusion?
W. Verhoeven, Venray, Netherlands

S-49-06 Subclinical attention deficit/hyperactivity disorder and adjustment disorders
A. Bobrov, Moscow, Russia

SECTION SYMPOSIUM SS-12

08.30 - 10.00 h Gasteig - Carl-Orff Saal
Track T-6 Interdisciplinary
Pain and psychiatry
Chairperson: Manfred Ackenheil, Munich, Germany
Co-Chairperson: D. Pongratz, Munich, Germany

SS-12-01 Classification of neuropathic pain
D. Pongratz, Munich, Germany

SS-12-02 Epidemiology of fibromyalgia
F. Blotman, Montpellier, France
E. Thomas

SS-12-03 The pathophysiology of pain
W. Zieglgänsberger, Munich, Germany

SS-12-04 Is there a common genetic basis for depression and the fibromyalgia syndrome?
B. Bondy, Munich, Germany

SS-12-05 Current trend in treatments of neuropathic pain
M. Ackenheil, Munich, Germany

SECTION SYMPOSIUM SS-13

08.30 - 10.00 h Gasteig - Room 0.131
Track T-6 Interdisciplinary
Physical illness in mentally disordered
Chairperson: Povl Munk-Jørgensen, Aalborg, Denmark
Co-Chairperson: Norman Sartorius, Geneva, Switzerland

SS-13-01 General introduction
P. Munk-Jørgensen, Aalborg, Denmark

SS-13-02 Physical illness in mentally disordered in Nigeria
R. Uwakwe, Nnewe, Nigeria

SS-13-03 Obesity and diabetes in mentally disordered
S. Leucht, Munich, Germany

SS-13-04 Physical illness in people with mental disorder:
First results of an international project and future plans
N. Sartorius, Geneva, Switzerland
WORKSHOP W-14

08.30 - 10.00 h Holiday Inn - Room 5
Track T-6 Interdisciplinary
Cox-2 inhibitors in the therapy of psychiatric disorders
Chairperson: Norbert Müller, Munich, Germany
Co-Chairperson: P. Egger, Greenford, United Kingdom
Speaker: M. J. Schwarz, Munich, Germany
B. Sperner-Unterweger, Innsbruck, Austria
M. Riedel, Munich, Germany
P. Egger, Greenford, United Kingdom
N. Müller, Munich, Germany

WORKSHOP W-13

08.30 - 10.00 h Holiday Inn - Room 4
Track T-7 Social Psychiatry
AEP Human Rights Workshop (Under the Auspices of the Secretary General of the Council of Europe, Mr. Terry Davis)
Chairperson: Paul Cosyns, Edegem, Belgium
Speaker: C. Orizet, Strasbourg, France
G. Niveau, Geneva, Switzerland
M. Kastup, Copenhagen, Denmark

EDUCATIONAL COURSE C-12

08.30 - 12.00 h Hilton - Salon Bialas
Track T-2 Psychotic disorders
Cognitive dysfunction in schizophrenia - brief clinical assessments and treatment strategies
Organizer: T. Sharma, Dartford, United Kingdom
Speaker: V. Kumari, London, United Kingdom

EDUCATIONAL COURSE C-14

08.30 - 12.00 h Hilton - Salon Studer
Track T-6 Interdisciplinary
Internet-based treatment in psychiatry
Organizer: N. Lindefors, Stockholm Sweden

EDUCATIONAL COURSE C-13

08.30 - 12.00 h Hilton - Salon Orff
Track T-7 Social Psychiatry
Principles of psychiatric interview how to examine and assess personal experiences
Organizer: G. Stanghellini, Florence, Italy
Speaker: B. Fulford, Coventry, United Kingdom

ORAL PRESENTATION O-07

08.30 - 10.00 h Holiday Inn - Room 7
Track T-2 Psychotic disorders
Psychotic disorders I
Chairperson: Philip McGuire, London, United Kingdom
Co-Chairperson: Georg Winterer, Mainz, Germany

O-07-01 Intracellular events preceding excitotoxic neurodegeneration - Implications for schizophrenia as a disorder of glutamate neurotransmission
J. Genius, Munich, Germany
D. Rujescu, H.-J. Möller

O-07-02 The impact of neurotransmitters on adult neural stem cells derived from mouse hippocampus
J. Benninghoff, Munich, Germany
A. Gritti, H.-J. Möller, D. Rujescu, A. Vescovi

O-07-03 Neuronal dysfunction in patients with schizophrenia and their association with psychopathology
S. Karch, Munich, Germany

O-07-04 Instability of cortical signal processing in schizophrenia - A combined Event-Related fMRI- and MEG-Study
G. Winterer, Mainz, Germany

O-07-05 Altered brain activity after standardized emotion discrimination training in patients with schizophrenia: An fMRI study
K. Koch, Aachen, Germany

O-07-06 Gender differences in brain activity in patients with schizophrenia and healthy controls
K. Pauly, Aachen, Germany

O-07-07 Relationship between neurological soft signs and verbal fluency with psychopathology in first-episode psychosis
A. Fontalba Navas, Granada, Spain
M. L. Barrigón Estévez, M. Ruiz Vegilla, M. Anguita Romero, L. Gomis Fletcher
ORAL PRESENTATION  O-07

O-07-08 Central monoaminergic dysfunction in psychiatric disorders as assessed by neurophysiological and neuroimaging techniques
O. Pogarell, Munich, Germany

O-07-09 Association between early development at age 1 year and the course of illness in adult schizophrenia - a 34-year follow-up of the northern Finland 1966 birth cohort
E. Lauronen, Oulu, Finland
J. Miettunen, J. Veijola, G. K. Murray, M. John, P. B. Jones, M. Isohanni

O-07-10 Length of first hospitalization and relapse in psychoses - The Northern Finland 1966 birth cohort study
J. Miettunen, Oulu, Finland
E. Lauronen, J. Veijola, M. Isohanni

YP-BREAKFAST MEETING  YP-BF-02

08.45 - 09.30 h Gasteig - Young Psych. Lounge
Track T-6 Interdisciplinary
Is Psychotherapy relevant for good psychiatric practice?
Chairperson: Iris Calliess, Hannover, Germany
Speaker: F. Hohagen, Lübeck, Germany

PLENARY LECTURE  L-03

10.30 - 11.15 h Gasteig - Philharmonie
Track T-0 Dementia
Dementia: Aetiopathogenesis and future perspectives in the treatment
Chairperson: J. Förstl, Munich, Germany
Speaker: K. Beyreuther, Heidelberg, Germany

PLENARY LECTURE  L-04

10.30 - 11.15 h Gasteig - Carl-Orff Saal
Track T-1 Substance related disorders
Addiction
Chairperson: Karl Mann, Mannheim, Germany
Medications development in alcoholism: The translation strategy of the National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Speaker: M. Heilig, Bethesda, USA

MEET-THE-EXPERT SESSION  M-03

11.15 - 12.15 h Gasteig - Black Box
Track T-6 Interdisciplinary
Meet the experts: Alzheimer
Speaker: J. Förstl, Munich, Germany

POSTER PRESENTATION  P-12

11.15 - 12.15 h Gasteig - Foyers
Track T-3 Affective disorders
Affective disorders II
Chairperson: Jules Angst, Zurich, Switzerland
Co-Chairperson: Eduard Vieta, Barcelona, Spain

POSTER PRESENTATION  P-13

11.15 - 12.15 h Gasteig - Foyers
Track T-4 Anxiety-related and eating disorders
PTSD and eating disorders
Chairperson: Roman A. Evsegneev, Minsk, Belarus
Co-Chairperson: Fernando Fernandez-Aranda, Barcelona, Spain

LUNCHEON SYMPOSIUM  LS-05

12.30 - 14.00 h Gasteig - Carl-Orff Saal
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning
Chairperson: Hans-Jürgen Möller, Munich, Germany
Speaker: M. Riedel, Munich, Germany
K.U. Kühn, Bonn, Germany
M. Dobmeier, Regensburg, Germany
M. Lambert, Hamburg, Germany
Supported by an unrestricted educational grant from AstraZeneca

SYMPOSIUM  S-51

14.15 - 15.45 h Gasteig - Philharmonie
Track T-2 Psychotic disorders
Treatment of first episode schizophrenia
Chairperson: Wolfgang Gaebel, Düsseldorf, Germany
Co-Chairperson: Wolfgang Fleischhacker, Innsbruck, Austria
S-51-01 Outcome in first episode patients under naturalistic conditions
R. Bottlender, Munich, Germany
**SYMPOSIUM S-51**

**S-51-02** Treatment of first episode schizophrenia  
W. Gaebel, Düsseldorf, Germany  
W. Fleischhacker, R. Bottlender,  
W. Gaebel, R. Kahn, W. Fleischhacker,  
W. Wölwer

**S-51-03** Side effects and compliance in first episode schizophrenia  
W. Fleischhacker, Innsbruck, Austria

**S-51-04** Neuropsychological correlates of prodromal symptoms in first episode schizophrenia  
W. Wölwer, Düsseldorf, Germany  
W. Gaebel

**SYMPOSIUM S-55**

**S-55-01** Theory and practice in quantitative genetics: The use of endophenotypes in detecting QTLs for schizophrenia  
D. Posthuma, Amsterdam, Netherlands

**S-55-02** Genetic variations underlying electrophysiological endophenotypes in schizophrenia  
F. Thibaut, Rouen, France

**S-55-03** Genetic analyses using eye movement disturbances as endophenotypic marker in schizophrenia  
F. Rybakowski, Poznan, Poland  
A. Borkowska, P. Czerski, J. Hauser

**S-55-04** Endophenotypes for molecular genetic studies in schizophrenia  
D. Rujescu, Munich, Germany

**SYMPOSIUM S-03**

**S-03-01** Therapeutic drug monitoring of risperidone in relation to MDR1 genotype and hormone levels  
M. Riedel, Munich, Germany

**S-03-02** Therapeutic drug monitoring of quetiapine and its major metabolites quetiapine-sulfoxide and 7-hydroxy-quetiapine  
M. J. Schwarz, Munich, Germany  
I. Spellmann, A. Müller-Arends,  
S. Dehning, R. Musil, M. Opger-Rhein,  
J. Zach, H.-D. Li, N. Müller, H.-J. Möller,  
M. Riedel

**SYMPOSIUM S-53**

**S-53-01** Daytime microsleep, GABAergic mechanisms and neuroendocrine secretion in relation sleep deprivation response in patients with major depression  
U. Hemmeter, Marburg, Germany  
M. Hatzinger, E. Seifritz, E. Holsboer-Trachsler

**S-53-02** Sleep deprivation in depression: Involvement of the Renin-Angiotensin-Aldosteron system?  
H. Murck, Stirling, United Kingdom  
M. Uhr, M. Ziegenbein, H. Kuenzel,  
K. Held, I. Antonijevic

**S-53-03** HPA system and neurosteroid regulation in relation to sleep deprivation in major depression  
C. Schüle, Munich, Germany  
T. Baghai, P. Zwanzger, D. Eser,  
C. Nothdurfter, R. Rupprecht

**S-53-04** The role of brain monoamines in the antidepressant response to sleep deprivation  
F. Benedetti, Milan, Italy  
B. Barbini, A. Bernasconi, , M. Cigala  
Fulgosi, C. Colomba, S. Dallaspезia,  
A. Pontiggia, E. Smeraldi

**S-53-05** Therapeutic efficacy of sleep deprivation and other sleep-wake-manipulations in major depression  
D. Riemann, Freiburg, Germany
### SYMPOSIUM S-54

14.15 - 15.45 h  
Gasteig - Room 0.131  
Track T-4 Anxiety-related and eating disorders  
Dissociation across the trauma spectrum - neurobiology and treatment issues  
Chairperson: Eric Vermetten, CX Utrecht, Netherlands  
Co-Chairperson: Christian Schmahl, Mannheim, Germany

- **S-54-01** Neuroimaging of dissociative states in PTSD  
  R. Lanius, London, Ontario, Canada  
  P. Williamson, K. Boksman, M. Densmore, R. Neufeld, J. Gati, R. Menon

- **S-54-02** Dissociative symptoms in patients with borderline personality disorder  
  C. Schmahl, Mannheim, Germany  
  M. Bohus

- **S-54-03** Current findings in neurobiology and treatment in traumatic dissociation  
  E. Vermetten, Utrecht, Netherlands  
  R. Lanius, R. Lanius

### SYMPOSIUM S-56

14.15 - 15.45 h  
Holiday Inn - Room 2  
Track T-7 Social Psychiatry  
Added value? European multi-centre service studies  
Chairperson: Stefan Priebe, London, United Kingdom  
Co-Chairperson: Thomas Kallert, Dresden, Germany

- **S-56-01** The impact of outcome management in community health care - the MECCA study  
  S. Priebe, London, United Kingdom  
  J. Bullenkamp, W. Rossler, L. Hansson, D. Wiersma, F. Torres Gonzalez

- **S-56-02** Assessment of long-term outcomes and treatment seeking following posttraumatic stress - the STOP study and the CONNECT study  
  D. Lecic-Tosevski, Belgrad, Serbia + Montenegro

- **S-56-03** Involuntary hospital admissions in Europe - EUROMIA  
  T. Kallert, Dresden, Germany  

### SYMPOSIUM S-57

14.15 - 15.45 h  
Holiday Inn - Room 6  
Track T-7 Social Psychiatry  
The many facets of stalking  
Chairperson: Christine Kuehner, Mannheim, Germany  
Co-Chairperson: Harald Dreßing, Germany

- **S-57-02** Stalking and domestic violence: Theoretical implications and empirical results  
  H.-G. Voss, Darmstadt, Germany

- **S-57-03** Prevalence, nature and social consequences of stalking in the community  
  P. Gass, Mannheim, Germany

- **S-57-04** Mental health impact of stalking on victims - a community-based study  
  C. Kuehner, Mannheim, Germany

- **S-57-05** Stalking and the helping professional: Importance of the setting  
  G. M. Galeazzi, Sassuolo, Italy

### SECTION SYMPOSIUM SS-14

14.15 - 15.45 h  
Holiday Inn - Room 3  
Track T-6 Interdisciplinary  
Emotional neuroscience in psychiatry (under aegis of AEP neuroimaging section)  
Chairperson: Andreas Heinz, Berlin, Germany  
Co-Chairperson: Sophia Frangou, London, United Kingdom

- **SS-14-01** Title unknown  
  J. O’Doherty, London, United Kingdom

- **SS-14-02** Reduced ventral striatal activation during expectancy of reward but not loss in untreated schizophrenics - association with negative symptoms  
  G. Juckel, Berlin, Germany  
  J. Wrase, A. Heinz, F. Schlagenhauf, B. Knutson
<table>
<thead>
<tr>
<th>SECTION SYMPOSIUM</th>
<th>SS-14</th>
</tr>
</thead>
<tbody>
<tr>
<td>SS-14-03 Brain imaging in bipolar disorder</td>
<td>S. Frangou, London, United Kingdom</td>
</tr>
<tr>
<td>SS-14-04 Neuroimaging of Aggression and Impulsivity</td>
<td>S. C. Herpertz, Rostock, Germany T. Vloet, B. Herpertz-Dahlmann, I. Marx, G. Fink</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOP</th>
<th>W-17</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15 - 15.45 h</td>
<td>Holiday Inn - Room 8</td>
</tr>
<tr>
<td>Track T-1 Substance related disorders</td>
<td>Addictive behaviours across the lifespan of a doctor</td>
</tr>
<tr>
<td>Chairperson: Miquel Casas, Barcelona, Spain</td>
<td>Co-Chairperson: Antonio Gual Sole, Barcelona, Spain</td>
</tr>
<tr>
<td>Speaker: M. Dahlin, Stockholm, Sweden M. Casas, Barcelona, Spain P. Lusilla, Barcelona, Spain R. Tyssen, Oslo, Norway</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOP</th>
<th>W-15</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15 - 15.45 h</td>
<td>Holiday Inn - Room 4</td>
</tr>
<tr>
<td>Track T-3 Affective disorders</td>
<td>Comorbidity in bipolar disorders</td>
</tr>
<tr>
<td>Chairperson: Peter Brieger, Halle, Germany</td>
<td>Co-Chairperson: Zoltan Rihmer, Budapest, Hungary</td>
</tr>
<tr>
<td>Speaker: G. Perugi, Pisa, Italy A. Erfurth, Augsburg, Germany Z. Rihmer, Budapest, Hungary I. Maremmani, Pisa, Italy P. Brieger, Halle, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WORKSHOP</th>
<th>W-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15 - 15.45 h</td>
<td>Holiday Inn - Room 5</td>
</tr>
<tr>
<td>Track T-5 Personality and behavioural disorders</td>
<td>Stress and personality: How personality factors correlate with coping styles</td>
</tr>
<tr>
<td>Chairperson: Carlo Pruneri, Monza, Italy</td>
<td>Co-Chairperson: Fabio Furlani, Monza, Italy</td>
</tr>
<tr>
<td>Speaker: S. Damiano, Monza, Italy I. Alberton, Monza, Italy E. Pellegrini, Monza, Italy M. Gatti, Monza, Italy F. Furlani, Monza, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRO-AND CON-DEBATE</th>
<th>D-05</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15 - 15.45 h</td>
<td>Gasteig - Carl-Orff-Hall</td>
</tr>
<tr>
<td>Track T-6 Interdisciplinary</td>
<td>The results of meta-analysis give the highest level of evidence</td>
</tr>
<tr>
<td>Chairperson: Jules Angst, Zurich, Switzerland</td>
<td>Pro-Author: H.-J. Möller, Munich, Germany</td>
</tr>
<tr>
<td>Con-Author: W. Maier, Bonn, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EDUCATIONAL COURSE</th>
<th>C-15</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15 - 17.45 h</td>
<td>Hilton - Salon Bialas</td>
</tr>
<tr>
<td>Track T-1 Substance related disorders</td>
<td>Alcohol dependence</td>
</tr>
<tr>
<td>Organizer: K. Mann, Mannheim, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EDUCATIONAL COURSE</th>
<th>C-16</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15 - 17.45 h</td>
<td>Gasteig - Stimmzimmer 1.213</td>
</tr>
<tr>
<td>Track T-7 Social Psychiatry</td>
<td>Masterclass on ‘patient-level needs assessment’</td>
</tr>
<tr>
<td>Organizer: M. Slade, London, United Kingdom M. Ruggeri, Verona, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EDUCATIONAL COURSE</th>
<th>C-17</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15 - 17.45 h</td>
<td>Hilton - Salon Studer</td>
</tr>
<tr>
<td>Track T-3 Affective disorders</td>
<td>Interpersonal psychotherapy of depression</td>
</tr>
<tr>
<td>Organizer: T. Grüttert, Düsseldorf, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EDUCATIONAL COURSE</th>
<th>C-18</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15 - 14.45 h</td>
<td>Hilton - Salon Orff</td>
</tr>
<tr>
<td>Track T-6 Interdisciplinary</td>
<td>How to write and publish a scientific paper (editor in chief Acta Psychiatrica Scandinavica)</td>
</tr>
<tr>
<td>Organizer: P. Munk-Jorgensen, Aarlborg, Denmark</td>
<td></td>
</tr>
</tbody>
</table>
14.15 - 15.45 h  Holiday Inn - Room 7
Track T-2 Psychotic disorders
Psychotic disorders II
Chairperson: Michael Musalek, Vienna, Austria
Co-Chairperson: Gerd Laux, Wasserburg, Germany

O-08-01 How ill are persons at risk for psychosis? A comparison with first-episode schizophrenia and non-psychotic affective disorder
F. Schultze-Lutter, Cologne, Germany
S. Ruhrmann, H. Picker, A. Wieneke, E.-M. Steinmeyer, J. Klosterkötter

O-08-02 Family psychoeducation in schizophrenia: Health and social outcomes. Prospective Follow-up field study
L. Motlova, Prague, Czech Republic

O-08-03 Course of treatment and compliance of schizophrenic patients after four years
R. Borbe, Tübingen, Germany
K. Kammer, G. Längle

O-08-04 Effect of ziprasidone on lipid levels
H. Nasrallah, Cincinnati, USA
A. Loebel, S. Murray, E. Batzar

O-08-05 Atypical antipsychotics and metabolic syndrome
G. Laux, Wasserburg, Germany
M. Fric, S. Artmann

O-08-06 Attitudes of German psychiatrists towards different strategies of antipsychotic treatment – results from a national survey
M. Franz, Gießen, Germany
J. Ranger, M. Matheis, B. Gallhofer

O-08-07 Psychosis in an inpatient unit: Types of patients and treatment
B. Perez Ramirez, Almeria, Spain
M. Marin Ollalla

O-08-08 Structure of complementary care of schizophrenic patients
V. Lambolez, Nancy, France

O-08-09 Cognitive-behavioural treatment for schizophrenic patients in routine care: Results of a RCT
G. Wiedemann, Frankfurt, Germany
S. Klingberg, A. Wittorf, A. Fischer, K. Jakob-Deters, G. Buchkremer

O-08-10 Effect of a adherence counselling training package for case managers on relapse for patients with schizophrenia: cluster randomised controlled trial
R. Gray, London, United Kingdom
D. Robson

16.15 - 17.45 h  Holiday Inn - Room 7
Track T-2 Psychotic disorders
Psychotic disorders II
Chairperson: Michael Musalek, Vienna, Austria
Co-Chairperson: Gerd Laux, Wasserburg, Germany

O-08-01 How ill are persons at risk for psychosis? A comparison with first-episode schizophrenia and non-psychotic affective disorder
F. Schultze-Lutter, Cologne, Germany
S. Ruhrmann, H. Picker, A. Wieneke, E.-M. Steinmeyer, J. Klosterkötter

O-08-02 Family psychoeducation in schizophrenia: Health and social outcomes. Prospective Follow-up field study
L. Motlova, Prague, Czech Republic

O-08-03 Course of treatment and compliance of schizophrenic patients after four years
R. Borbe, Tübingen, Germany
K. Kammer, G. Längle

O-08-04 Effect of ziprasidone on lipid levels
H. Nasrallah, Cincinnati, USA
A. Loebel, S. Murray, E. Batzar

O-08-05 Atypical antipsychotics and metabolic syndrome
G. Laux, Wasserburg, Germany
M. Fric, S. Artmann

O-08-06 Attitudes of German psychiatrists towards different strategies of antipsychotic treatment – results from a national survey
M. Franz, Gießen, Germany
J. Ranger, M. Matheis, B. Gallhofer

O-08-07 Psychosis in an inpatient unit: Types of patients and treatment
B. Perez Ramirez, Almeria, Spain
M. Marin Ollalla

O-08-08 Structure of complementary care of schizophrenic patients
V. Lambolez, Nancy, France

O-08-09 Cognitive-behavioural treatment for schizophrenic patients in routine care: Results of a RCT
G. Wiedemann, Frankfurt, Germany
S. Klingberg, A. Wittorf, A. Fischer, K. Jakob-Deters, G. Buchkremer

O-08-10 Effect of a adherence counselling training package for case managers on relapse for patients with schizophrenia: cluster randomised controlled trial
R. Gray, London, United Kingdom
D. Robson

16.15 - 17.45 h  Gasteig - Bibliothek
Track T-1 Substance related disorders
Difficult to treat addicted patients
Chairperson: Anne-Marie Pezous, Paris, France
Co-Chairperson: Christian Haasen, Hamburg, Germany

S-59-01 Heroin assisted treatment of opiate dependence in five European countries
C. Haasen, Hamburg, Germany

S-59-03 Comorbidity of drug dependence and ADHD syndrome
M. Casas, Barcelona, Spain

S-59-04 Street work with crack addicted patients in the North of Paris
A.-M. Pezous, Paris, France

S-59-05 Resistant patients are not difficult patients. The role of compliance.
A. Gual Sole, Barcelona, Spain

16.15 - 17.45 h  Holiday Inn - Room 7
Track T-2 Psychotic disorders
Psychotic disorders II
Chairperson: Michael Musalek, Vienna, Austria
Co-Chairperson: Gerd Laux, Wasserburg, Germany

O-08-01 How ill are persons at risk for psychosis? A comparison with first-episode schizophrenia and non-psychotic affective disorder
F. Schultze-Lutter, Cologne, Germany
S. Ruhrmann, H. Picker, A. Wieneke, E.-M. Steinmeyer, J. Klosterkötter

O-08-02 Family psychoeducation in schizophrenia: Health and social outcomes. Prospective Follow-up field study
L. Motlova, Prague, Czech Republic

O-08-03 Course of treatment and compliance of schizophrenic patients after four years
R. Borbe, Tübingen, Germany
K. Kammer, G. Längle

O-08-04 Effect of ziprasidone on lipid levels
H. Nasrallah, Cincinnati, USA
A. Loebel, S. Murray, E. Batzar

O-08-05 Atypical antipsychotics and metabolic syndrome
G. Laux, Wasserburg, Germany
M. Fric, S. Artmann

O-08-06 Attitudes of German psychiatrists towards different strategies of antipsychotic treatment – results from a national survey
M. Franz, Gießen, Germany
J. Ranger, M. Matheis, B. Gallhofer

O-08-07 Psychosis in an inpatient unit: Types of patients and treatment
B. Perez Ramirez, Almeria, Spain
M. Marin Ollalla

O-08-08 Structure of complementary care of schizophrenic patients
V. Lambolez, Nancy, France

O-08-09 Cognitive-behavioural treatment for schizophrenic patients in routine care: Results of a RCT
G. Wiedemann, Frankfurt, Germany
S. Klingberg, A. Wittorf, A. Fischer, K. Jakob-Deters, G. Buchkremer

O-08-10 Effect of a adherence counselling training package for case managers on relapse for patients with schizophrenia: cluster randomised controlled trial
R. Gray, London, United Kingdom
D. Robson

16.15 - 17.45 h  Holiday Inn - Room 7
Track T-2 Psychotic disorders
Psychotic disorders II
Chairperson: Michael Musalek, Vienna, Austria
Co-Chairperson: Gerd Laux, Wasserburg, Germany

O-08-01 How ill are persons at risk for psychosis? A comparison with first-episode schizophrenia and non-psychotic affective disorder
F. Schultze-Lutter, Cologne, Germany
S. Ruhrmann, H. Picker, A. Wieneke, E.-M. Steinmeyer, J. Klosterkötter

O-08-02 Family psychoeducation in schizophrenia: Health and social outcomes. Prospective Follow-up field study
L. Motlova, Prague, Czech Republic

O-08-03 Course of treatment and compliance of schizophrenic patients after four years
R. Borbe, Tübingen, Germany
K. Kammer, G. Längle

O-08-04 Effect of ziprasidone on lipid levels
H. Nasrallah, Cincinnati, USA
A. Loebel, S. Murray, E. Batzar

O-08-05 Atypical antipsychotics and metabolic syndrome
G. Laux, Wasserburg, Germany
M. Fric, S. Artmann

O-08-06 Attitudes of German psychiatrists towards different strategies of antipsychotic treatment – results from a national survey
M. Franz, Gießen, Germany
J. Ranger, M. Matheis, B. Gallhofer

O-08-07 Psychosis in an inpatient unit: Types of patients and treatment
B. Perez Ramirez, Almeria, Spain
M. Marin Ollalla

O-08-08 Structure of complementary care of schizophrenic patients
V. Lambolez, Nancy, France

O-08-09 Cognitive-behavioural treatment for schizophrenic patients in routine care: Results of a RCT
G. Wiedemann, Frankfurt, Germany
S. Klingberg, A. Wittorf, A. Fischer, K. Jakob-Deters, G. Buchkremer

O-08-10 Effect of a adherence counselling training package for case managers on relapse for patients with schizophrenia: cluster randomised controlled trial
R. Gray, London, United Kingdom
D. Robson
SCIENTIFIC PROGRAM
TUESDAY, 5 APRIL 2005

SYMPOSIUM S-60

S-60-04 Pathways to care in the prodromal phase of psychosis
S. Ruhrmann, Cologne, Germany

S-60-05 Title unknown
M. Birchwood, Birmingham, United Kingdom

SYMPOSIUM S-61

16.15 - 17.45 h Holiday Inn - Room 2
Track T-2 Psychotic disorders
Overlapping of schizophrenic and affective spectra
Chairperson: Andreas Marneros, Halle, Germany
Co-Chairperson: Eduard Vieta, Barcelona, Spain

S-61-01 Overlapping of schizophrenic and affective spectra: The clinical argument
A. Marneros, Halle, Germany

S-61-02 Cognitive deficits in schizophrenic and bipolar disorder
E. Vieta, Barcelona, Spain
C. Daban, A. Martinez-Aran

S-61-03 Diagnosis-specific or unspecific disposition genes for schizophrenia and affective disorders?
W. Maier, Bonn, Germany

S-61-04 Depression in schizophrenia and affective disorder - clues to affective-emotional dysfunction from the viewpoint of functional psychopathology
W. Gaebel, Düsseldorf, Germany

SYMPOSIUM S-58

S-58-01 Placebo controlled studies to establish efficacy and safety of antidepressants: Regulatory requirements for the development of antidepressive drugs
K. Broich, Bonn, Germany
A. Koch

S-58-02 Placebo-controlled studies in depression: Necessary, ethical and feasible
D. Baldwin, Southhampton, United Kingdom

S-58-03 Placebo-controlled studies in depression from the patient's point of view: Efficacy and safety
S. Kasper, Vienna, Austria
R. Frey

S-58-04 The feasibility of placebo-controlled studies in depression in Europe: A survey by GlaxoSmithKline
D. Angersbach, Munich, Germany

SYMPOSIUM S-62

16.15 - 17.45 h Holiday Inn - Room 3
Track T-4 Anxiety-related and eating disorders
Trauma- and stress-related disorders: New research findings
Chairperson: Michael Kellner, Hamburg, Germany
Co-Chairperson: Christian Otte, Hamburg, Germany

S-62-01 Association between childhood trauma and catecholamine response to psychological stress in police academy recruits
C. Otte, Hamburg, Germany
T. Neylan, R. Yehuda, C. Marmar

S-62-02 Long term health consequences: Relation of central nervous system hyperarousal and immune and hemodynamic indices in PTSD
D. G. Baker, Cincinnati, USA
T. Geracioli, N. Ekhator, J. Strawn, B. Dashevsky, H. Paul

S-62-03 Early psychopathological consequences of rape in childhood
T. Kolesnichenko, Chelyabinsk, Russia

S-62-04 Anxiety in combat-related posttraumatic stress disorder
N. Atamanova, Chelyabinsk, Russia

S-62-05 Brain imaging, neurocognition, and HPA status in PTSD
T. Neylan, San Francisco, USA
C. Otte, M. Weiner, C. Marmar
### SYMPOSIUM S-20

**16.15 - 17.45 h**
Holiday Inn - Room 8

**Track T-6**

**Interdisciplinary**

**Evolutionary psychiatry**

Chairperson: Pierre Schulz, Chêne-Bourg, Switzerland

Co-Chairperson: Thierry Steimer, Geneva, Switzerland

**S-20-01**
What is evolutionary psychiatry?
T. Steimer, Geneva, Switzerland

**S-20-03**
Therapeutic implications of Darwinian psychiatry
A. Troisi, Rome, Italy

**S-20-04**
The human nature of animals
J. Koolhaas, Haren, Netherlands

### SYMPOSIUM S-63

**16.15 - 17.45 h**
Holiday Inn - Room 6

**Track T-7**

**Social Psychiatry**

**Future directions of mental health care**

Chairperson: Stefan Priebe, London, United Kingdom

Co-Chairperson: Angelo Fioritti, Rimini, Italy

**S-63-01**
Trust and choice in mental health - some postmodern implications for the future
R. Laugharne, Exeter, United Kingdom

**S-63-02**
Re-institutionalisation in different European countries
S. Priebe, London, United Kingdom
A. Badesconyi, A. Fioritti, L. Hansson, R. Kilian, F. Torres Gonzalez, T. Turner, D. Wiersma

**S-63-03**
Changing legal frameworks for mental health care in Europe
A. Fioritti, Rimini, Italy

**S-63-04**
Integrative treatment in schizophrenia
T. Burns, Oxford, United Kingdom

### SECTION SYMPOSIUM SS-15

**16.15 - 17.45 h**
Gasteig - Black Box

**Track T-2**

**Psychotic disorders**

**Cognitive endophenotypes and pharmacological treatment of schizophrenia**

Chairperson: Tonmoy Sharma, Dartford, United Kingdom

Co-Chairperson: Wolfgang Fleischhacker, Innsbruck, Austria

**SS-15-01**
Long-term effect of low dose risperdone in high risk relatives of schizophrenia
F. Rybakowski, Poznan, Poland

**SS-15-02**
Effects of Antipsychotics on Early Information Processing Deficits in Schizophrenia
V. Kumari, London, United Kingdom

**SS-15-03**
Memory disorders and functional MRI in schizophrenia
W. Fleischhacker, Innsbruck, Austria

**SS-15-04**
Cognitive enhancement in schizophrenia
T. Sharma, Dartford, United Kingdom

### SECTION SYMPOSIUM SS-16

**16.15 - 17.45 h**
Gasteig - Room 0.131

**Track T-3**

**Affective disorders**

**Biological rhythm in psychiatry**

Chairperson: Manfred Ackenheil, Munich, Germany

Co-Chairperson: J.P. Macher, Rouffach, France

**SS-16-01**
Chronobiology and mood disorders
A. Wirz-Justice, Basel, Switzerland

**SS-16-02**
Role of melatonin in the circadian system, melatonin and circadian organization of functions, melatonin and biological rhythms
P. Pevet, Strasbourg, France

**SS-16-03**
Sleep deprivation and antidepressant treatment
U. Voderholzer, Freiburg, Germany
M. Berger, D. Riemann

**SS-16-04**
Sleep-wake rhythm disturbances in major depression and primary insomnia: A study of sleep microstructure
L. Staner, Rouffach, France

**SS-16-05**
Treatment of seasonal affective disorder
K. V. Danilenko, Novosibirsk, Russia
WORKSHOP  W-18

16.15 - 17.45 h  Holiday Inn - Room 4
Track T-3 Affective disorders
Fate of psychotropic drugs at the blood-brain-barrier and in
the brain: Pharmacokinetic, pharmacodynamic and clinical
consequences
Chairperson:  Pierre Baumann, Prilly-Lausanne, Switzerland
Co-Chairperson: Georg Nikisch, Fulda, Germany
Speaker:  G. Nikisch, Fulda, Germany
P. Baumann, Prilly-Lausanne, Switzerland
J. Sacher, Vienna, Austria
C. Hiemke, Mainz, Germany
F. Bengtsson, Linköping, Sweden

WORKSHOP  W-20

16.15 - 17.45 h  Holiday Inn - Room 5
Track T-7 Social Psychiatry
Future directions of soteria-concepts in the treatment of acute
psychosis
Chairperson:  I. Callies, Hannover, Germany
Co-Chairperson: John R. Bola, Los Angeles, USA
Speaker:  John R. Bola, Los Angeles, USA
W. Eymer, Haar, Germany
H. Hoffmann, Bern, Switzerland
I. Callies, Hannover, Germany

DEBATE  D-06

16.15 - 17.45 h  Gasteig - Carl-Orff-Hall
Track T-6 Interdisciplinary
Psychiatry: Nature and Nature Interplay
Chairperson:  Dan Rujescu, Munich, Germany
Discussants: F. Thibaut, Rouen, France
R. Kerwin, London, United Kingdom

ORAL PRESENTATION  O-09

16.15 - 17.45 h  Holiday Inn - Room 7
Track T-1 Substance related disorders
Substance-related disorders
Chairperson:  Mats Berglund
Co-Chairperson: Ulrich Preuss, Greifswald, Germany

0-09-01 Genetic variants of the glutamate system and
their role in alcohol dependence withdrawal
U. Preuss, Greifswald, Germany
G. Schumann, D. Rujescu, A. Szegedi,
N. Dahmen, M. Depner, B. Bondy,
I. Giegling, G. Koller, M. Soyka

0-09-02 Neuroendocrinology of alcohol seeking behaviour,
craving and relapse
F. Kiefer, Mannheim, Germany
K. Wiedemann

0-09-03 Longterm follow-up of 180 chronic alcoholics
during and after comprehensive integrated out-
patient treatment: Relation of deterrent medica-
tion and outcome
H. Krampe, Göttingen, Germany
S. Stawicki, T. Wagner, C. Bartels, C. Aust,
E. Ruether, W. Poser, H. Ehrenreich

0-09-04 Alcohol abuse among adolescents and its socio-
economic parameters
I. Licanin, Sarajevo, Bosnia and
Herzegovina
A. Redzic, J. Delilovic, M. Spremo

0-09-05 A comparison of Swiss and U.S. substance use
disorder treatment programs: The effect of treat-
ment characteristics and comorbid psychiatric
disorders on one-year outcomes
F. Moggi, Bern, Switzerland
A. Giovanoli, R. H. Moos

0-09-06 Anxiety and dissociative symptomatology in sub-
stance abuse disorders
M. L. Figueira, Lisbon, Portugal
SCIENTIFIC PROGRAM
TUESDAY, 5 APRIL 2005

ORAL PRESENTATION  O-09

0-09-07 Schizophrenia following cannabis-induced psychosis: Follow-up study of 535 incident cases
M. Arendt, Risskov, Denmark
P. Munk-Jørgensen

0-09-08 How social and biological factors impact the formation of relationship of young population to the usage of psycho-active substances in Chechnya
M. Dalsaev, Grozny, Russia
M. Dalsaev, Q. Idrisov, R. Dalsaeva

0-09-09 Mortality in the offspring of people admitted for psychiatric treatment: A population-based cohort study with 26 years follow-up
R. Webb, Manchester, United Kingdom
K. Abel, A. Pickles, P. B. Mortensen, L. Appleby

0-09-10 Cognitive dysfunction in pathological gamblers
D. Marazziti, Pisa, Italy
L. Vivarelli, F. Mungai, M. Catena

POSTER PRESENTATION  P-14

18.00 - 19.30 h Gasteig - Foyers
Track T-2 Psychotic disorders
Psychotic disorders VI
Chairperson: Norman Sartorius, Geneva, Switzerland
Co-Chairperson: Nikola Ilankovic, Belgrad, Serbia + Montenegro

POSTER PRESENTATION  P-15

18.00 - 19.30 h Gasteig - Foyers
Track T-3 Affective disorders
Affective disorders IV
Chairperson: Siegfried Kasper, Vienna, Austria

POSTER PRESENTATION  P-16

18.00 - 19.30 h Gasteig - Foyers
Track T-5 Personality and behavioural disorders
Personality and behavioural disorders
Chairperson: Constantin Soldatos, Athens, Greece
Co-Chairperson: Gil Zalsman, New York, USA
SCIENTIFIC PROGRAM
WEDNESDAY, 6 APRIL 2005

SYMPOSIUM S-65
08.30 - 10.00 h Gasteig - Philharmonie
Track T-2 Psychotic disorders
New challenges to the dichotomy schizophrenia versus affective disorder - Part II
Chairperson: Wolfgang Maier, Bonn, Germany
Co-Chairperson: Heinz Häfner, Mannheim, Germany
S-65-01 Glutamate psychopharmacology of schizophrenia and bipolar disorder: A neuroscientific dissection
S. Dursun, Manchester, United Kingdom
S-65-02 Neurotrophic factors in schizophrenia and affective disorders: Basis for novel therapeutic approaches?
Ehrenreich, Göttingen, Germany
S-65-03 Gene expression profiling: Disease-specific or common patterns?
P. Falkai, Homburg, Germany
S-65-04 Are atypical antipsychotics effective in schizophrenia and affective disorders?
W. Fleischhacker, Innsbruck, Austria
S-65-05 Synthesis of part I and part II
W. Maier, Bonn, Germany

SYMPOSIUM S-66
08.30 - 10.00 h Gasteig - Carl-Orff Saal
Track T-3 Affective disorders
Bipolar disorder – Differential diagnosis as basis for differential treatment
Chairperson: Andreas Marneros, Halle, Germany
Co-Chairperson: Giulio Perugi, Pisa, Italy
S-66-01 The mixed state phenomenon
A. Marneros, Halle, Germany
S-66-02 Recognition and treatment implications of comorbidity in bipolar children and adolescents
G. Perugi, Pisa, Italy
S-66-03 Soft bipolarity: The mask of anxiety, panic and obsessions-compulsions
E.-G. Hantouche, Paris, France
S-66-04 Clinical and psychosocial factors predicting response to prophylactic lithium
W. Greil, Munich, Germany
N. Kleindienst
S-66-05 Treatments for different presentations of bipolar disorder
J. C. Cookson, London, United Kingdom

SYMPOSIUM S-69
08.30 - 10.00 h Holiday Inn - Room 1
Track T-2 Psychotic disorders
Imaging genomics in psychiatric research
Chairperson: Eva Meisenzahl, Munich, Germany
Co-Chairperson: Colm McDonald, London, United Kingdom
S-69-01 A brain bank for the identification of genes affecting brain structure
E. Meisenzahl, Munich, Germany
S-69-02 Genes which influence the structure of the normal brain
I. Giegling, Munich, Germany
S-69-03 The brain structural phenotypes of schizophrenia and bipolar disorder
C. McDonald, London, United Kingdom
S-69-04 Title unknown
J. Gallinat, Berlin, Germany

SYMPOSIUM S-67
08.30 - 10.00 h Gasteig - Black Box
Track T-3 Affective disorders
Influence of neurobiological factors on the course of depressive disorders
Chairperson: Matthias Rothermundt, Münster, Germany
Co-Chairperson: Detlef E. Dietrich, Hannover, Germany
S-67-01 The influence of neuronal restructuring on the course of depressive disorders
M. Rothermundt, Münster, Germany
G. Ponath, G. Hetzel, D. E. Dietrich, V. Arolt
S-67-02 The HPA system in depression: Indicator of vulnerability and treatment response
A. Zobel, Bonn, Germany
### SCIENTIFIC PROGRAM

#### WEDNESDAY, 6 APRIL 2005

**SYMPOSIUM S-67**

<table>
<thead>
<tr>
<th>S-67-03</th>
<th>Influence of Borna disease virus infection on the course of depression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D. E. Dietrich, Hannover, Germany</td>
</tr>
<tr>
<td></td>
<td>C. Spannhuth, H. M. Emrich</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-67-04</th>
<th>Hippocampal changes and white matter lesions in early-onset depression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>J. Janssen, Utrecht, Netherlands</td>
</tr>
<tr>
<td></td>
<td>H. Hulshoff Pol, I. Lamp, H. Schnack, F. E. de Leeuw, R. Kahn, T. Heeren</td>
</tr>
</tbody>
</table>

**SYMPOSIUM S-68**

<table>
<thead>
<tr>
<th>S-68-01</th>
<th>Dynamic causal modelling of evoked brain responses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>K. Friston, London, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>K. E. Stephan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-68-02</th>
<th>Exploring the human declarative memory system by functional neuroimaging</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>G. Fernandez, Nijmegen, Netherlands</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-68-03</th>
<th>E-motion: The importance of optimised fMRI strategies to study emotions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>E. Moser, Vienna, Austria</td>
</tr>
<tr>
<td></td>
<td>S. Robinson, C. Windischberger, U. Habel, B. Hoheisel</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-68-04</th>
<th>Learning to play pong with fMRI neurofeedback: Implications for clinical applications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>R. Goebel, Maastricht, Netherlands</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-68-05</th>
<th>Neural correlates of emotion and cognition as key components in the understanding of the pathophysiology of psychiatric disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>F. Schneider, Aachen, Germany</td>
</tr>
</tbody>
</table>

**SYMPOSIUM S-70**

<table>
<thead>
<tr>
<th>08.30 - 10.00 h</th>
<th>Holiday Inn - Room 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Track T-4</td>
<td>Anxiety-related and eating disorders</td>
</tr>
<tr>
<td></td>
<td>Posttraumatic stress disorders and quality of life after intensive care treatment</td>
</tr>
<tr>
<td>Chairperson:</td>
<td>Hans-Peter Kapfhammer, Graz, Austria</td>
</tr>
<tr>
<td>Co-Chairperson:</td>
<td>G. Schelling, Munich, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-70-01</th>
<th>Epidemiology and course of cardiac surgery-related PTSD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>H. B. Rothenhäusler, Graz, Austria</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-70-02</th>
<th>Medical disorders as a cause of psychological trauma and PTSD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>H.-P. Kapfhammer, Graz, Austria</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-70-03</th>
<th>Effects of glucocorticoids on human memory functions - Implications for post-traumatic stress disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D. F. De Quervain, Zurich, Switzerland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-70-04</th>
<th>Liquid chromatography-tandem mass spectrometry - a promising new technology in clinical stress research</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M. Vogeser, Munich, Germany</td>
</tr>
<tr>
<td></td>
<td>G. Schelling</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-70-05</th>
<th>Traumatic memory and neuroendocrine changes in patients with PTSD. Mechanisms and therapeutic implications</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>G. Schelling, Munich, Germany</td>
</tr>
</tbody>
</table>

**SYMPOSIUM S-71**

<table>
<thead>
<tr>
<th>08.30 - 10.00 h</th>
<th>Holiday Inn - Room 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Track T-7</td>
<td>Social Psychiatry</td>
</tr>
<tr>
<td>The QUATRO study - an European randomised controlled trial of compliance therapy</td>
<td></td>
</tr>
<tr>
<td>Chairperson:</td>
<td>Thomas Becker, Günzburg, Germany</td>
</tr>
<tr>
<td>Co-Chairperson:</td>
<td>Morven Leese, London, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-71-01</th>
<th>Does adherence therapy improve quality of life?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>T. Becker, Günzburg, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-71-02</th>
<th>Mediated relation of adherence to medication and quality of life in people suffering from schizophrenia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B. Puschner, Günzburg, Germany</td>
</tr>
<tr>
<td></td>
<td>A. Gießler, A. Born, H. Helm, T. Becker, The Quatro Study Group</td>
</tr>
</tbody>
</table>
SYMPOSIUM
S-71

S-71-03 Developing adherence therapy
R. Gray, London, United Kingdom

S-71-04 The cost-effectiveness of adherence therapy for people with schizophrenia
A. Patel, London, United Kingdom
P. McCrone, M. Knapp, K. Martijn, H. Helm, F. Amaddeo, M. Leese, M. Moreno

SECTION SYMPOSIUM
SS-17

08.30 - 10.00 h Gasteig - Room 0.131
Track T-0 Dementia
Specialised geriatric inpatient wards: Benefits and disadvantages
Chairperson: Tilo Kircher, Aachen, Germany
Co-Chairperson: Gabriela Stoppe, Basel, Switzerland

SS-17-01 The efficacy of specialised old age psychiatric wards: A multicenter randomised clinical trial
T. Kircher, Aachen, Germany
G. Buchkremer, H. Wormstall, C. Meisner

SS-17-02 7-year follow-up investigations and comparison of the geriatric psychiatric inpatient service in a separated care at a state hospital and an integrated care at a university hospital in Goettingen, Germany
G. Stoppe, Basel, Switzerland

SS-17-03 Geriatric psychiatry and in-patients wards for treatment of the elderly in Romania
N. Tataru, Oradea, Romania

WORKSHOP
W-21

08.30 - 10.00 h Holiday Inn - Room 5
Track T-6 Interdisciplinary
Psychotropic drugs in pregnancy and lactation
Chairperson: Cyril Höschl, Prague, Czech Republic
Co-Chairperson: Dagmar Seifertova, Prague, Czech Republic
Speaker: W. Seifertova, Prague, Czech Republic
P. Mohr, Czech Republic
E. Hermann, Prague, Czech Republic
C. Höschl, Prague, Czech Republic

WORKSHOP
W-22

08.30 - 10.00 h Holiday Inn - Room 6
Track T-7 Social Psychiatry
Semiotic between neuro-myths and social romanticism - Part II Semiotics and social psychiatry
Chairperson: Hans Pfefferer-Wolf, Hannover, Germany

EDUCATIONAL COURSE
C-19

08.30 - 12.00 h Hilton - Salon Bialas
Track T-2 Psychotic disorders
Delusions - diagnosis and treatment
Organizer: M. Musalek, Vienna, Austria

EDUCATIONAL COURSE
C-20

08.30 - 12.00 h Hilton - Salon Orff
Track T-5 Personality and behavioural disorders
Treatment of sexual abusers
Organizer: P. Cosyns, Edegem, Belgium
E. Mirke, Edegem, Belgium

ORAL PRESENTATION
O-10

08.30 - 10.00 h Holiday Inn - Room 7
Track T-4 Anxiety-related and eating disorders
Anxiety-related and eating disorders
Chairperson: George Christodoulou, Athens, Greece
Co-Chairperson: Stefano Pini, Pisa, Italy

O-10-01 A retrospective and prospective study of delayed sleep-phase shift in patients with severe, chronic obsessive-compulsive disorder (OCD)
L. Drummond, London, United Kingdom
N. A. Fineberg, S. Mukhopadhyay, J. Turner, H. Ghodse

O-10-02 Typical and atypical neuroleptics in the treatment of obsessive-compulsive symptoms in schizophrenia patients
I. Reznik, Bat-Yam, Israel
I. Reznik, M. Reznik, A. Weizman
**ORAL PRESENTATION O-10**

**O-10-03** Overnight metyrapone tests in patients with panic disorder
M. Kellner, Hamburg, Germany
M. Schick, A. Yassouridis, T. Struttmann, K. Wiedemann, B. Alm

**O-10-04** Peripheral-type benzodiazepine receptor binding sites in platelets of patients with panic disorder associated to separation anxiety symptoms
S. Pini, Pisa, Italy
C. Martini, M. Abelli, M. Muti, M. Preve, M. Montali, B. Chelli, A. Lucacchini, G. B. Cassano

**O-10-05** Aripiprazol as main treatment of the obsessional-compulsive symptoms.
J. R. Lippi, Belo Horizonte, Brazil

**O-10-06** Social phobia symptoms and comorbidity with specific phobia: a study of 850 Israeli young soldiers
I. Iancu, Beer Yaakov, Israel

**O-10-07** Leptin and leptin-receptor of inpatients with anorexia nervosa in progression of treatment
G. Ristow, Mannheim, Germany
A. Maras, C. Goepel, M. H. Schmidt, C. Goepel

**O-10-08** Brief hospitalization plus outpatient group therapy in bulimia nervosa: Analysis of the effectiveness of a combined therapy
F. Fernandez-Aranda, Barcelona, Spain
A. Badia, R. Solano, J. Vallejo Ruiloba

**O-10-09** The effect appraisal of profilactics of nutrition disturbances project
K. Bargiel-Matusiewicz, Katowice, Poland
K. Kucia

**O-10-10** Body image and suicidality among youth
M. Pompili, Rome, Italy
P. Girardi, A. Ruberto, R. Tatarelli

---

**PLENARY LECTURE L-05**

**10.30 - 11.15 h**
Gasteig - Philharmonie
Track T-3 Affective disorders
Modern classification of affective disorders
Chairperson: Marianne Kastrup, Copenhagen, Denmark
Speaker: J. Angst, Zurich, Switzerland

---

**MEET-THE-EXPERT SESSION M-04**

**11.15 - 12.15 h**
Gasteig - Black Box
Track T-6 Interdisciplinary
Meet the experts: Sleep and its disorders
Speaker: C. Soldatos, Athens, Greece

---

**POSTER PRESENTATION P-17**

**11.15 - 12.15 h**
Gasteig - Foyers
Track T-0 Dementia
Dementia and Child psychiatry
Chairperson: Sam Tyano, Petah-Tiqvah, Israel
Co-Chairperson: Michael Rapp, New York, USA

---

**POSTER PRESENTATION P-18**

**11.15 - 12.15 h**
Gasteig - Foyers
Track T-2 Psychotic disorders
Psychotic disorders IV
Chairperson: Julio Bobes Garcia, Oviedo, Spain
Co-Chairperson: Celso Arango, Madrid, Spain
POSTER PRESENTATION
SUNDAY, 3 APRIL 2005

POSTER PRESENTATION P-01

11.15 - 12.15 h Gasteig - Foyers
Track T-1 Substance related disorders
Substance-related disorders I
Chairperson: Karl Mann, Mannheim, Germany
Co-Chairperson: Ulrich Preuss, Greifswald, Germany

P-01-01 Neuroimaging in alcoholism: Voxel-based-morphometry shows correlation of cingulate and frontal lobe atrophy with lifetime drinking history
A. Diehl, Mannheim, Germany
A. Jatzko, G. Ende, H. Welzel, T. Demirakca, K. Mann

P-01-02 Alcohol craving and the A1 allele of the D2 dopamine receptor gene
E. Pinto, Liège, Belgium
P. Gorwood, J. Reggers, D. Vaira, S. Fuchs, W. Pitchot, M. Ansseau

P-01-03 Asialotransferrin: A poor biomarker of alcohol abuse
R. Schwan, Clermont-Ferrand, France
F. Legros, V. Nuyens, L. Malet, I. Chéreau-Boudet, P. M. Llorca

P-01-04 Oxcarbazepine in the detoxification of chronic alcoholics
A. Gual Sole, Barcelona, Spain
S. Mondon, J. Jou

P-01-05 The effect of detoxification on sleep in a sample of alcohol dependent individuals
T. Paparrigopoulos, Athens, Greece
J. Liappas, P. Theodoropoulos, E. Tzavellas, C. Soldatos

P-01-06 Fast-track referrals to an alcohol treatment unit over a 6 month period
K. Naidoo, Aughton, United Kingdom

P-01-07 Depressive disorders among the patients hospitalized because of alcohol withdrawal syndrome in the course of alcoholic dependence
M. Dosiaik, Ruda Slaska, Poland
E. Wojtyna

P-01-08 Excessive drinking situations in abstinent German alcoholics: A one-factor model
H. Nakovics, Mannheim, Germany

P-01-09 A pragmatic follow-up in primary care to identify predictors of withdrawal in alcohol dependence
L. Malet, Clermont Ferrand, France
P.-M. Llorca, O. Blanc, M. Reynaud, B. Falissard

P-01-10 Cue-reactivity of alcohol dependent patients as a predictor of relapse: Are there changes after cue-exposure treatment?
S. Löber, Mannheim, Germany
B. Croissant, A. Heinz, H. Flor, K. Mann

P-01-11 Predictors and correlates of suicide attempts in alcohol-dependent men and women
U. Preuss, Greifswald, Germany
M. A. Schuckit, T. Smith, G. Danko, K. Bucholz, V. Hesselbrock

P-01-12 Dimensions of psychopathology and personality in Dutch alcohol dependent patient
J. I. M. Egger, Venray, Netherlands
J. I. Egger, H. De Mey, S. Tuinier, W. Verhoeven

P-01-13 Psychiatric characteristics of the wives of alcoholic patients with a high suicidal risk
M. Kubo, Hamamatsu, Japan
S. Shigeru, K. Takeshi

P-01-14 Childhood predictors of frequent drunkenness in late adolescence: A 10-year population-based follow-up study
S. Niemelä, Turku, Finland
A. Sourander, K. Poikolainen, H. Helenius

POSTER PRESENTATION P-02

11.15 - 12.15 h Gasteig - Foyers
Track T-2 Psychotic disorders
Psychotic disorders II
Chairperson: Cyril Höschl, Prague, Czech Republic
Co-Chairperson: Kenneth Kaufman, New Brunswick, USA

P-02-01 The monitoring of cognitive processes in patients with schizophrenia treated with amisulpride during a 12 month period
A. Klasik, Katowice, Poland
I. Krupka-Matuszczyn, K. Krysta, I. Ziajka
P-02-02  Efficacy of quetiapine in schizophrenic patients: A retrospective real-life study
M. Tafalla, Madrid, Spain

P-02-03  A naturalistic study of aripiprazole treatment in a general psychiatric setting in Europe
J.-N. Beuzen, Paris, France
M. Pans, S. Modell, P. Hagens, R. McQuade, T. Iwamoto, W. Carson

P-02-04  Ziprasidone induced priapism requiring surgical treatment
K. Kaufman, New Brunswick, USA
L. Stern, A. Mohebati

P-02-06  Neuropsychological outcome before administration atypical and classical antipsychotic treatment. A pilot study
O. Pino, Barcelona, Spain
J. E. Rojo, D. Carmona, G. Guilera, J. Gómez

P-02-07  Ziprasidone vs Olanzapine: Contrasts in CHD risk
A. Cheli, New York, USA
D. Harrison, A. Loebel, S. Murray

P-02-08  Olanzapine-treated patients with psychotic disorders improved after changing to risperidone long-acting injectable
W. Chrzanowski, Choroszcz, Poland
M. Latif, M. Masialak, R. Medori, M. Gastpar

P-02-09  Intramuscular olanzapine in acutely agitated manic or schizophrenic patients. A naturalistic study
L. San, Barcelona, Spain
B. Arranz, R. Dueñas, J. de la Gandara, V. Perez

P-02-10  Olanzapine velotab 20 mg.: an experience of SPDC - USL 7 of Siena
A. Giovannoni, Siena, Italy

P-02-11  QT changes associated to treatment with clozapine
A. Pons, Barcelona, Spain
V. Valls, A. Romero, G. Massana, M. García-Amador

P-02-12  Haematoic follow-up of patients treated with clozapine
A. Pons, Barcelona, Spain
A. Romero, X. Carné, G. Massana

P-03-01  Lithium blood level and polarity of recurrence in bipolar disorder
E. Severus, Munich, Germany
N. Kleindienst, W. Greil, H.-J. Möller

P-03-02  Are low lithium levels needed to prevent bipolar depression and high lithium levels to prevent mania?
E. Severus, H.-J. Möller, W. Greil

P-03-03  Efficacy and safety of Ziprasidone in bipolar disorder: Long-term data
M. Versiani, Rio de Janeiro, Brazil
P. Keck, S. Potkin, G. Ellenor, E. Batzar

P-03-04  Ziprasidone in bipolar mania: Efficacy across patient subgroups
A. Weizman, Petah Tiqva, Israel
P. Keck, S. Potkin, L. Warrington, F. Mandel

P-03-05  Efficacy and tolerability of ziprasidone in acute bipolar mania: 12-week, double-blind study
J. Dunn, New York, USA
T. Ramey, E. Giller, P. English, R. Riesenberg, J. Trivedi, V. Tochilov
P-03-06  Glutamate and glycine in bipolar mania
W. Verhoeven, Venray, Netherlands
R. Hoekstra, D. Fekkes,
A. Loonen, L. Peppinkhuizen

P-03-07  A systematic review of MRI brain volumes in bipolar disorder: A comparison with healthy controls and patients with schizophrenia
A. McIntosh, Edinburgh, United Kingdom
D. Gerber, K. Ullyat, J. Cavanagh,
S. Lawrie

P-03-08  The in vivo effect of lithium on gray matter volume and relation to clinical outcome in bipolar I patients: preliminary results of an MRI study
A. Forsthoff, Munich, Germany
E. Meisenzahl, H. Grunze

P-03-09  Effect of comorbidity and number of past episodes on outcome of the patients with bipolar disorders-report of a cohort of patients aged 65 years and above
F. Galland, Clermont-Ferrand, France
E. Vaille-Perret, A. Mulliez, L. Gerbaud,
I. Jalenques

P-03-10  Mixed depression
F. Benazzi, Cervia, Italy

P-03-11  How representative are patients in drug trials on mania?
R. W. Licht, Risskov, Denmark

P-03-12  Evaluation of groups for relatives of patients with bipolar disorder in the Ludwig-Maximilian University, Munich, Germany: preliminary results
B. Bernhard, Munich, Germany

P-03-13  Evaluation of a cognitiv-psychoeducative group therapy with bipolar patients in the Ludwig-Maximilian University, Munich, Germany: preliminary results
B. Bernhard, Munich, Germany

P-03-14  Bipolar disorder and quality of life
M. Centeno, Granollers, Spain
M. Centeno, S. Arranz, A. Rodriguez,
M. Garcia, D. Gonyalons

P-03-16  Cerebral blood flow and neuropsychological assessment in a patient with Cotard’s Syndrome
F. Van den Eynde, Gent, Belgium
M. Portzky, F. Jacobs, S. De Saedeleer,
K. Audenaert, C. van Heeringen

P-04-01  Chromosome 3q29: Possible Schizophrenia Susceptibility Region
A. Schosser, Vienna, Austria
K. Fuchs, F. Leisch, U. Bailer, S. Kasper,
W. Sieghart, K. Hornik, H. N. Aschauer

P-04-02  Identification of schizophrenia genes in an animal model for psychosis
A. Hartmann, Munich, Germany
J. Genius, I. Giegling, K. Freitag,
K. Strimmer, J. Schäfer, H. Möller,
D. Rujescu

P-04-03  Looking for susceptibility genes in schizophrenia
K. Thierfelder, Munich, Germany
I. Giegling, L. Mühlenhoff, P. Muglia,
J. Müller, T. Betekcenc, T. Meitinger,
H.-J. Möller, D. Rujescu

P-04-04  Psychotic disorders and genetic syndromes
W. Verhoeven, Venray, Netherlands
C. Van Ravenswaay - Arts, J. Tuerlings,
S. Tuinier

P-04-05  An unusual combination of syndromes: XYY and PWS
W. Verhoeven, Venray, Netherlands
B. Hamel, S. Duffels, B. Otten, S. Tuinier

P-04-06  Genetic syndromes and psychoses: The issue of schizophrenia
S. Tuinier, Venray, Netherlands
J. Tuerlings, B. Hamel, W. Verhoeven
<table>
<thead>
<tr>
<th>POSTER PRESENTATION</th>
</tr>
</thead>
</table>
| **P-04-07** Genetic liability to schizophrenia or bipolar disorder and its relationship to brain structure  
A. McIntosh, Edinburgh, United Kingdom  
| **P-04-08** Brain magnetic resonance imaging findings in individuals at-risk for schizophrenia  
S. J. Borgwardt, Basel, Switzerland  
| **P-04-09** In vivo imaging of the dopaminergic neurotransmitter system in an animal model  
E. Meisenzahl, Munich, Germany  
G. Schmitt, T. Zetzsche, T. Frodl, H.-J. Möller, C. la Fougere, K. Hahn, S. Dresel, M. Keck, M. Müller |
| **P-04-10** Voxel-based morphometry compared to regions-of-interest techniques in a cross-sectional MRI study of schizophrenic patients and healthy controls  
N. Koutsouleris, Munich, Germany  
T. Frodl, T. Zetzsche, S. Holzinger, G. Leinsinger, K. Hahn, H.-J. Möller, E. Meisenzahl |
| **P-04-11** Anterior cingulate gyrus in schizophrenic patients and controls: A structural magnetic resonance imaging evaluation  
T. Zetzsche, Munich, Germany  
D. Watz, T. Frodl, H.-J. Möller, G. Leinsinger, E. Meisenzahl |
| **P-04-12** Neuronal network disconnection in never-treated first-episode schizophrenic patients: An fMRI study  
S. Ufer, Munich, Germany  
M. Wiesmann, M. Käpernick, N. Kathmann, H. Brückmann, H.-J. Möller, E. Meisenzahl |
| **P-04-13** Functional cerebral dysfunctions in patients with catatonic schizophrenia: An fMRI evaluation  
S. Ufer, Munich, Germany  
M. Wiesmann, H. Brückmann, H.-J. Möller, E. Meisenzahl |
| **P-04-14** Are interhemispheric interactions abnormal in schizophrenics?  
V. Florio, Bolzano, Italy |
| **P-04-15** Palinacousis leading to the diagnosis of temporal lobe seizures in a patient with schizophrenia  
C. Prueter, Gangelt, Germany  
T. D. Waberski, C. Norra, K. Podoll, H. Sass |
| **P-04-16** The influence of emotional prosody on semantic processing in patients with schizophrenia: a study with ERP  
C. Prueter, Gangelt, Germany  
B. Singer, W. Kawohl, H.-J. Kunert, A. Schrimer, A. D. Friederici, P. Hoff |
| **P-04-17** P50 suppression in bipolar and schizophrenics patients  
E. Sanchez Morla, Cuenca, Ecuador  
M. A. Garcia Jimenez, J. Martinez Mena, R. M. Sanchez Honrubia, V. Martinez-Vizcaico, M. Solera, J. L. Santos |
| **P-04-18** Neuropsychological function in schizophrenia and bipolar disorder  
E. Sanchez Morla, Cuenca, Ecuador  
J. L. Santos, M. A. Prieto, M. Solera, M. Martinez-Abad, A. Aparicio, M. J. Vega, V. Martinez Vizcaino |
| **P-04-19** Psychopathologic dimensions and neurological soft signs in first-episodes psychosis  
M. L. Barrigon, Granada, Spain  
M. Ruiz-Veguilla, A. Fontalba-Navas, M. Anguita-Romero, I. Gomis Fletcher |
| **P-04-20** Deficits in attention and executive functions in individuals at risk for schizophrenia  
M. O. Pflueger, Basel, Switzerland  
U. Gschwandtner, J. Aston, K. Goetz, R. Stieglitz, A. Riecher-Roessler |
| **P-04-21** Clinical, neuropsychological and neurophysiological deficits in first episode unmedicated schizophrenic patients (a pilot study)  
O. Pino, Barcelona, Spain  
J. E. Rojo, D. Carmona, J. Marco, L. Fuentemilla, C. Grau |
P-04-22 An integrated neurophysiologic and neuropsychologic follow-up pilot study with first episode naïf schizophrenic patients: pre and post classical antipsychotic treatment
L. Fuentemila, Barcelona, Spain
J. Marco, J. E. Rojo, O. Pino, D. Carmona, C. Grau

P-04-23 Sensorimotor and cognitive slowing in the symbol digit substitution test in schizophrenia
M. Morrens, Jette, Belgium

P-04-24 Does gender predict neuropsychological functioning in schizophrenic outpatients?
M. Barcelo-Campana, Sant Boi de Llobregat, Spain

P-04-25 Dermatoglyphics in patients with schizophrenia and bipolar affective disorder
A. Suwalska, Poznan, Poland
G. Liczbinska, A. Tarnowska, D. Lojko, M. Chlopcka-Wozniak, A. Heymann-Szachcinska, F. Rybakowski

P-05-03 Concentrations of the neuroactive steroid 3α, 5α-Tetrahydrodeoxycorticosterone (3α, 5α-THDOC) after panic induction with cholecystokinin-tetrapeptide (CCK-4)
D. Eser, Munich, Germany
F. di Michele, P. Zwanzger, A. Pasini, T. C. Baghai, C. Schüle, E. Romeo, R. Rupprecht

P-05-06 Particularities of the onset of panic disorder
D. Podea, Arad, Romania

P-05-08 Study of the relationship between anxiety and depression among students of Islamic Azad University-Iran
A. A. Bayani, Azadshahr, Iran

P-05-09 A study of GPs’ diagnostic skills concerning major depressive episode and generalized anxiety disorder
I. Ostby-Deglum, Ottestad, Norway
A. Mykletun, A. A. Dahl

P-05-12 Efficacy of Pregabalin in the treatment of anxiety symptoms associated with depression
B. Bandelow, Göttingen, Germany

P-05-13 Pregabalin’s sustained effects in treating somatic symptoms in patients with gad
K. Rickels, Philadelphia, USA
F. Mandel, G. Farfel, G. Zornberg

P-05-14 Drug abusers suffering from social phobia show more avoidance tendencies than patients with social phobia alone
A. Buecking, Prilly-Lausanne, Switzerland
M. Stankovic, G. Zimmermann, S. Krenz, Y. Khazaal, F. Borgeat, D. F. Zullino
P-05-15 Clinical subgroups in social anxiety disorder (SAD)
M. Lader, London, United Kingdom
D. Stein, D. Stein, E. W. Andersen, R. Nil

P-05-16 Impaired word recognition in obsessive-compulsive disorder: An event-related potential study
Y. Zhang, Hannover, Germany

P-05-17 Comparison of 18F-FDG PET and 1H MRS data in patients with intractable forms of anxiety-obsessive disorders (AOD)
A. Stanzhevsky, Saint-Petersburg, Russia
A. Korzenev, A. Stanzhevsky, L. Tyutin, A. Pozdniakov, N. Kostenikov, T. Skoromets

P-05-18 Pathogenesis of malignant forms of anxiety-obsessive disorders (AOD) and assessment of objective findings for surgical treatment to be planned
A. Stanzhevsky, Saint-Petersburg, Russia

P-05-19 Neurasthenia managing by Enerion
N. Butorina, Chelyabinsk, Russia
E. Bondarchuk

18.00 - 19.30 h Gasteig - Foyers Track T-6 Interdisciplinary Interdisciplinary II
Chairperson: Marianne Kastrup, Copenhagen, Denmark
Co-Chairperson: Borys Mykhaylov, Kharkov, Ukraine

P-06-01 The ill child and his quality of life
A. Michopoulou, Palea Pendeli, Athens, Greece
G. Stefanou, E. Chatzioannidou, A. Michopoulou, A. Iliadou, D. Panagiotou, P. Georgiadou

P-06-02 Validity of general health questionnaire-12 in a student mental health clinic
S. M. Rezaki, Ankara, Turkey
H. Ozdemir

P-06-03 Patient's satisfaction assessment in mental health care within community mental health centers services
D. Salcic Dizdarevic, Sarajevo, Bosnia and Herzegovina
A. Bravo Mehmedbasic, A. Kucukalic, S. Popovic

P-06-04 Attitudes of senior high school students toward three mental disorders
G. Arbanas, Karlovac, Croatia

P-06-05 Migration in child and adolescent psychiatry - differences and equalities
M. Marin Olalla, Almeria, Spain
B. Perez Ramirez, J. Diaz Atienza, P. Blanquez Rodriguez
<table>
<thead>
<tr>
<th>POSTER PRESENTATION</th>
<th>P-06</th>
</tr>
</thead>
</table>
| P-06-06 Migrants and mental disorders in the emergency room | J. J. Carballo, Madrid, Spain  
M. Garcia-Moreno, B. Poza, L. Giner,  
P. Garcia-Parajua, A. M. Roche,  
L. Garcia-Thuring, L. De Ugarte,  
L. Caballero, E. Baca |
| P-06-07 Culture in mental health - diversity and disparity | C. Shah, Los Angeles, USA |
| P-06-08 The history-metodological investigation of ukrainian psychotherapy creation | B. Mykhaylov, Kharkov, Ukraine  
A. A. Martynenko, G. P. Andrukh |
| P-06-09 Psychotherapy of somatoform disorders | B. Mykhaylov, Kharkov, Ukraine  
I. Romanova, N. Myroshnichenko,  
B. Mykhaylov |
| P-06-10 Cross cultural training and supervision in clinical psychodrama | V. Milosevic, Belgrade, Serbia + Montenegro |
| P-06-11 Are treatment recommendations in psychiatric expertises helpful? A retrospective evaluation of 30 psychiatric follow-up expertises | T. Apfel, Basel, Switzerland  
A. Riecher-Rössler |
| P-06-12 Pathographies as a challenge for hermeneutics and ethics in psychiatry. A structural analysis of knowledge, judgement and wisdom in modern psychiatry. | E. H. Hische, Frankfurt, Germany |
| P-06-14 Application of POC-therapy in sanatorium conditions | I. Miroshnik, Kharkov, Ukraine  
E. Gavrilin, B. Mykhaylov |
| P-06-15 Method of a synergic interactive musicotherapy (SIM) | I. Miroshnik, Kharkov, Ukraine |
| P-06-17 Towards a psychodynamic conception of psycho-neuroimmunology | E. Fabian, Munich, Germany |
| P-06-18 Improvement of Executive Cognitive Function by Aroma Therapy | M. Kubo, Hamamatsu, Japan  
S. Shigeru, K. Takeshi |
| P-06-19 A pattern of expressive activity in rehabilitation: Colors of the body | G. Di Cesare, Rome, Italy  
G. Aloisio |
| P-06-20 Parents’ divorce and having a romantic relationship affects mental health of soldiers | G. Giaglis, Katerini, Greece  
B. Michailidou, G. Angelidis |
| P-06-21 Expectations and attitudes of a closing psychiatric hospital’s staff towards deinstitutionalization and mental illness | G. Giaglis, Katerini, Greece  
B. Michailidou, A. Georgios |
| P-06-22 Perceptions of conflicts and justice at work and their impact on job satisfaction of a psychiatric hospital’s staff | G. Giaglis, Katerini, Greece  
B. Michailidou, A. Georgios |
| P-06-23 Towards a theory of human sciences | G. Medicus, Hall, Austria |
| P-06-24 Destigmatization - Challenge in a changing society. It’s not the problem to treat only the mental disease, but the whole person | A. Dangellia, Tirana, Albania |
| P-06-25 The diagnostic problems of atypical depression | B. Burba, Kaunas, Lithuania  
A. Kungeliene |
| P-06-26 Psychosexual disorders of androgenic women | B. Burba, Kaunas, Lithuania  
G. Sukyte |
<table>
<thead>
<tr>
<th>POSTER PRESENTATION</th>
<th>P-07</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11.15 - 12.15 h</strong></td>
<td>Gasteig - Foyers</td>
</tr>
<tr>
<td><strong>Track T-1</strong></td>
<td>Substance related disorders</td>
</tr>
<tr>
<td><strong>Substance-related disorders II</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chairperson:</strong> Valery Krasnov, Moscow, Russia</td>
<td></td>
</tr>
<tr>
<td><strong>Co-Chairperson:</strong> Johanna Koskinen, Oulu, Finland</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-01</th>
<th>A french study on alcohol and tobacco use in pregnant women</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. de Chazeron, Clermont-Ferrand, France</td>
<td>D. Boussiron, D. Lemery, P.-M. Llorca</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-02</th>
<th>Codependence of drug, alcohol and tobacco abuse in adolescent risk behavior</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. Spremo, Banja Luka, Bosnia and Herzegovina</td>
<td>L. Ifeta, M. Burgic, S. Spremo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-03</th>
<th>Alcohol use and alcoholism in schizophrenia subjects – A population based study</th>
</tr>
</thead>
<tbody>
<tr>
<td>J. Koskinen, Oulu, Finland</td>
<td>J. Miettunen, E. Lauronen, P. Laine, H. Koponen, M. Isohanni</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-04</th>
<th>Substance abuse in schizophrenia – A systematic review on research</th>
</tr>
</thead>
<tbody>
<tr>
<td>J. Koskinen, Oulu, Finland</td>
<td>J. Miettunen, E. Lauronen, H. Koponen, M. Isohanni</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-05</th>
<th>Dietary intervention on antipsychotics induced weight gain: A six to 48 month follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y. Khazaal, Prilly-Lausanne, Switzerland</td>
<td>E. Fresard, D. F. Zullino</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-06</th>
<th>Cocaine dependence, craving, impulsivity and topiramate treatment</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-07</th>
<th>Risperidone long-acting injectable in dual diagnosed patients</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-08</th>
<th>Application of risperidone in treatment and rehabilitation programs at the heroin addicts</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Kozlov, Moscow, Russia</td>
<td>I. V. Dorovskih, L. Tchistyakova, D. V. Ogar</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-09</th>
<th>Prediction of efficacy of inpatient treatment in metamphetamine dependence</th>
</tr>
</thead>
<tbody>
<tr>
<td>L. Hosak, Prague, Czech Republic</td>
<td>L. Csemy, M. Preiss, E. Cermakova</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-10</th>
<th>Psychopathology among treatment-seeking cannabis users: Significance for treatment outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. Arendt, Risskov, Denmark</td>
<td>L. Foldager, R. Rosenberg, G. Perto, P. Munk-Jorgensen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-11</th>
<th>Overreporting of recent cannabis use in subjects entering an inpatient detoxification unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>D. F. Zullino, Prilly-Lausanne, Switzerland</td>
<td>S. Krenz, D. Lounici, A. Buecking, E. Frésard, Y. Khazaal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-12</th>
<th>The evaluation of quantitative research on the medicinal use of cannabinoids in cancer- and AIDS-related anorexia and cachexia, Tourette’s Syndrome and Multiple Sclerosis-related spasticity</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. Rysheuvels, Antwerp, Belgium</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-13</th>
<th>Smoking initiation and schizophrenia: A replication study in a Spanish sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>J. M. Martinez Ortega, Granada, Spain</td>
<td>M. Gurpegui, M. C. Aguilar, F. J. Diaz, H. M. Quintana</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-14</th>
<th>Cognitive functioning in schizophrenics addicted and nonaddicted to illicit drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>K. Krzysztof, Katowice, Poland</td>
<td>I. Krupka-Matuszczyk, A. Klasik, L. Hubicki</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION P-07-15</th>
<th>Nicotine dependence and psychosis onset</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. Ruiz-Veguilla, Granada, Spain</td>
<td>A. Fontalba Navas, M. L. Barrigón Estevez, L. Anguita Romero, L. Gomis Fletcher</td>
</tr>
<tr>
<td>POSTER PRESENTATION P-08</td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>11.15 - 12.15 h</strong> Gasteig - Foyers</td>
<td></td>
</tr>
<tr>
<td><strong>Track T-2 Psychotic disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Psychotic disorders III</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chairperson:</strong> Hans-Jürgen Möller, Munich, Germany</td>
<td></td>
</tr>
<tr>
<td><strong>Co-Chairperson:</strong> Dieter Naber, Hamburg, Germany</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-01 Risperidone long-acting injectable in patients with a new diagnosis of psychosis</strong></td>
<td></td>
</tr>
<tr>
<td>E. Parellada, Barcelona, Spain</td>
<td></td>
</tr>
<tr>
<td>W. Chrzanowski, R. Andrezina, V. Milanova, P. Glue, R. Medori, M. Masiak</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-02 Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies</strong></td>
<td></td>
</tr>
<tr>
<td>H.-J. Möller, Munich, Germany</td>
<td></td>
</tr>
<tr>
<td>P.-M. Llorca, E. Sacchetti, S. Martin, R. Medori, E. Parellada</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-03 Long-acting injectable risperidone – a direct transition from oral atypical antipsychotics</strong></td>
<td></td>
</tr>
<tr>
<td>M. Schmauß, Augsburg, Germany</td>
<td></td>
</tr>
<tr>
<td>A. Schreiner</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-04 Long-acting Injectable Risperidone – A direct transition from conventional antipsychotics</strong></td>
<td></td>
</tr>
<tr>
<td>D. Naber, Hamburg, Germany</td>
<td></td>
</tr>
<tr>
<td>A. Schreiner</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-05 Compliance, therapeutic alliance and patient satisfaction with long-acting risperidone</strong></td>
<td></td>
</tr>
<tr>
<td>A. Schreiner, Neuss, Germany</td>
<td></td>
</tr>
<tr>
<td>F.-G. Pajonk</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-06 Long-acting risperidone – Experience in more than 600 patients</strong></td>
<td></td>
</tr>
<tr>
<td>F.-G. Pajonk, Homburg, Germany</td>
<td></td>
</tr>
<tr>
<td>A. Schreiner</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-07 Treatment of psychotic and affective symptoms with risperidone</strong></td>
<td></td>
</tr>
<tr>
<td>P. Bräunig, Chemnitz, Germany</td>
<td></td>
</tr>
<tr>
<td>S. Krüger, A. Schreiner</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-08 Risperidone fast dissolving tablets in the treatment of acutely exacerbated schizophrenic patients</strong></td>
<td></td>
</tr>
<tr>
<td>C. Normann, Freiburg, Germany</td>
<td></td>
</tr>
<tr>
<td>A. Schreiner</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-09 Weight gain and patient satisfaction in psychotic patients treated with risperidone or olanzapine</strong></td>
<td></td>
</tr>
<tr>
<td>S. Heger, Neuss, Germany</td>
<td></td>
</tr>
<tr>
<td>A. Schreiner, F.-G. Pajonk</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-10 Psychotropic drug-induced weight gain: A six-months weight loss management from in-patient to out-patient unit</strong></td>
<td></td>
</tr>
<tr>
<td>A. Viala, Paris, France</td>
<td></td>
</tr>
<tr>
<td>O. Ruetsch, H. Bardou, F. Caroli</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-11 Improved symptom control with risperidone long-acting injectable In psychotic patients previously treated with an oral atypical antipsychotic</strong></td>
<td></td>
</tr>
<tr>
<td>P. Glue, Middelfart, Denmark</td>
<td></td>
</tr>
<tr>
<td>W. Chrzanowski, W. Kissling, D. Buccomino, R. Medori, E. Parellada</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-12 Risperidone long-acting injectable improves efficacy and safety in schizophrenic patients after changing from oral risperidone</strong></td>
<td></td>
</tr>
<tr>
<td>J. Kusters, Sint-Truiden, Belgium</td>
<td></td>
</tr>
<tr>
<td>P. Glue, K. Katsafouros, H. Boon, R. Medori, E. Parellada</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-13 Changing from polytherapy to risperidone long-acting injectable improved symptom control in schizophrenia patients</strong></td>
<td></td>
</tr>
<tr>
<td>M. Tzanakaki, Chania, Greece</td>
<td></td>
</tr>
<tr>
<td>K. Kontis, R. Andrezina, R. Medori, C.-S. Peretti</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-14 Schizoaffective disorders: Significant improvements following therapy change to risperidone long-acting injectable</strong></td>
<td></td>
</tr>
<tr>
<td>A. Mohl, Baden, Switzerland</td>
<td></td>
</tr>
<tr>
<td>K. Westly, S. Opjordsmoen, A. Lex, P. Bräunig</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-15 Beneficial effect of long-acting injectable risperidone on the neurocognitive deficit of a schizophrenic patient: a case report</strong></td>
<td></td>
</tr>
<tr>
<td>K. N. Fountoulakis, Aretou, Greece</td>
<td></td>
</tr>
<tr>
<td>S. Kantartzis, M. Siamboulis, P. Panagiotidis, S. G. Kaprinis, A. Lacovides</td>
<td></td>
</tr>
<tr>
<td><strong>P-08-16 Diabetes mellitus, metabolic syndrome and antagonism of the H1 receptors by atypical antipsychotics</strong></td>
<td></td>
</tr>
<tr>
<td>A. De Nayer, Montignies sur Sambre, Belgium</td>
<td></td>
</tr>
<tr>
<td>POSTER PRESENTATION</td>
<td>P-09</td>
</tr>
<tr>
<td>---------------------</td>
<td>-----</td>
</tr>
<tr>
<td><strong>18.00 - 19.30 h</strong></td>
<td>Gasteig - Foyers</td>
</tr>
<tr>
<td>Track T-2 Psychotic disorders</td>
<td></td>
</tr>
<tr>
<td>Psychotic disorders V</td>
<td></td>
</tr>
<tr>
<td>Chairperson: Wulf Rössler, Zurich, Switzerland</td>
<td></td>
</tr>
<tr>
<td>Co-Chairperson: Stephan Ruhrmann, Cologne, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-01</th>
<th>Comorbid disorders in the potential initial prodrome of psychosis and in first-episode schizophrenia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S. Ruhrmann, Cologne, Germany F. Schultze-Lutter, J. Klosterkötter, S. Ruhrmann, I. Becker</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-02</th>
<th>A new instrument for the prediction of schizophrenia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>H. Picker, Cologne, Germany F. Schultze-Lutter, S. Ruhrmann, A. Wieneke, E.-M. Steinmeyer, J. Klosterkötter</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-03</th>
<th>Premorbid characteristics of first-admitted patients with schizophrenia in Poland</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>K. Gorna, Poznan, Poland K. Gorna, K. Jaracz, F. Rybakowski, J. Rybakowski</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-04</th>
<th>Psychopathological symptoms as determinants of quality of life and social functioning in a first episode of schizophrenia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>K. Gorna, Poznan, Poland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-05</th>
<th>Early schizophrenia prevention help center in Ukraine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>I. Martsenkovsky, Kiev, Ukraine L. Butenko, Y. Bikshaeva</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-06</th>
<th>The Basel FEPSY Study: Sample description and transition to psychosis of individuals at risk</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>P-09-07</th>
<th>Dysfunctional working models of self and others and psychopathological symptoms of schizophrenia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>K. Katarasinska-Pierzgalska, Warsaw, Poland A. Jarek, A. Gruszczynska-Mlodozeniec, M. Jedrasik, T. Szafranski, A. Szaniawska-Bartnicka</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-08</th>
<th>Is patients' self-report of the anxiety symptoms in schizophrenia reliable?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. Jarek, Warsaw, Poland A. Gruszczynska-Mlodozeniec, M. Jedrasik, K. Katarasinska-Pierzgalska, A. Szaniawska-Bartnicka</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-09</th>
<th>Is it possible to assess depression and anxiety separately in schizophrenia?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. Szaniawska-Bartnicka, Warsaw, Poland A. Jarek, A. Gruszczynska-Mlodozeniec, M. Jedrasik, K. Katarasinska-Pierzgalska, T. Szafranski</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-10</th>
<th>Gender differences in negative symptoms among patients with first episode psychosis and patients with chronic schizophrenia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Z. Bronowska, Warsaw, Poland T. Szafranski</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-11</th>
<th>The influence of mechanisms of psychological defence on chronization and resistance of acoustic hallucinations at paranoid schizophrenia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. S. Kim, Russia E. Manjos, J. Thai</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-12</th>
<th>Depressive symptoms among patients with first episode psychosis and patients with chronic schizophrenia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>T. Szafranski, Warsaw, Poland Z. Bronowska</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-13</th>
<th>Atypicality: A clinical study concerning atypical psychoses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S. Tuintier, Venray, Netherlands F. Van der Heijden, W. Verhoeven, R. Kahn</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-14</th>
<th>Change of diagnoses from schizophrenia to bipolar disorder in long-term course</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>J. Röder, Frankfurt, Germany B. Pflug</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-15</th>
<th>Heredity burden and sexual self-perception in schizophrenic patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M. Vucic Peitl, Rijeka, Croatia A. Peitl, E. Pavlovic</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-09-16</th>
<th>Transsexual behaviour and schizophrenia: A case report</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>L. Borras, Brussels, Belgium A. Eytan, E. Constant, P. Huguelet</td>
</tr>
</tbody>
</table>
**POSTER PRESENTATION**

**MONDAY, 4 APRIL 2005**

### POSTER PRESENTATION P-09

**P-09-17** Sexuality disorders of schizophrenics  
I. V. Miclutia, Cluj-Napoca, Romania  
R. Macrea

**P-09-18** Assessing the ability to express sexual consent in a population of acute psychotic patients  
S. Ferracuti, Roma, Italy  
S. Ferracuti, M. C. De Marco,  
S. Zangaro, D. Accorrà, M. Raja,  
A. Azzoni, R. Tatarrelli

**P-09-19** Parents personality characterized of schizophrenic patients  
F. Shamsaei, Hamedan, Iran  
F. Cheraghi

**P-09-20** Aspects of Piaget’s cognitive developmental psychology and neurobiology in psychotic disorders  
S. Gebhardt, Marburg, Germany  
M. T. Huber

**P-09-21** Perspective evaluation of psychotic patients treatment in a “parents and sons” ambulatory  
C. Cecchetto, Padova, Italy  
S. Bressan, M. Civiero, M. Pierri

**P-09-22** Life quality in patients with schizophrenia  
D. Degmecic, Osijek, Croatia  
I. Pozgain, N. Blagojevic-Damasek,  
V. Perekovic, M. Orgic

### POSTER PRESENTATION P-10

**P-10-01** In vivo Imaging of the serotonergic neurotransmitter system in an animal model  
E. Meisenzahl, Munich, Germany  
G. Schmitt, C. La Fougere, T. Zetzsche,  
T. Frodl, M. Keck, M. Müller, K. Hahn,  
H.-J. Möller, S. Dresel

**P-10-02** Hippocampal and amygdala changes in patients with major depression and healthy controls during a one-year follow-up  
T. Frodl, Munich, Germany  
T. Höhne, T. Zetzsche, M. Jäger,  
R. Bottlender, M. Reiser, H.-J. Möller,  
E. Meisenzahl

**P-10-03** Effects of electroconvulsive therapy in major depression measured by diffusion tensor imaging  
N. Koutsouleris, Munich, Germany  
T. Schlossbauer, C. Born, M. Reiser,  
H.-J. Möller, E. M. Meisenzahl

**P-10-04** Brain-mapping in depressions: Antidepressants with the different mechanism of action  
E. Grigorieva, Yaroslavl, Russia  
A. Dyakonov

**P-10-05** Sham stimulation in TMS: How suitable is a commercial placebo coil?  
Freudenmann, Ulm, Germany  
C. Schönfeld-Lecuona, A. Thielcher,  
T. Kammer

**P-10-06** Accuracy of a frameless stereotaxic TMS-positioning system  
C. Schönfeld-Lecuona, Ulm, Germany  
C. Schönfeld-Lecuona, U. Herwig,  
T. Kammer, M. Spitzer, R. Freudenmann

**P-10-07** Transcranial magnetic stimulation in motor conversion disorder  
C. Schönfeld-Lecuona, Ulm, Germany  
C. Schönfeld-Lecuona, B. J. Conne-  
mann, U. Herwig, T. Kammer,  
R. Freudenmann

**P-10-08** Modulation of cortical excitatory aminoacids by clomipramine treatment in a rat model of depression  
N. Kokras, Athens, Greece  
E. Anderzhanova, C. Dalla,  
K. Antoniou, Z. Papadopoulou Daifo

**P-10-09** Depressive symptoms in young females abused in childhood: effect of serotonin transporter gene  
F. Rybakowski, Poznan, Poland  
M. Weglarz, A. Slopien, A. Rajewski,  
J. Hauser
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-10-10</td>
<td>Pharmacological therapy of depressions in the primary medical network</td>
<td>Y. L. Rivkina, Moscow, Russia</td>
</tr>
<tr>
<td>P-10-11</td>
<td>Atypical depression: Is there still evidence for superiority of MAO-inhibitors?</td>
<td>V. Henkel, Munich, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R. Mergl, U. Hegerl</td>
</tr>
<tr>
<td>P-10-12</td>
<td>Treatment of atypical depression in primary care</td>
<td>V. Henkel, Munich, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R. Mergl, J. C. Coyne, A.-K. Allgaier,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. Hautzinger, R. Kohnen, H.-J. Möller,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>U. Hegerl</td>
</tr>
<tr>
<td>P-10-13</td>
<td>Efficacy and tolerability of duloxetine: Comparison of 30mg QD and 60 mg QD starting doses</td>
<td>M. Wohlreich, Indianapolis, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D. Dunner, C. Mallinckrodt, W. Estergard,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Watkin, M. Fava</td>
</tr>
<tr>
<td>P-10-14</td>
<td>Daily measurements elucidate effects of initial dosing of duloxetine on emotional and painful physical symptoms of depression</td>
<td>M. Wohlreich, Indianapolis, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Mundt, C. Mallinckrodt, A. Andorn,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Greist, L. Arnold, M. Fava, H. Moore</td>
</tr>
<tr>
<td>P-10-15</td>
<td>Duloxetine vs. placebo in the treatment of elderly patients with MDD</td>
<td>J. Raskin, Indianapolis, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. Wiltse, J. Dinkel, A. Siegal, J. Sheikh,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Xu, B. Rotz, R. Mohs</td>
</tr>
<tr>
<td>P-10-16</td>
<td>Global benefit-risk evaluation for the treatment of major depressive disorder with duloxetine: results from six pooled placebo- and ssri-controlled clinical trials</td>
<td>D. Perahia, Indianapolis, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Y. Lu-Fritchett, R. Tamura, M. Detke,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D. D’Souza, P. Tran</td>
</tr>
<tr>
<td>P-10-17</td>
<td>Case study on the effect of quetiapine (Seroquel) on the symptoms</td>
<td>M. Weber, Ravensburg, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. Jandl, W. Kaschka</td>
</tr>
<tr>
<td>P-10-18</td>
<td>Alteration of DHEA-S level during the tianeptine treatment</td>
<td>Y. Kochetkov, Moscow, Russia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>K. Beltikova</td>
</tr>
<tr>
<td>P-10-19</td>
<td>Metyrapone as additive treatment in major depression: A double-blind and placebo-controlled trial</td>
<td>H. Jahn, Hamburg, Germany</td>
</tr>
<tr>
<td>P-10-20</td>
<td>Quality of life and side effects of pharmacological treatment in patients with affective disorders</td>
<td>A. Suwalska, Poznan, Poland</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D. Lojko, M. Chlopocka-Wozniak, F. Rybakowski, F. Rybakowski</td>
</tr>
<tr>
<td>P-10-21</td>
<td>Dysphoria and mixed states: An empirical study</td>
<td>G. Bertschy, Geneva, Switzerland</td>
</tr>
<tr>
<td>P-10-22</td>
<td>Neurocognitive differences between female and male with major depression</td>
<td>G. Faludi, Budapest, Hungary</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Sarosi, G. Balogh</td>
</tr>
<tr>
<td>P-10-23</td>
<td>Mood disorders and their treatment in patients with epilepsy</td>
<td>C. Prueter, Gangelt, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. Norra</td>
</tr>
<tr>
<td>Title</td>
<td>Author(s)</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>The role of cognitive-behavioural intervention in improving psychophysical health in hemodialysis patients</td>
<td>K. Bargiel-Matusiewicz, Katowice, Poland, K. Kucia, A. Trzcieniecka-Green, A. Trzcieniecka-Green</td>
<td></td>
</tr>
<tr>
<td>Improvement of psychosocial adjustment to HIV-1 infection through a cognitive-behavioral oriented group psychotherapy program</td>
<td>J. Blanch, Barcelona, Spain, A. Rousaud, M. Hautzinger, E. Martinez, J. M. Peri, J. De Pablo, J. M. Gatell</td>
<td></td>
</tr>
<tr>
<td>Attention and working memory deficits in systemic lupus erythematosus patients with mild depressive and anxiety symptoms</td>
<td>K. Krzysztof, Katowice, Poland, A. Klasik, I. Krupka-Matuszczyk, P. Kotyla, E. J. Kucharz, B. Sliwinska-Kotyla</td>
<td></td>
</tr>
<tr>
<td>The problem of anosognosia in acute period of brain concussion</td>
<td>I. V. Dorovskikh, Moscow, Russia</td>
<td></td>
</tr>
<tr>
<td>The burden of day care for patients in psychosomatic rehabilitation</td>
<td>M. Linden, Teltow/Berlin, Germany</td>
<td></td>
</tr>
<tr>
<td>Impact of expected and unexpected cardiac events on patients coping strategies</td>
<td>J. Grkovic, Rijeka, Croatia, T. Franciskovic, I. Roncivic</td>
<td></td>
</tr>
<tr>
<td>Cerebrolysin in the combined treatment of abuse headache</td>
<td>T. Larikova, Perm, Russia, N. Starikova</td>
<td></td>
</tr>
<tr>
<td>The origin of language and mind</td>
<td>R. Kalb, Erlangen, Germany</td>
<td></td>
</tr>
<tr>
<td>Make it easy, make it simple, make it fun - Which psychiatric information service do primary care physicians want?</td>
<td>D. F. Zullino, Prilly-Lausanne, Switzerland, Y. Khazaal, M. Preissig, E. Frésard, M. Stankovic, F. Borgeat</td>
<td></td>
</tr>
<tr>
<td>Psychologists and social workers self-perception of DSM-IV psychopathology in Israel</td>
<td>T. Nachshoni, Beer Yaakov, Israel, R. Strous</td>
<td></td>
</tr>
<tr>
<td>The schedules for clinical assessment in neuropsychiatry (SCAN): version 2.1 experiences in using computerised diagnostic algorithms: Concordance between computerised iShell- and research diagnoses</td>
<td>L. Jurjanz, Dresden, Germany, M. Schützwohl, T. Kallert</td>
<td></td>
</tr>
<tr>
<td>Psychopathology scales derived from the schedules for clinical assessment in neuropsychiatry (SCAN 2.1)</td>
<td>M. Schützwohl, Dresden, Germany, M. Schützwohl, T. W. Kallert, L. Jurjanz</td>
<td></td>
</tr>
<tr>
<td>Towards medical audit in a psychiatric training hospital</td>
<td>W. Verhoeven, Venray, Netherlands, K. D’Hoine, J. I. Egger, S. Tuinier</td>
<td></td>
</tr>
<tr>
<td>Help-seeking behaviour in the general population</td>
<td>K. Dahlberg, Skövde, Sweden, B. Runeson, Y. Forsell, K. Damström-Thakker</td>
<td></td>
</tr>
<tr>
<td>Psychiatric episode severity and competence to consent to psychiatric hospitalization</td>
<td>D. Fraguas, Madrid, Spain, J. J. De la Peña, E. Chapela, S. Terán, F. García-Solano, A. Calcedo</td>
<td></td>
</tr>
<tr>
<td>Psychiatric illness severity and competence to consent to psychiatric hospitalization</td>
<td>J. J. de la Peña Esbri, Madrid, Spain, D. Fraguas Herráez, S. Teran, E. Chapela, F. García Solano, A. Calcedo Barba</td>
<td></td>
</tr>
<tr>
<td>Ethical and methodical solutions for conducting a randomized controlled trial comparing seclusion and restraint</td>
<td>J. Bergk, Ravensburg, Germany, T. Steinert</td>
<td></td>
</tr>
<tr>
<td>A randomized controlled trial comparing seclusion and restraint in psychiatry. Preliminary results</td>
<td>J. Bergk, Ravensburg, Germany, T. Steinert</td>
<td></td>
</tr>
</tbody>
</table>
### POSTER PRESENTATION P-11

<table>
<thead>
<tr>
<th>P-11-21</th>
<th>The course of early career job stress in physicians with emphasis on interference with family and social life</th>
</tr>
</thead>
<tbody>
<tr>
<td>R. Jan Ole, Oslo, Norway</td>
<td></td>
</tr>
<tr>
<td>R. Tyssen</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-11-22</th>
<th>Mother-and-Baby Unit: An alternative treatment of psychiatric disorders in women</th>
</tr>
</thead>
<tbody>
<tr>
<td>G. Laux, Wasserburg, Germany</td>
<td></td>
</tr>
<tr>
<td>M. Fric, S. Eigner, S. Artmann</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-11-23</th>
<th>Internal referrals in a Mental Health Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. Panagoulas, P. Psychiko-Athens, Greece</td>
<td></td>
</tr>
<tr>
<td>P. Papadopoulos, D. Malvidelis, K. Dailianis</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-11-24</th>
<th>Bioethical principles in treatment of psychiatric patients in croatia</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. Katalinic, Opatija, Croatia</td>
<td></td>
</tr>
<tr>
<td>A. Frkovic</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-11-25</th>
<th>Rapidly measurable general muscle relaxation induced by local back massage with an automated massage chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>D. F. Zullino, Prilly-Lausanne, Switzerland</td>
<td></td>
</tr>
<tr>
<td>C. Eichenberger, E. Panchaud, R. Marbehant, S. Krenz, M. Stankovic, E. Frésard, F. Borgeat, Y. Khazaal</td>
<td></td>
</tr>
</tbody>
</table>

### POSTER PRESENTATION P-12

<table>
<thead>
<tr>
<th>P-12-01</th>
<th>Olanzapine/fluoxetine and olanzapine treatment for bipolar depression: Open-label continuation in rapid cycling patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. Corya, Indianapolis, USA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-12-02</th>
<th>A 24-week open-label extension study of olanzapine/fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. Corya, Indianapolis, USA</td>
<td></td>
</tr>
<tr>
<td>D. Williamson, M. Case, D. Lin, M. Tohen</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-12-03</th>
<th>Safety and tolerability of quetiapine in bipolar mania</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. Adler, Cincinnati, USA</td>
<td></td>
</tr>
<tr>
<td>S. M. Strakowski, D. Fleck, M. Brecher</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-12-04</th>
<th>Double-blind comparison of divalproex versus quetiapine monotherapy for adolescent patients with mania</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. Adler, Cincinnati, USA</td>
<td></td>
</tr>
<tr>
<td>M. DelBello, R. Kowatch, K. E. Stanford, J. Welge, D. Barzman, S. Strakowski</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-12-05</th>
<th>Efficacy of quetiapine in improving quality of life in patients with bipolar depression</th>
</tr>
</thead>
<tbody>
<tr>
<td>J. Endicott, New York City, USA</td>
<td></td>
</tr>
<tr>
<td>K. Rajagopalan, W. Macfadden, M. Minkwitz, J. Gaddy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-12-06</th>
<th>Anti-anxiety effects of quetiapine in bipolar depression</th>
</tr>
</thead>
<tbody>
<tr>
<td>W. Macfadden, Wilmington, USA</td>
<td></td>
</tr>
<tr>
<td>J. R. Calabrese, R. McCoy, M. Minkwitz, E. Wilson, J. Mullen</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-12-07</th>
<th>Double-blind, placebo-controlled study of quetiapine in bipolar depression</th>
</tr>
</thead>
<tbody>
<tr>
<td>W. Macfadden, Wilmington, USA</td>
<td></td>
</tr>
<tr>
<td>T. Suppes, J. R. Calabrese, R. McCoy, M. Minkwitz, E. Wilson, J. Mullen</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-12-08</th>
<th>Mania remission rates and euthymia with quetiapine combination therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. Sussman, New York, USA</td>
<td></td>
</tr>
<tr>
<td>J. Mullen, D. E. Sweitzer</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-12-09</th>
<th>Quetiapine for the treatment of rapid-cycling bipolar depression</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. Vieta, Barcelona, Spain</td>
<td></td>
</tr>
<tr>
<td>J. R. Calabrese, W. Macfadden, M. Minkwitz, J. Mullen</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-12-10</th>
<th>Remission and response in the treatment of bipolar depression: Time-To-Event and NNT analyses from a large, randomized, controlled study of quetiapine</th>
</tr>
</thead>
<tbody>
<tr>
<td>J. C. Cookson, London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>P. E. Keck, Jr., T. A. Ketter, W. Macfadden, M. Minkwitz, J. Mullen</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-12-11</th>
<th>Placebo-level eps and akathisia during quetiapine treatment for mania</th>
</tr>
</thead>
<tbody>
<tr>
<td>B. Paulsson, Södertäje, Sweden</td>
<td></td>
</tr>
<tr>
<td>H. Nasrallah</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-12-12</th>
<th>Quetiapine for agitation and aggression in bipolar mania</th>
</tr>
</thead>
<tbody>
<tr>
<td>B. Paulsson, Södertäje, Sweden</td>
<td></td>
</tr>
<tr>
<td>P. F. Buckley, M. Brecher</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-12-13</th>
<th>Sustained remission/euthymia with quetiapine monotherapy for bipolar mania</th>
</tr>
</thead>
<tbody>
<tr>
<td>B. Paulsson, Södertäje, Sweden</td>
<td></td>
</tr>
<tr>
<td>T. A. Ketter, M. Jones</td>
<td></td>
</tr>
</tbody>
</table>
POSTER PRESENTATION
TUESDAY, 5 APRIL 2005

POSTER PRESENTATION P-12

P-12-14 Risperidone utilization in serious bipolar mood disorders
G. Tavormina, Provolagio d’Iseo, Italy

P-12-15 SSRI’s during pregnancy: Do they really hurt the babies?
M. Steiner, Hamilton, Canada
L. Ross, L. Born

POSTER PRESENTATION P-13

11.15 - 12.15 h Gasteig - Foyers
Track T-4 Anxiety-related and eating disorders

PTSD and eating disorders
Chairperson: Roman A. Evsegneev, Minsk, Belarus
Co-Chairperson: Fernando Fernandez-Aranda, Barcelona, Spain

P-13-01 Changes in the profile of psychological health in the 11-M attack: Assessment one month and six months following the attack
O. Medina, Madrid, Spain
O. Medina Ortiz, D. Fraguas Herráez, J. Conejo-Galindo, S. Terán Sedano, E. Sainz Cortón, C. Arango López

P-13-02 Posttraumatic stress disorder (ptsd) among victims of march 11th terrorist attacks in madrid and their families
S. Teran, Madrid, Spain
D. Fraguas, J. Conejo-Galindo, O. Medina, E. Sainz-Cortón, C. Arango

P-13-03 Posttraumatic stress disorder (ptsd) and psychopathology in the 11-M attack: Assessment one month and six months following the attack
J. Conejo-Galindo, Madrid, Spain

P-13-04 Posttraumatic Stress Disorder (PTSD) in the 11-M attack
D. Fraguas, Madrid, Spain
S. Teran, J. Conejo-Galindo, O. Medina, E. Sainz-Cortón, C. Arango

P-13-05 Psychological factors in the repeated accident: A preliminary study at the emergency department of the general hospital of padua
C. Civiero, Padova, Italy
M. Zordan, C. Cecchetto, M. Pierri

P-13-06 Mental and behavioral disorders at the teenagers, undergone to rape
O. Zaytsev, Kiev, Ukraine

P-13-07 Group psychodynamic psychotherapy of female’s victims of family sexual abuse
A. Bravo-Mehmedbasic, Sarajevo, Bosnia and Herzegovina
D. Salcic Dizdarevic, A. Kucukalic, L. Cakovic, S. Popovic

P-13-08 The acute period of posttraumatic stressful disorder at military men in conditions of the local confrontation
A. S. Zakovriashin, Moscow, Russia

P-13-09 The psychological and social malfunctioning in PTSD patients
T. Milenkovic, Serbia + Montenegro
M. Simonovic

P-13-10 And then the dog died
K. Kaufman, New Brunswick, USA
N. Kaufman

P-13-11 Are body image disorders precursors of eating disorders?
G. L. Mansi, Bosisio Parini, Italy
A. Fumagalli, R. Bergomi, I. Floriani, M. Molleni

P-13-12 Eating disorder males and therapy effectiveness: A pilot study
F. Fernandez-Aranda, Barcelona, Spain
R. Solano, A. Aitken, J. Vallejo Ruiloba

P-13-13 Bulimia nervosa and impulse control disorders: A comparison study of common and differential personality risk factors
F. Fernandez-Aranda, Barcelona, Spain
S. Jimenez-Murcia, N. Jaurrieta, C. Martinez, J. Rodriguez, E. Alvarez, J. Vallejo

P-13-14 Tourette’s disorder misdiagnosed as an eating disorder
F. Van den Eynde, Gent, Belgium
M. Vervaet, N. Arbyn, S. de Saedeleer, K. H. Naudts, K. Audenaert, C. van Heeringen

P-13-15 Dissociation and self-injurious behavior in anorexia and bulimia nervosa
D. Nutzinger, Bad Bramstedt, Germany
K. Schroeter, T. Paul
P-14-01 Exploratory Clinical Training on Autobiographical Memory
D. Lecompte, Brussels, Belgium
A. Neumann, H. Nachtergael, S. Blairy, P. Philippot

P-14-02 Medication Adherence Rating Scale (MARS) – new compliance scale for schizophrenic patients.
A. Wozniak, Warsaw, Poland

P-14-03 Recovery from schizophrenia - a systematic review
E. Lauronen, Oulu, Finland
J. Miettunen, J. Koskinen, J. Veijola, J. McGrath, M. Isohanni

P-14-04 Dynamic group therapy for schizophrenia: novel or obsolete?
K. Ademmer, Frankfurt, Germany
P. Hartwich

P-14-05 What works in group psychotherapy for schizophrenic patients?
K. Ademmer, Frankfurt, Germany

P-14-06 Effect of an educational anti-stigma project for police officers to reduce social distance towards schizophrenic patients
K. Wundsam, Munich, Germany
G. Pitschel-Walz, W. Kissling

P-14-07 “Schizophrenia – What’s that?”: A school project to educate students about schizophrenia and to reduce their social distance towards psychiatric patients
K. Wundsam, Munich, Germany
G. Pitschel-Walz, W. Kissling

P-14-08 Effectiveness of inpatient treatment programs for dually diagnosed patients
B. De Wilde, Schellebelle, Belgium

P-14-09 Changes in defense mechanism of people suffering from schizophrenia – spectrum disorder as a result of therapy in Day Treatment Center
L. Cichocki, Cracow, Poland
J. Bomba, J. Franczyk

P-14-10 Case report: Multidisciplinary approach to the chronic psychiatric patient
A. de Sebastian, Madrid, Spain
R. Sanz, A. de Sebastian, A. Perez, D. Bragado

P-14-11 Cognitive treatment for... perseveration
D. M. Gerulaitiene, Kaunas, Lithuania

P-14-12 The VILAN Method: New approach in treatment of motor disturbances in acute psychosis
N. Ilankovic, Belgrade, Serbia + Montenegro
V. Ilankovic, A. Ilankovic, L. M. Ilankovic

P-14-13 What is an antipsychotic drug for? Everything you psychiatrists always wanted by a drug...but (perhaps) were afraid to ask
R. Mancusi, Napoli, Italy

P-14-14 Family intervention co-therapy in schizophrenia: An effective practice
V. Fricchione Parise, Avellino, Italy

P-14-15 Needs and service utilisation in outpatients with schizophrenia
U. Judith, Sant Boi de Llobregat, Spain

P-14-16 The pathway of a patient affected by schizophrenia
G. De Mattia, Naples, Italy
A. Rossi, C. Mingione, G. Parolise, S. Petrullo, C. Ragozzino

P-14-17 Adherence to treatment in patients with psychiatric disorder according to different clinical setting
M. Centeno, Granollers, Spain
S. Arranz, M. Centeno, D. Bergé, E. Palomer, P. Salgado

P-14-18 Religious coping among outpatients suffering from chronic schizophrenia
S. Mohr, Chene-Bourg, Switzerland
P. Huguelet

P-14-19 Religiousness and medication adherence among patients with schizophrenia
L. Borras, Brussels, Belgium
S. Mohr, P. Huguelet

P-14-20 Schizophrenia - Creative speech as a therapeutic method
M. T. Krsamanovic, Belgrade, Serbia + Montenegro

P-14-21 The impact of transgenerational transmission on schizophrenia
M. Ammon, Berlin, Germany

P-14-22 Sequential treatment plan for resistant schizophrenia
J. Aguado Manas, Valladolid, Spain
<table>
<thead>
<tr>
<th>POSTER PRESENTATION</th>
<th>P-15</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.00 - 19.30 h</td>
<td>Gasteig - Foyers</td>
</tr>
<tr>
<td>Track T-3</td>
<td>Affective disorders</td>
</tr>
<tr>
<td>Affective disorders IV</td>
<td></td>
</tr>
<tr>
<td>Chairperson:</td>
<td>Siegfried Kasper, Vienna, Austria</td>
</tr>
<tr>
<td>P-15-01</td>
<td>Escitalopram in the treatment of severe depression</td>
</tr>
<tr>
<td></td>
<td>S. Kasper, Vienna, Austria</td>
</tr>
<tr>
<td></td>
<td>P. Ninan, D. Ventura, J. Wang</td>
</tr>
<tr>
<td>P-15-02</td>
<td>The efficacy and tolerability of escitalopram in depressed patients with or without concomitant anxiety</td>
</tr>
<tr>
<td></td>
<td>J.-P. Olie, Paris, France</td>
</tr>
<tr>
<td></td>
<td>B. Tonnoir, I. Florea</td>
</tr>
<tr>
<td>P-15-03</td>
<td>A comparison of escitalopram and mirtazapine and placebo in driving performance, psychomotor performance and cognitive function in healthy subjects</td>
</tr>
<tr>
<td></td>
<td>S. Langer, Hamburg, Germany</td>
</tr>
<tr>
<td></td>
<td>M. Wingen, H. Andersen, J. Bothmer, J. Ramaekers</td>
</tr>
<tr>
<td>P-15-04</td>
<td>The effect of escitalopram versus sertraline versus duloxetine on CYP 2D6 function</td>
</tr>
<tr>
<td></td>
<td>T. Burt, New York, USA</td>
</tr>
<tr>
<td></td>
<td>S. Preskorn, A. Klick-Davis, M. Ramadan, B. Baker, K. Omo, M. Erickson, M. Erickson, T. Burt</td>
</tr>
<tr>
<td>P-15-05</td>
<td>Depression and sleep disturbance: the effect of escitalopram</td>
</tr>
<tr>
<td></td>
<td>M. Lader, London, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>E. Reine, H. F. Andersen</td>
</tr>
<tr>
<td>P-15-06</td>
<td>The tolerability and safety of Bupropion XL versus Escitalopram in the treatment of major depressive disorder</td>
</tr>
<tr>
<td></td>
<td>J. Horrigan, Research Triangle Park, USA</td>
</tr>
<tr>
<td></td>
<td>D. Wightman, J. Modell</td>
</tr>
<tr>
<td>P-15-07</td>
<td>Treating mood disorders during pregnancy: safety considerations</td>
</tr>
<tr>
<td></td>
<td>M. Eberhard-Gran, Norway</td>
</tr>
<tr>
<td></td>
<td>A. Eskild, S. Opjordsmoen</td>
</tr>
<tr>
<td>P-15-08</td>
<td>Postnatal depression- does it exist as a specific entity?</td>
</tr>
<tr>
<td></td>
<td>M. Eberhard-Gran, Norway</td>
</tr>
<tr>
<td></td>
<td>K. Tambs, S. O. Samuelsen, A. Skrondal, S. Opjordsmoen, A. Eskild</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSTER PRESENTATION</th>
<th>P-15</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-15-09</td>
<td>The European Alliance Against Depression - EAAD</td>
</tr>
<tr>
<td></td>
<td>T. Pfeiffer-Gerschel, Munich, Germany</td>
</tr>
<tr>
<td>P-15-10</td>
<td>Depression guidelines: how useful are they to the clinician?</td>
</tr>
<tr>
<td></td>
<td>M. Livingston, Glasgow, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>M. Livingston</td>
</tr>
<tr>
<td>P-15-11</td>
<td>Do past life change events still have an impact on post-MI depression in the PTCA era?</td>
</tr>
<tr>
<td></td>
<td>M. Abreu, Lisbon, Portugal</td>
</tr>
<tr>
<td></td>
<td>F. Simoes-Couto, A. Matos-Pires, F. Arriaga</td>
</tr>
<tr>
<td>P-15-12</td>
<td>Dimensions of response styles in a unipolar depressive and in a population based sample</td>
</tr>
<tr>
<td></td>
<td>C. Burger, Mannheim, Germany</td>
</tr>
<tr>
<td></td>
<td>C. Kuehner</td>
</tr>
<tr>
<td>P-15-13</td>
<td>EPID - Epidemiology of depression in Slovakia: Recurrence of depression in connection to socio-demographic factors</td>
</tr>
<tr>
<td></td>
<td>A. Heretik, Bratislava, Slovakia</td>
</tr>
<tr>
<td></td>
<td>A. Heretik, sen., V. Novotny, J. Pecenak, A. Ritomsky</td>
</tr>
<tr>
<td>P-15-14</td>
<td>Group treatment for depression in mothers of young infants: A controlled study</td>
</tr>
<tr>
<td></td>
<td>U. Frisch, Basel, Switzerland</td>
</tr>
<tr>
<td></td>
<td>M. Hofecker Fallahpour, P. Ley, C. Neuhofer Katz, R.-D. Stieglitz, A. Riecher-Rössler</td>
</tr>
<tr>
<td>P-15-15</td>
<td>Outpatient Electroconvulsive Therapy</td>
</tr>
<tr>
<td></td>
<td>S. Barrio, Donostia-San Sebastian, Spain</td>
</tr>
<tr>
<td></td>
<td>S. Barrio, J. Marton, A. Sanchez, L. Perez, T. Piza, J. I. Andonegui</td>
</tr>
<tr>
<td>P-15-16</td>
<td>Psychopathological and somatic comorbidity in major depressive disorders</td>
</tr>
<tr>
<td></td>
<td>D. Vasile, Bukarest, Romania</td>
</tr>
<tr>
<td></td>
<td>M. Gheorghe, O. Vasiliu, E. Lungut</td>
</tr>
<tr>
<td>P-15-17</td>
<td>The impact of sexual dysfunctions on mood and quality of life in patients with diabetes</td>
</tr>
<tr>
<td></td>
<td>D. Lojko, Poznan, Poland</td>
</tr>
<tr>
<td></td>
<td>A. Suwalska, K. Gorna, F. Rybakowski</td>
</tr>
<tr>
<td>P-15-18</td>
<td>Prevalence of depression among hemodialysis patients: Analysis of possible factors related to depression</td>
</tr>
<tr>
<td></td>
<td>V. Popovic, Belgrad, Serbia + Montenegro</td>
</tr>
<tr>
<td></td>
<td>J. Popovic, A. Jovanovic, N. Dimkovic</td>
</tr>
<tr>
<td>Poster</td>
<td>Title</td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
</tr>
<tr>
<td>P-16-03</td>
<td>Identification of differentially expressed genes in the brains of suicide victims; a microarray analysis</td>
</tr>
<tr>
<td>P-16-04</td>
<td>Neurotrophin levels in postmortem brains of suicide victims: Effects of ante mortem diagnosis and psychotropic drugs</td>
</tr>
<tr>
<td>P-16-05</td>
<td>Suicide Among Viennese Minors: 1946-2002</td>
</tr>
<tr>
<td>P-16-06</td>
<td>Attitudes towards suicide in Hungarian and Austrian adolescents</td>
</tr>
<tr>
<td>P-16-07</td>
<td>Psychological autopsy suicide during the period of 1998-2003: typical profile soldier’s suicide completer</td>
</tr>
<tr>
<td>P-16-08</td>
<td>Increased risk of Parkinson’s disease in patients treated for affective disorders?</td>
</tr>
<tr>
<td>P-16-09</td>
<td>Effect on mood after subthalamic stimulation in Parkinson disease</td>
</tr>
<tr>
<td>P-16-10</td>
<td>Correlates of platelet serotonin transporter binding, serotonin transporter promoter polymorphism, and clinical phenotype in ashkenazi suicidal adolescent</td>
</tr>
<tr>
<td>P-16-11</td>
<td>Personality disorders and primary care</td>
</tr>
<tr>
<td>P-16-12</td>
<td>Personality and behavioural disorders Chairperson: Constantin Soldatos, Athens, Greece; Co-Chairperson: Gil Zalsman, New York, USA</td>
</tr>
<tr>
<td>P-15-19</td>
<td>Modafinil Treatment of Depressive Symptoms Pre- and Post- Cardiac Transplant: Case Report</td>
</tr>
<tr>
<td>P-15-20</td>
<td>Prevalence depressive disorder with inpatients in poststroke period in neurologic clinic</td>
</tr>
<tr>
<td>P-15-21</td>
<td>Social functioning and quality of life under depressive disorders</td>
</tr>
<tr>
<td>P-15-22</td>
<td>Why is the involutional depression in the female destiny?</td>
</tr>
<tr>
<td>P-15-23</td>
<td>Increased risk of Parkinson’s disease in patients treated for affective disorders?</td>
</tr>
<tr>
<td>P-15-24</td>
<td>Effect on mood after subthalamic stimulation in Parkinson disease</td>
</tr>
<tr>
<td>P-15-19</td>
<td>Identification of differentially expressed genes in the brains of suicide victims; a microarray analysis</td>
</tr>
<tr>
<td>P-15-04</td>
<td>Neurotrophin levels in postmortem brains of suicide victims: Effects of ante mortem diagnosis and psychotropic drugs</td>
</tr>
<tr>
<td>P-15-05</td>
<td>Suicide Among Viennese Minors: 1946-2002</td>
</tr>
<tr>
<td>P-15-07</td>
<td>Psychological autopsy suicide during the period of 1998-2003: typical profile soldier’s suicide completer</td>
</tr>
<tr>
<td>P-15-08</td>
<td>Increased risk of Parkinson’s disease in patients treated for affective disorders?</td>
</tr>
<tr>
<td>P-15-09</td>
<td>Effect on mood after subthalamic stimulation in Parkinson disease</td>
</tr>
</tbody>
</table>
P-16-12  Personality disorders diagnosis in psychiatric patients: comparison of DSM vs ICD criteria (preliminary data)
K. N. Fountoulakis, Aretsou, Greece
S. G. Kaprinis, M. Siamouli, P. PanagiotiDias, S. Kantartzis, A. Lacovides

P-16-13  Possible structural hippocampal alterations and HPA axis dysregulation in patients with borderline personality disorder
T. Zetzsche, Munich, Germany

P-16-14  Personality disorders in patients with traumatic brain injury
S. Koponen, Turku, Finland

P-16-15  Pornography consumption in Denmark and associated factors
G. M. Hald, Aarhus, Denmark

P-16-16  Olanzapine and aggressive behavior in forensic-psychiatric patients
C. Stadtland, Munich, Germany

P-16-17  The management of the psychomotor agitation in the Swiss emergency departments
C. Damsa, Geneva, Switzerland
M. Kelley-Puskas, C. Lazignac, A. Cicotti, A. Andreoli

P-16-18  Detection of partner violence in a crises intervention unit at the University Hospital Basel
P. Hartman, Basel, Switzerland
E. Nyberg, P. Berger, R.-D. Stieglitz, A. Riecher-Rossler

P-16-19  Strategies how to manage violent attacks
U. Busch-Wübenna, Munich, Germany
C. Kick, R. Kuckelsberg, J. Hinrichs

P-16-20  People with mental retardation in a low-secure inpatient setting: Comparison of offenders and non offenders
K. Xenitidis, London, United Kingdom
S. Reed, A. Russell, D. Murphy, K. Xenitidis

P-16-21  Hospitalization and psychoanalytic psychotherapy for personality disorders: A psychoanalytic approach
G. Vaslamatzis, Athens, Greece
H. Karamanolaki, M. Coccossis, M. Chatziandreou, I. Ioannovich, S. Vondikaki

P-16-22  The role of the dialogue in the personality development
I. Serhiyenko, Ukraine

P-17-01  Developmental outcomes of long-term atomoxetine treatment in ADHD
D. Michelson, Indianapolis, USA
T. Spencer, M. Bangs, S. Zhang, D. Ruff, H. Gao, P. Feldman

P-17-02  Atomoxetine's efficacy over time in children and adolescents with ADHD
V. Sutton, Indianapolis, USA

P-17-03  An analysis of baseline functional disability in a cohort of employed adult patients with attentiondeficit/hyperactivity disorder
L. Levine, Indianapolis, USA
R. Tamura, A. Rogers, H. Detke, A. J. Allen

P-17-04  Sleep of children with ADHD compared with healthy control subjects
J. Owens, Providence, USA

P-17-05  A modelled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with Attention-Deficit/Hyperactivity Disorder in the United Kingdom
J. Bae, Indianapolis, USA
J. Arellano, M. Aristides, S. Cottrell, E. Edgell, P. Robinson, D. Tilden

P-17-06  A polymorphism at 3' untranslated region of the human CLOCK gene is possibly associated with adult attention-deficit hyperactivity disorder
J. Thome, Swansea, United Kingdom
C. Kissling, S. Wiemann, A. Coogan, C. Freitag, M. Rössler, W. Retz

P-17-07  The Zurich-Study: ADHD-Subscale derived from SCL and psychopathological associations
D. Eich-Höchli, Zurich, Switzerland
A. Bosca

P-17-08  Communication impairments in mental retardation: Autism?
S. Tuinier, Venray, Netherlands
S. Tuinier, B. Hamel, W. Verhoeven
P-17-09  Differential diagnosis of autism: Comparison of autism-spectrum disorder and schizotypal personality disorder
  J. I. Egger, Venray, Netherlands
  S. Tuinier, T. Klaassen, H. De Mey, W. Verhoeven

P-17-11  18q deletion syndrome: A case report and review of the literature
  W. Verhoeven, Venray, Netherlands
  C. Van Ravenswaay - Arts, A. Van Beurden, T. Siegfried

P-17-12  Serotonin uptake inhibitors in patients with intellectual disabilities
  W. Verhoeven, Venray, Netherlands
  S. Tuinier

P-17-13  Psychological and clinical peculiarities of cognitive impairments at delayed pupils
  G. Butorin, Chelyabinsk, Russia

P-17-15  Psychological aspects of Roland’s epilepsy
  B. Burba, Kaunas, Lithuania
  I. Laukiene, K. Dambrukskiene, B. Burba

P-17-16  Differentiated approach to treatment of psychovegetative disorders at cerebral asthenia of residual-organic genesis in children
  L. Benko, Chelyabinsk, Russia

P-17-17  Child psychiatry in Ukraine
  L. Butenko, Kiev, Ukraine
  I. Martsenkovsky, Y. Bikshaeva

P-17-18  Peculiarities of clinic and treatment ecology-induced mental disorders of children
  N. Govorin, Chita, Russia

P-17-19  Discognitive type of school disadaptation of children with benign mental handicap
  N. Rytchkova, Chelyabinsk, Russia

P-17-20  Training Classifiers to predict brain states and to find discriminative regions
  A. Bokde, Munich, Germany
  J. Mourão-Miranda, M. Stetter, H. Hampel

P-17-21  Neuropsychological differences in late-onset versus recurrent geriatric depression
  M. Rapp, New York, USA
  J. Gorman

P-17-22  A telerehabilitation program in a group of patients with Alzheimer disease
  M. L. Onor, Trieste, Italy
  E. Aguglia, S. Misan

P-17-23  Estimation of factors having an influence on functioning of persons in elder age in the sphere of basic and complex life activities
  M. Dosiak, Ruda Slaska, Poland
  E. Wojtyna

P-17-24  The use of trazodone in the elderly with dementia
  P. Kouniakis, Thessaloniki, Greece
  P. Ioannidis, E. Tsirogianni, M. Baltatzis, D. Dimelis, G. Garyfallos, G. Lavrentiadis, A. Hatzitolios, I. Giouzepas

P-18-01  Psychopharmacological treatment of acutely agitated patients in an intensive care unit
  A. Naderi-Heiden, Vienna, Austria
  R. Wimmer, R. Frey, S. Kasper

P-18-02  Assessment of dependence between therapy with neuroleptics and incidence of symptoms of the restless legs syndrome
  A. Nitka-Sieminska, Gdansk, Poland
  J. Landowski, W. M. Nyka

P-18-04  Topiramate in smoking cessation
  Y. Khazaal, Prilly-Lausanne, Switzerland
  E. Frésard, M. Stankovic, A. Buecking, F. Borget, F. D. Zullino

P-18-07  Persistency and Compliance Evaluation (PACE): Germany population with schizophrenia or bipolar disorder analysis of persistency with initially prescribed antipsychotics
  R. Simons, Summit, USA
P-18-08  The influence of patients’ and doctors’ social characteristics on the selection of treatment strategies for schizophrenia in Germany
M. Franz, Gießen, Germany
J. Ranger, M. Matheis, B. Gallhofer

P-18-09  Longer time to All-Cause Antipsychotic Discontinuation is associated with better schizophrenia treatment outcomes
E. Dunayevich, Indianapolis, USA

P-18-10  Overall treatment effectiveness as measured by time continuing on antipsychotic therapy
C. Beasley, Indianapolis, USA
V. Stauffer, C. Mitchell, H. Liu-Seifert, J. Davis, E. Dunayevich

P-18-13  Effects of Zuclopenthixol on destructive behaviour of adults with mental retardation
F. Haessler, Rostock, Germany
T. Glaser

P-18-14  Relation of change in clinical symptoms to cognitive improvement with atypical antipsychotics
J. Dunn, New York, USA
F. Canas, P. Harvey, M. Green, C. Bowie, A. Loebel

P-18-15  Clinical status course and quality of life after the first 2 years of treatment: Result from the European schizophrenia outpatient health outcomes (SOHO) study
D. Novick, Indianapolis, USA
J. Haro, M. Belger, D. Novick, S. Tzivelekis, M. Ratcliffe

P-18-16  Atypical antipsychotics and risk of first-time idiopathic venous thromboembolism: A case report
L. Borras, Brussels, Belgium
A. Eytan, E. Constant, P. Huguelet
Dear Colleagues,

in 2003 an AEP initiative newly established a Young Psychiatrists Program which was held for the first time on a European psychiatric conference during the past Congress in Geneva, Switzerland. Under the presidency of Professor Henning Sass the AEP and its scientific and organizing committees have made a special effort to continue the tradition of a Young Psychiatrists Program at the upcoming conference in Munich in April 2005. In 1999 Professor Norman Sartorius and the WPA together with the organizing Young Psychiatrists Committee established the first Young Psychiatrists Program at the XI World Congress of Psychiatry in Hamburg, Germany. The idea was to pay special attention to young psychiatrists attending international psychiatric conferences. Due to its great success young psychiatrists programs today are an integral part of national, European and international congresses of psychiatry.

The AEP’s Young Psychiatrists Program in 2005 will focus on “New Challenges for Young Psychiatrists in Europe”. We are able to offer an exquisite scientific and social program to young congress attendees at all stages of their career. The next columns give you an overview of the program.

YOUNG PSYCHIATRISTS PROGRAM COMMITTEE

President of the German Trainee Association (DGPPN)
Iris Calliess

WPA-YPDC Delegate
Kai Treichel

Julian Beezhold
Past President of EFPT

YOUNG PSYCHIATRISTS LOUNGE

Meeting point for young psychiatrists and trainees, located in the foyer above the Carl-Orff-Hall, Gasteig.
Opening hours are:

3 to 5 April 2005, from 10.00 – 18.00 h,
and
on 6 April 2005 from 10.00 h
until the Closing Ceremony.

MEET-THE-EXPERT

There will take place Meet the Expert sessions at the Young Psychiatrists Coffee Lounge. The Meet the Expert sessions are designed to primarily target psychiatrists of the younger generation. The experts are leading figures of European psychiatry who are asked to contribute to aspects of “New Challenges of Young Psychiatrists in Europe”. The Meet the Expert sessions are deliberately conceptualized as informal discussions in a relaxed atmosphere so guarantee a maximum of free interaction with the audience.

Meet the Expert sessions take place in the Young Psychiatrists Lounge. The sessions are limited to 100 participants. Pre-Registration are possible the lounge or at the front check-in desk. The introductory meet the expert session is named in the Final Program others will be announced during the congress in the Coffee lounge.

Opening Meet the Expert Session with Professor
Norman Sartorius, Switzerland
Sunday, 3 April 2005, 14.15 – 15.15 h
Gasteig, Young Psychiatrists Lounge

WORKSHOP

In cooperation with the European Federation of Psychiatric Trainees (EFPT) and the World Association of Young Psychiatrists and Trainees (WAYPT) there is organized a workshop to enable congress participants to learn more about European and worldwide networks of young psychiatrists and trainees.

European and International networks of Young Psychiatrists and trainees
YOUNG PSYCHIATRISTS PROGRAM

BREAKFAST MEETINGS

Monday, 4 April 2005
14.15 – 15.45 h  Holiday Inn, Room 8

Two breakfast meetings are organized on topics of special interest for European young psychiatrists: on the relevance of psychotherapy for psychiatric practice and on standards of writing scientific papers.

Sunday, 3 April 2005
How to write a scientific paper?
8.45 – 9.30 h  Gasteig, Young Psychiatrists Lounge

4 April 2005
Is psychotherapy relevant for good psychiatric practice?
8.45 – 9.30 h  Gasteig, Young Psychiatrists Lounge

YOUNG PSYCHIATRISTS SYMPOSIUM

This is a special symposium for young psychiatrists highlighting “New challenges for Young Psychiatrists in Europe”. What are new challenges for young psychiatrists? What can we learn from the leaders in psychiatry? The symposium will focus on the question what necessary skills for young psychiatrists are in times of a unifying world on the one hand and rapid changes of several subsystems of society such as health, communication, ethics, politics and economics on the other?

Monday, 4 April 2005
New Challenges for Young Psychiatrists in Europe
8.30 – 10.00 h  Holiday Inn, Room 4
### LIST OF EXHIBITORS

<table>
<thead>
<tr>
<th>EXHIBITOR</th>
<th>BOOTH NO.</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
<td>4</td>
</tr>
<tr>
<td>Avon &amp; Wilshire NHS, Mental Health Trust</td>
<td>6</td>
</tr>
<tr>
<td>Blackwell Publishing Ltd.</td>
<td>20</td>
</tr>
<tr>
<td>Bristol-Myers Squibb GmbH</td>
<td>16</td>
</tr>
<tr>
<td>Elsevier</td>
<td>23</td>
</tr>
<tr>
<td>FBI Fred Berninger Importe HOG</td>
<td>2</td>
</tr>
<tr>
<td>Hormosan Pharma GmbH</td>
<td>15</td>
</tr>
<tr>
<td>IMS Recruitment Ltd.</td>
<td>22</td>
</tr>
<tr>
<td>Inomed Medizintechnik GmbH</td>
<td>14</td>
</tr>
<tr>
<td>S. Karger AG</td>
<td>13</td>
</tr>
<tr>
<td>Kompetenznetz Schizophrenie</td>
<td>12</td>
</tr>
<tr>
<td>Eli Lilly &amp; Company</td>
<td>3</td>
</tr>
<tr>
<td>Medtronic AIS</td>
<td>7</td>
</tr>
<tr>
<td>Merz Pharmaceuticals GmbH</td>
<td>5</td>
</tr>
<tr>
<td>Pfizer Inc.</td>
<td>19</td>
</tr>
<tr>
<td>Publex Ltd.</td>
<td>21</td>
</tr>
<tr>
<td>Servier International</td>
<td></td>
</tr>
<tr>
<td>3 W Informed</td>
<td>8</td>
</tr>
<tr>
<td>Wisepress Online Bookshop</td>
<td>18</td>
</tr>
<tr>
<td>Wyeth Pharma GmbH</td>
<td>1</td>
</tr>
<tr>
<td>AEP</td>
<td>9</td>
</tr>
<tr>
<td>AEP Congress 2006</td>
<td>10</td>
</tr>
<tr>
<td>ECNP</td>
<td>11</td>
</tr>
</tbody>
</table>

---

**Overview of Floorplan of Exhibitors in the foyer of Gasteig**

![Floorplan Image]

*Gasteig, Munich 1st floor*
# List of Chairpersons and Presenters

<table>
<thead>
<tr>
<th>NAME</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

91